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Abstract 
Climate change, globalisation and increased travel, increasing urban populations, 
overcrowding, continued poverty, and the breakdown of public health infrastructure are 
among the factors contributing to the 30-fold increase in total dengue incidence in the past 
50 years. Consequently, with an estimated 40% of the world’s population at risk of infection, 
dengue is now the world’s most important mosquito-borne viral infection.  
However estimates of dengue transmissibility and burden remain ambiguous. Since the 
majority of infections are asymptomatic, surveillance systems substantially underestimate 
true rates of infection. With advances in the development of novel control measures and 
the recent licensing of the Sanofi Dengvaxia® dengue vaccine, obtaining robust estimates of 
average dengue transmission intensity is key for estimating both the burden of disease from 
dengue and the likely impact of interventions. Given the highly spatially heterogeneous 
nature of dengue transmission, future planning, implementation, and evaluation of control 
programs are likely to require a spatially targeted approach.  
Here we collate existing age-stratified seroprevalence and incidence data and develop 
catalytic models to estimate the burden of dengue as quantified by the force of infection 
( )  and basic reproduction number 0(R ) . We identified a paucity of serotype-specific age-
stratified seroprevalence surveys in particular but showed that non-serotype specific data 
could give robust estimates of baseline transmission. Chapters explore whether estimates 
derived from different data types are comparable. Using these estimates we mapped the 
estimated number of dengue cases across the globe at a high spatial resolution allowing us 
to assess the likely impact of targeted control measures. 
  
Page 7 of 228 
 
Contents 
Declaration of originality ........................................................................................................... 2 
Copyright declaration ................................................................................................................ 3 
Acknowledgements .................................................................................................................... 4 
Relevant Publications ................................................................................................................. 5 
Abstract ...................................................................................................................................... 6 
Contents ..................................................................................................................................... 7 
List of figures ............................................................................................................................ 11 
List of tables ............................................................................................................................. 16 
List of abbreviations and acronyms ......................................................................................... 18 
1 Introduction ..................................................................................................................... 19 
1.1 Background ................................................................................................................ 19 
1.2 Clinical Symptoms and Natural history ..................................................................... 19 
1.3 Immunity ................................................................................................................... 21 
1.4 Diagnostic Methods and Limitations ........................................................................ 22 
1.4.1 Virological Assays ............................................................................................... 23 
1.4.2 Serological Assays .............................................................................................. 23 
1.4.3 Dengue Virus Serotyping ................................................................................... 25 
1.5 Current Estimates of Dengue Burden ....................................................................... 26 
1.6 Novel Control Methods ............................................................................................. 27 
1.6.1 Genetically Modified Mosquitoes ...................................................................... 29 
1.6.2 Biological Control: Wolbachia ............................................................................ 30 
1.6.3 Sustainability and Scalability of Novel Control Methods................................... 31 
1.6.4 Dengue Vaccine.................................................................................................. 32 
1.7 Catalytic Models and Estimating the Force of Infection ........................................... 34 
1.8 Thesis outline ............................................................................................................ 38 
Page 8 of 228 
 
2 Estimating Dengue Transmission Intensity from Non-serotype Specific Seroprevalence 
Surveys ..................................................................................................................................... 39 
2.1 Introduction............................................................................................................... 39 
2.2 Methods .................................................................................................................... 42 
2.2.1 Literature Search ................................................................................................ 42 
2.2.2 Catalytic Models................................................................................................. 44 
2.2.3 Estimating the Basic Reproduction Number ...................................................... 49 
2.3 Results ....................................................................................................................... 54 
2.4 Discussion .................................................................................................................. 65 
2.5 References for Figures............................................................................................... 69 
2.6 ISO Abbreviations ...................................................................................................... 72 
3 Estimating Dengue Transmission Intensity from Serotype-specific Seroprevalence 
Surveys and a Comparison of Data Types ................................................................................ 73 
3.1 Introduction............................................................................................................... 73 
3.2 Methods .................................................................................................................... 73 
3.2.1 Literature Search ................................................................................................ 73 
3.2.2 Catalytic Models................................................................................................. 73 
3.2.3 Estimating the Basic Reproduction Number, R0 ................................................ 78 
3.2.4 Multiple Linear Regression ................................................................................ 81 
3.3 Results ....................................................................................................................... 82 
3.3.1 Parameter Estimates .......................................................................................... 82 
3.3.2 Regression Analysis ............................................................................................ 95 
3.4 Discussion .................................................................................................................. 98 
3.5 References for Figures............................................................................................. 101 
3.6 ISO Abbreviations .................................................................................................... 102 
Page 9 of 228 
 
4 Estimating Dengue Transmission Intensity from Case-notification Data from Multiple 
Countries ................................................................................................................................ 103 
4.1 Introduction............................................................................................................. 103 
4.2 Methods .................................................................................................................. 105 
4.2.1 Literature Search .............................................................................................. 105 
4.2.2 Estimating the Force of Infection and Reporting Rates ................................... 105 
4.2.3 Calculating the Basic Reproduction Number (R0i) ........................................... 112 
4.2.4 Comparing Force of Infection Estimates by Data Type ................................... 114 
4.2.5 Multiple Linear Regression .............................................................................. 115 
4.3 Results ..................................................................................................................... 117 
4.3.1 Literature Search .............................................................................................. 117 
4.3.2 Additional Seroprevalence Surveys ................................................................. 121 
4.3.3 Parameter Estimates ........................................................................................ 121 
4.3.4 Comparison of Estimates Obtained from Seroprevalence and Incidence data.
 166 
4.3.5 Regression Analysis .......................................................................................... 167 
4.4 Discussion ................................................................................................................ 170 
4.5 Acknowledgements ................................................................................................. 173 
5 Estimating the global burden of dengue and the impact of control measures ............ 174 
5.1 Introduction............................................................................................................. 174 
5.2 Methods .................................................................................................................. 175 
5.2.1 Regression of Presence-absence Against Force of Infection ........................... 175 
5.2.2 Mapping the Estimated Burden of Dengue ..................................................... 178 
5.2.3 Estimating the Basic Reproduction Number .................................................... 178 
5.2.4 Calculating the Expected Number of Cases ..................................................... 180 
5.2.5 Incorporating Temporary Cross-immunity ...................................................... 181 
Page 10 of 228 
 
5.2.6 Estimating the Global Burden of Dengue Under Different Reporting Scenarios
 182 
5.3 Results ..................................................................................................................... 183 
5.3.1 Linear and Non-linear Regression .................................................................... 183 
5.3.2 The estimated annual global burden of dengue.............................................. 186 
5.4 Discussion ................................................................................................................ 195 
5.5 Acknowledgements ................................................................................................. 198 
6 Discussion....................................................................................................................... 199 
6.1 Summary of Findings ............................................................................................... 199 
6.2 Future Work and Limitations .................................................................................. 200 
6.3 Implications of Research ......................................................................................... 203 
6.4 Conclusions.............................................................................................................. 204 
7 References ..................................................................................................................... 205 
 
  
Page 11 of 228 
 
List of figures 
Figure 1.1: Timeline of symptoms and corresponding diagnostic assays. .............................. 22 
Figure 1.2: Map showing countries at risk of dengue in 2013. ............................................... 26 
Figure 1.3: New and existing vector control methods. ........................................................... 28 
Figure 1.4: Release of insects carrying a dominant-lethal allele (RIDL). ................................. 29 
Figure 1.5: Summary of how the release of Wolbachia-infected mosquitoes affect the wild 
type population and subsequent offspring. ............................................................................ 31 
Figure 1.6: Summary of dengue vaccine candidates currently in development. .................... 33 
Figure 2.1: Flowchart describing the literature search process for dengue seroprevalence 
surveys. .................................................................................................................................... 43 
Figure 2.2: Compartmental model showing the flow of individuals in a catalytic model. ...... 44 
Figure 2.3: Compartmental model showing the flow of individuals in a catalytic model where 
individuals may lose seropositivity/antibodies. ...................................................................... 45 
Figure 2.4: A) Force of infection and B) corresponding R0i estimates from constant force of 
infection model (model A) fitted to cross-sectional non-serotype specific datasets. ............ 57 
Figure 2.5: Model fits from the constant force of infection model (model A) fit to IgG data 
(points). .................................................................................................................................... 58 
Figure 2.6: Model fits from the antibody decay model (model B) fit to IgG data (points). .... 60 
Figure 2.7: Estimated time-varying A) serotype-specific force of infection in individuals under 
the threshold age and B) R0i derived by fitting the time-varying force of infection model 
(model C) to Nicaraguan data (2001 – 2007)........................................................................... 63 
Figure 2.8: Observed (dots) and estimated (line) cross-sectional seroprevalence in Nicaragua 
from 2001 to 2007 using the age-threshold model with time-varying force of infection 
(model C). ................................................................................................................................. 64 
Figure 3.1: Serotype-specific estimates of A) force of infection, λi, and B) R0i estimates 
derived from model D2 (equal interaction) fitted to the PRNT datasets. ............................... 84 
Figure 3.2: Model fits from the multi-serotype no interaction model (D1) fit to PRNT data 
(points). .................................................................................................................................... 85 
Figure 3.3: Model fits from the multi-serotype equal interaction model (D2) fit to PRNT data 
(points). .................................................................................................................................... 87 
Page 12 of 228 
 
Figure 3.4: Model fits from the multi-serotype primary interaction model (D3) fit to PRNT 
data (points). ............................................................................................................................ 89 
Figure 3.5: Model fits from the multi-serotype secondary interaction model (D4) fit to PRNT 
data (points). ............................................................................................................................ 91 
Figure 3.6: Total force of infection (λ) estimates (for all 4 serotypes) derived from models A 
(constant force of infection), D1-D4 (no interaction, equal interaction, primary interaction, 
and secondary interaction models) fitted to PRNT datasets (treating PRNT data as IgG data).
.................................................................................................................................................. 94 
Figure 3.7: Model A (constant force of infection) fit to PRNT data (points) ........................... 95 
Figure 3.8: Scatterplots showing the relationship between estimated force of infection, and 
demographic and environmental covariates. .......................................................................... 96 
Figure 4.1: Flowchart describing the literature search process for age-stratified incidence 
data. ....................................................................................................................................... 117 
Figure 4.2: Model fits from non-serotype specific constant force of infection model (A) fitted 
to the extra seroprevalence datasets .................................................................................... 121 
Figure 4.3: Total force of infection and corresponding R0i estimates from models 1A (single 
reporting rate) fitted to yearly incidence data grouped by country. .................................... 122 
Figure 4.4:  Total force of infection and corresponding R0i estimates from models 2A (age-
dependent reporting rate) fitted to yearly incidence data grouped by country. ................. 123 
Figure 4.5: Model fits of models 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Brazil (Cordeiro et al. [193]). ............................... 137 
Figure 4.6: Model fits of models 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Brazil (Penna et al. [180]).................................... 138 
Figure 4.7: Model fits of models 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Cambodia (Vong et al. [194] and Wichmann et al. 
[195]). ..................................................................................................................................... 139 
Figure 4.8: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Laos (Anker et al., [185] Prasith et al., [196] and 
Khampapongpane et al. [197]). ............................................................................................. 140 
Figure 4.9: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from the Philippines (Anker et al. [185]). .................... 141 
Page 13 of 228 
 
Figure 4.10: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Puerto Rico (Rigau-Perez et al., [200] Ramos et al., 
[198] Tomashek et al., [199] and Sharp et al. [175]). ............................................................ 142 
Figure 4.11: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Singapore (Anker et al., [185] Koh et al., [201] and 
Ler et al. [187]). ...................................................................................................................... 143 
Figure 4.12: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Sri Lanka (Anker et al. [185]). ............................. 144 
Figure 4.13: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Thailand (Limkittikul et al. [203]). ....................... 145 
Figure 4.14: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Thailand (Wichmann et al., [195] and data from 
Bangkok, Ratchaburi, and Rayong [189]). .............................................................................. 146 
Figure 4.15: Model fits from model 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Yemen (Ghouth et al. [204]). .............................. 146 
Figure 4.16: Total force of infection and corresponding R0i estimates from model 1B (single 
reporting rate) fitted to cumulative incidence data grouped by country. ............................ 147 
Figure 4.17:  Total force of infection and corresponding R0i estimates from model 2B (age-
dependent reporting rate) fitted to cumulative incidence data grouped by country. ......... 148 
Figure 4.18: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from Brazil (Cordeiro et al., [193] Cardoso et al., 
[183] and Penna et al. [180]). ................................................................................................ 154 
Figure 4.19: Model fits of models 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from Cambodia (Vong et al. [194] and Wichmann et 
al. [195]). ................................................................................................................................ 154 
Figure 4.20: Model fits of models 1 (single reporting rate) and 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from China (Luo et al. [192] and Guo et al. [91]).155 
Figure 4.21: Model fits of model 1 (single reporting rate) and model 2 (age-dependent 
reporting rate) fitted to cumulative incidence data from Laos (Anker et al. [185]). ............ 155 
Figure 4.22: Model fits of model 1 (single reporting rate) and model 2 (age-dependent 
reporting rate) fitted to cumulative incidence data from Nicaragua (Hammond et al. [186]).
................................................................................................................................................ 156 
Page 14 of 228 
 
Figure 4.23: Model fits of model 1 (single reporting rate) and model 2 (age-dependent 
reporting rate) fitted to cumulative incidence data from the Philippines (Anker et al. [185]).
................................................................................................................................................ 156 
Figure 4.24: Model fits of model 1 (single reporting rate) and model 2 (age-dependent 
reporting rate) fitted to yearly incidence data from Puerto Rico (Rigau-Perez et al. [200]). 157 
Figure 4.25: Model fits of model 1 (single reporting rate) and model 2 (age-dependent 
reporting rate) fitted to cumulative incidence data from Singapore (Anker et al. [185] and 
Ler et al. [187]). ...................................................................................................................... 157 
Figure 4.26: Model fits from model 1 (single reporting rate) and model 2 (age-dependent 
reporting rate) fitted to cumulative incidence data from Sri Lanka (Kulatilaka et al. [202] and 
Anker et al. [185]). ................................................................................................................. 158 
Figure 4.27: Model fits from model 1 (single reporting rate) and model 2 (age-dependent 
reporting rate) fitted to cumulative incidence data from Taiwan (Lin et al. [188]). ............. 158 
Figure 4.28: Model fits from model 1 (single reporting rate) and model 2 (age-dependent 
reporting rate) fitted to cumulative incidence data from Thailand (Limkittikul et al. [203] and 
Wichmann et al. [195]). ......................................................................................................... 159 
Figure 4.29: Model fits from model 1 (single reporting rate) and model 2 (age-dependent 
reporting rate) fitted to cumulative incidence data from Vietnam (Cuong et al. [191]). ..... 159 
Figure 4.30: Boxplots of estimated reporting rates by model type ...................................... 161 
Figure 4.31: Comparison of baseline reporting rates (, Y, O ) and estimated age (years) at 
which reporting rates change (Athreshold) by model. ............................................................... 162 
Figure 4.32: Comparison of weighted deming regression of force of infection estimates by 
country from cumulative incidence data and seroprevalence data ...................................... 166 
Figure 4.33: Comparison of force of infection estimates derived from incidence data and 
seroprevalence data. ............................................................................................................. 167 
Figure 4.34: Scatterplots showing the relationship between estimated force of infection, and 
demographic and environmental covariates. ........................................................................ 168 
Figure 5.1: Linear regression of probability of occurrence on force of infection. ................. 183 
Figure 5.2: Non-linear exponential model regression of probability of occurrence on force of 
infection. ................................................................................................................................ 184 
Figure 5.3: Non-linear power model regression of probability of occurrence on force of 
infection. ................................................................................................................................ 185 
Page 15 of 228 
 
Figure 5.4: Minimum convex polygon of 5000 parameter sets randomly sampled from the 
95% confidence region of the two parameters of the power function fitted to 
seroprevalence survey results only (Fig. 5.1a). ..................................................................... 186 
Figure 5.5: Global A) probability of dengue occurrence, B) force of infection, C) R0, and D) 
observed dengue cases in 2010 at 5x5km spatial resolution. ............................................... 189 
Figure 5.6: Comparisons of the estimated burden of dengue in Africa to estimates from 
Bhatt et al. [109] and where reported, the WHO. ................................................................. 190 
Figure 5.7: Comparisons of the estimated burden of dengue in the Americas to estimates 
from Bhatt et al. [109] and where reported, the WHO. ........................................................ 191 
Figure 5.8: Comparisons of the estimated burden of dengue in Asia to estimates from Bhatt 
et al. [109] and where reported, the WHO. .......................................................................... 192 
Figure 5.9: Comparisons of the estimated burden of dengue in Europe and Oceania to 
estimates from Bhatt et al. [109] and where reported, the WHO. ....................................... 193 
Figure 5.10: Bayesian modelled relationship between the probability of occurrence and 
incidence for inapparent and apparent number of infections. Reproduced from Bhatt et al. 
[109]. The data are the points, the bold lines are the medians and the envelopes are the 
0.25, 0.5 and 0.95 credible intervals centred on the median displayed with progressively 
lighter shades. ........................................................................................................................ 196 
  
Page 16 of 228 
 
List of tables 
Table 1.1: Clinical presentation of dengue. ............................................................................. 20 
Table 1.2: Summary of virological methods available for diagnosis ....................................... 23 
Table 1.3: Summary of available serological assays ................................................................ 24 
Table 1.4: Algorithm for differentiating between primary and secondary infections. ........... 25 
Table 2.1: Summary of cross-sectional non-serotype specific datasets identified and 
associated demographics......................................................................................................... 56 
Table 2.2: Summary estimates from the fit of cross-sectional non-serotype specific datasets 
using model A (constant force of infection). ........................................................................... 59 
Table 2.3: Summary estimates from the fit of cross-sectional non-serotype specific datasets 
using model B. .......................................................................................................................... 61 
Table 2.4: Summary parameter estimates where the time-varying force of infection model 
(model C) was fitted to 7 years’ worth of cross-sectional data from Nicaragua. .................... 64 
Table 2.5: Justification of assay choice in each country where Japanese encephalitis (JE) 
cases had been previously reported. ....................................................................................... 67 
Table 3.1: Summary of PRNT surveys identified and associated demographics. .................... 83 
Table 3.2: Summary estimates of the strain-specific forces of infection (λ) and reproduction 
numbers (R0i) obtained from model D1 fitted to PRNT surveys assuming no inter-serotype 
interaction. ............................................................................................................................... 86 
Table 3.3: Summary estimates of the force of infection (λ) and serotype-specific 
reproduction number (R0i) assuming inter-serotype interactions are equal for all serotype 
combinations. Model D2 (equal interaction) fitted to PRNT data........................................... 88 
Table 3.4: Summary estimates of the force of infection (λ) and serotype-specific 
reproduction number (R0i) assuming inter-serotype interactions are dependent only on the 
primary infecting serotype. ..................................................................................................... 90 
Table 3.5: Summary estimates of the force of infection (λ) and serotype-specific 
reproduction number (R0i) assuming inter-serotype interactions are dependent only on the 
secondary infecting serotype. .................................................................................................. 92 
Table 3.6: DIC comparison of different model variants (A, D1-D4) for serotype-specific PRNT 
datasets. ................................................................................................................................... 93 
Page 17 of 228 
 
Table 3.7: Summary estimates where the constant force of infection model (A) was fitted to 
PRNT data ................................................................................................................................. 94 
Table 3.8: Weighted multiple regression results ..................................................................... 97 
Table 4.1: Incidence datasets matched to closest serology datasets by region, year, or 
country ................................................................................................................................... 116 
Table 4.2: Summary of cross-sectional incidence datasets identified and associated 
demographics. ........................................................................................................................ 119 
Table 4.3: Summary parameter estimates from four extra seroprevalence datasets .......... 120 
Table 4.4: Summary parameter estimates from model 1 fitted to yearly incidence data 
(model 1A).............................................................................................................................. 124 
Table 4.5: Summary parameter estimates from model 2 fitted to yearly incidence data 
(model 2A).............................................................................................................................. 129 
Table 4.6: Summary parameter estimates from model 1 fitted to cumulative incidence data
................................................................................................................................................ 149 
Table 4.7: Summary parameter estimates from model 2 fitted to cumulative incidence data 
by country .............................................................................................................................. 151 
Table 4.8: Summary DIC comparison of model fits to yearly incidence data. ....................... 163 
Table 4.9: Summary DIC comparison of model fits to cumulative incidence data. .............. 165 
Table 4.10: Weighted multiple regression results ................................................................. 169 
Table 5.1: Different scenarios under which the burden of dengue was calculated. ............. 182 
Table 5.2: Parameter estimates of the simple linear model and corresponding R2 values. . 183 
Table 5.3: Parameter estimates of the exponential model and corresponding 2R  values. . 184 
Table 5.4: Parameter estimates of the power model and corresponding R2 values. ............ 185 
Table 5.5: Global burden estimates and 95% CI under different assumptions. .................... 187 
Table 5.6: Comparison of R0 estimates to previously published estimates by country. ....... 188 
Table 5.7: Estimated global burden of disease (and 95% CI) with and without temporary 
cross immunity ....................................................................................................................... 194 
  
Page 18 of 228 
 
List of abbreviations and acronyms 
ADE antibody-dependent enhancement 
BRT boosted regression tree 
CDC Centers for Disease Control and Prevention 
CI confidence interval 
CrI credible interval 
DENV dengue virus 
DF dengue fever  
DHF dengue haemorrhagic fever 
DIC deviance information criterion 
DMN Dirichlet-multinomial 
DSS dengue shock syndrome 
E/M envelope/membrane 
ELISA enzyme-linked immunosorbent assay 
GDP gross domestic product  
GM genetically modified 
GPS global positioning system 
HI haemagglutination inhibition 
IE inhibition ELISA 
IgG immunoglobulin-G 
IgM immunoglobulin-M 
JEV Japanese encephalitis virus 
LnL log likelihood 
MAC-ELISA IgM antibody capture ELISA 
MH MCMC Metropolis-Hastings Markov Chain Monte Carlo  
MLE maximum likelihood estimate 
NS1 non-structural 1 
PBMC peripheral blood mononuclear cell 
PCR polymerase chain reaction 
PO probability of occurrence 
PRNT plaque reduction neutralisation test 
qPCR quantitative polymerase chain reaction 
RBC red blood cells 
RIDL release of insects carrying a dominant lethal allele 
RT-PCR reverse-transcription PCR 
SAGE Strategic Advisory Group of Experts 
SIT sterile insect technique 
TBE tick-borne encephalitis 
UN United Nations 
WHO World Health Organisation 
WNV West Nile virus 
CYD chimeric yellow fever-dengue 
YFV yellow fever virus 
Page 19 of 228 
 
1 Introduction 
1.1 Background 
Dengue viruses belong to the family Flaviviridae which include yellow fever virus (YFV), zika 
virus, West Nile (WNV), Japanese encephalitis (JEV) and tick-borne encephalitis (TBE) virus 
among others [1,2]. Dengue exists as four antigenically and genetically distinct serotypes 
(DENV-1, 2, 3, and 4) which can co-circulate. Infection with any of the four serotypes can 
result in dengue fever (DF). As a single stranded positive sense RNA arbovirus, they are 
transmitted primarily by the urban-adapted Aedes aegypti mosquito and increasingly by the 
Aedes albopictus mosquito [3–5]. Epidemiology can differ significantly between geographic 
areas – severe dengue pre-dominantly affects children in Southeast Asia in contrast to the 
Americas where disease more often manifests in adults as the milder dengue fever [6]. The 
four serotypes have shared epitopes which can be recognised by antibodies generated 
against any one of them, resulting in cross-reactive immune responses. A degree of cross-
reactivity is also observed between anti-dengue antibodies and other flaviruses, notably JEV 
and YF [7]. 
1.2 Clinical Symptoms and Natural history  
After infection by the bite of an infective mosquito, the incubation period generally lasts for 
3 – 7 days, followed by development of symptoms which can have up to 3 phases (Table 1.1) 
[4]. The clinical spectrum of dengue infection is variable, with symptoms also varying with 
patient age [8,9]. The majority of infections are asymptomatic or result in self-limited acute 
febrile illness. However a minority of infections can cause severe disease such as dengue 
haemorrhagic fever (DHF) and dengue shock syndrome (DSS) [5].  
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Table 1.1: Clinical presentation of dengue.  Adapted from [4,10]. 
 
All dengue-associated symptoms can be caused by any of the four dengue serotypes. The 
greatest risk factor for severe dengue is secondary infection by a heterologous serotype. 
The mechanism  underlying this observation is thought to be  antibody-dependent 
enhancement (ADE) [11,12], whereby antibodies against the previous dengue strain will 
enhance replication of the current strain rather than neutralise it. Upon infection by a 
second heterologous serotype, the virus-antibody complexes can activate complement 
resulting in amplification of the immune response which can enhance the infection of 
monocytic cells. The T-cell mediated lysis of virus infected cells releases cytokines and 
intracellular enzymes which in turn causes plasma leakage and DSS [13,14]. The observation 
that dengue-specific T-cells have a higher avidity for previous dengue serotypes compared 
with the infecting serotype has led to the proposal that original antigenic sin can also play a 
role in the severity of secondary infections compared to primary infections [15]. The time 
interval between primary and secondary infections also appears to play an important role in 
the risk of DHF and DSS [16]. Longer intervals leads to greater decay of dengue antibodies, 
so upon secondary infection antibodies are present at sub-neutralising titres, facilitating 
ADE which can cause normally mild infections to become life threatening [10,13,17,18]. The 
numerous but subtle genotypic variations within the dengue strains have not been 
conclusively demonstrated to have an impact on severity [4].  
 Phase  Symptoms  Comments  
Initial febrile  
(3 – 7 days)  
High temperature, vomiting, myalgias, 
joint pain, occasional transient 
maculopapular rash in children.  
Children are generally less 
symptomatic than adults in this phase. 
Classic dengue fever symptoms are 
associated with older children and 
adults.  
Critical  
(coincides with 
defervescence)  
In a small proportion of patients, 
symptoms of systemic vascular leakage 
may appear – e.g. bleeding 
manifestations and thrombocytopenia.  
If loss of plasma via leakage becomes 
critical, dengue shock syndrome can 
result. This requires urgent and careful 
fluid resuscitation. Delays can lead to 
death in 10% of cases.  
Spontaneous 
recovery  
Change in vascular permeability is 
generally transient and is followed by 
reversion to normal levels after 48-72 
hours coinciding with rapid recovery.  
Secondary rash may become apparent 
at this stage and in adults fatigue may 
persist for weeks after recovery.  
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1.3 Immunity  
Infection with one serotype is thought to be sufficient to confer protective immunity against 
subsequent infections from the same serotype [4]. However a recent study has suggested 
that there may be incomplete protection against homologous re-infection [19]. Cross-
reactive immunity is short-lived and the waning of antibody levels can facilitate ADE upon 
secondary heterologous infection increasing the risk of more severe outcomes of dengue 
such as DHF and DSS [2,4,20]. Estimates of the duration of short-term cross-protection vary 
widely: 4 months - 9 years [21], 5-12 months [22], 2 years [23], and 1-3 years [24]. However 
whether this protects against infection or clinically apparent disease is unknown and 
therefore individuals may still contribute to onward transmission [23,25–27]. The impact of 
cross-immunity on the risk of tertiary and quaternary infections remains unclear. While 
there is now evidence that tertiary and quaternary infections occur [25,28], clinically 
apparent cases are rarely reported and cannot be tested for retrospectively [25]. 
Wikramaratna et al. showed that tertiary and quaternary infections allowed for the high 
seroprevalence at very young ages observed in Haiti [29] and Nicaragua [30] better than 
when assuming complete protection after two heterologous infections [25]. However there 
is little quantitative data on the infectiousness or severity of such infections relative to 
primary and secondary infections. Therefore the contribution of tertiary and quaternary 
infections to onward transmission is not fully understood.  
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1.4 Diagnostic Methods and Limitations 
There are several laboratory assays available for the diagnosis of dengue infection. As an 
acute viral infection, the sensitivity of each assay depends on when patient samples are 
taken which may affect levels of detectable virus or detectable antibodies. Figure 1.1 
summarises the timeline of symptoms and corresponding diagnostic assays that can be used. 
 
Figure 1.1: Timeline of symptoms and corresponding diagnostic assays. Adapted from [4,20]. 
Diagnosis is largely based on clinical symptoms, but laboratory confirmation is crucial due to 
the extremely variable clinical presentation of dengue infection. The most common 
methods currently employed by diagnostic facilities are: virus isolation, serological assays to 
detect dengue-specific antibodies and antigens, and genomic detection via reverse-
transcription (RT) quantitative polymerase chain reaction (qPCR) [2,10,31]. However, as 
dengue is an acute infection with a viraemic period of only 2 – 7 days, there is a limited 
window of opportunity for virological testing [32]. As such, virological assays and case data 
will only ever identify individuals whose symptoms were severe enough to go to hospital for 
testing and individuals with poor access to healthcare will be overlooked [18]. Thus serology 
is the most widely available and utilised diagnostic method as it is less expensive and easy to 
perform. Serological methods are also not time limited (unlike virus isolation) and can 
identify individuals with prior asymptomatic infections, presenting a clearer and broader 
view of dengue epidemiology within the population [33]. However both diagnostic methods 
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come with their own set of limitations (see chapter 2). However it is important to note that 
the choice of assay will be dictated by and differ between clinical and research settings. 
1.4.1 Virological Assays  
Although dengue virus can be detected in plasma, leukocytes, and body tissues, serum is 
generally used for routine diagnosis. As a RNA virus, dengue is extremely fragile and heat 
labile, thus virological testing (Table 1.2) can be more difficult than serological methods 
[10,34]. Given the acute nature of infection, viraemia is short and samples for virological 
testing must be taken in the first 4 – 5 days of disease. Detection of viral antigens in acute 
phase serum has proved difficult due to the limited viraemic period and the presence of 
immune-complexes from previous heterologous infections. Recently assays have been 
developed that are able to detect dengue E/M antigens and the NS1 protein from the acute 
phase sera of both patients with primary and secondary infections. However antigen 
detection tests are still less reliable than other diagnostic methods currently available on the 
market [35–37]. 
Table 1.2: Summary of virological methods available for diagnosis  (Adapted from [10]). 
*Enzyme-linked immunosorbent assay, **peripheral blood mononuclear cell. 
 
1.4.2 Serological Assays  
In naïve individuals, infection produces a characteristic slow and low titre IgM response 
followed by low titres of IgG one week after the onset of disease. During a secondary 
infection, IgG titres rise rapidly and to a high level over two weeks. IgG antibodies are cross-
reactive with other flaviviruses and can be detected even in the acute phase of a secondary 
infection [32,38]. Plaque-reduction neutralisation tests (PRNTs) can be used to determine 
Assay  Method  Comments  
Virus isolation  Mosquito inoculation  The most sensitive method, however extremely 
time consuming, requiring specialist facilities 
and training.  
 Cell culture Quicker – preferred for routine diagnosis  
Viral antigen 
detection  
ELISA*  Detect viral antigens in serum and PBMCs**. 
Recent advances detect the NS1 protein on the 
viral envelope.  
Genome 
detection  
One-step RT-PCR, pan-dengue 
primer PCR, nested-PCR 
(flavivirus followed by serotype-
specific primers)  
Direct detection of the viral genome in patient 
samples. Provides accurate information on 
serotype and genotype. PCR for routine 
diagnosis can be difficult due to high costs.  
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the infecting serotype and measure the level of protective antibodies a patient has. 
However PRNTs are labour intensive and are generally not used for routine diagnosis [2]. 
The development of IgM enzyme-linked immunosorbent assays (ELISAs) for the detection of 
anti-dengue antibodies, in particular the MAC-ELISA (IgM antibody capture ELISA) has 
improved routine diagnosis, with 10% false negatives and 1.7% false positives reported [2]. 
However, there are numerous commercial kits available (Table 1.3) for detecting anti-
dengue antibodies, many of which have not been standardised. 
Table 1.3: Summary of available serological assays  (Adapted from [10,18]). 
*Red blood cells. ^Enzyme-linked immunosorbent assay. 
Of the serological assays available, IgM and/or IgG capture ELISAs and HI tests are the most 
popular. IgM/IgG ELISAs are now replacing the HI test for routine diagnosis due to their high 
sensitivity and specificity coupled with their simplicity and ease of automation [18]. As the 
primary response, IgM antibodies can be detected in serum, blood, and saliva samples taken 
5 days or more after the onset of fever [4,20]. The MAC-ELISA is a sandwich ELISA where 
human IgM is captured between anti-human-IgM antibodies and dengue-virus specific 
antigens. Current IgM ELISAs are not capable of determining the serotype due to the cross-
reactive nature of the antibodies. In addition, there is a lack of consensus on the extent of 
cross-reactivity of dengue with other flaviviruses: whilst the CDC guidelines state that there 
are issues with cross-reactivity with other flaviviruses where these pathogens co-circulate 
[39], the WHO guidelines state that cross-reactivity rarely occurs [2]. While detection of 
dengue-specific IgM antibodies by capture ELISA is indicative of active or recent infection, 
IgG ELISAs are used for the detection of past infections and use the same viral antigens as 
Assay  Method  Comments  
Haemagglutination 
inhibition assay (HI)  
(Non-serotype specific)  
Serial concentrations of 
patient serum incubated 
with RBCs* and virus.  
Presence of anti-dengue antibodies 
should inhibit virus from cross-linking 
RBCs*.  
ELISA^  
(Non-serotype specific)  
Pan-dengue IgM/IgG  Detects the presence of any anti-
dengue antibody of any serotype.  
 MAC-ELISA  IgM antibody capture ELISA, detects 
IgM vs. all serotypes.  
 IgG  Detects IgG antibodies of all serotypes  
Neutralisation tests  
(Serotype specific)  
Plaque reduction 
neutralisation test (PRNT)  
Cells are incubated with patient sera 
followed by cultured dengue virus at 
serial concentrations; presence of 
anti-dengue antibodies should prevent 
plaque formation.  
Other less utilised assays  Indirect immunofluorescent-antibody test, complement fixation. 
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the IgM ELISA. IgG ELISAs are also unable to differentiate between serotypes and are cross-
reactive with other flaviviruses [40]. These ELISAs are therefore mainly useful for diagnosing 
primary and secondary infections in paired serum samples using a simple algorithm (Table 
1.4). 
Table 1.4: Algorithm for differentiating between primary and secondary infections. Acute 
(symptomatic phase) and convalescent (post-recovery) serum samples are tested by comparing IgM 
and IgG ELISAs and their titres (typically the ratio of IgM:IgG) to determine infection type. Adapted 
from [2,18,39]. 
*ratio differs between different laboratories. + = positive test, - = negative test. 
1.4.3 Dengue Virus Serotyping  
Although the only truly accurate method of ascertaining dengue serotype requires samples 
to be taken during periods of acute viraemia, available methods for serotype-specific 
diagnosis include PRNT, viral isolation with serotype-specific monoclonal antibody 
immunofluorescence staining, and RT-PCR [33,41–43]. Among the above, PRNT is 
considered the gold standard for routine serotyping since RT-PCR (the true gold standard for 
dengue virus serotyping) remains expensive and beyond the resources of most dengue 
endemic countries [42]. However PRNTs are limited by the cross-reactivity of anti-dengue 
antibodies to multiple serotypes and other flaviviruses. Because of this, no universal 
standards have been developed for the interpretation of such PRNT data and the use of 
PRNTs to determine the infecting secondary and heterotypic serotype is generally 
discouraged [10]. The serotype with the highest titre is commonly accepted to be the (most 
recently) infecting serotype. However this may not be definitive due to original antigenic sin.  
Although attempts have been made to use E/M-specific capture IgM ELISAs to serotype 
dengue virus infection, the accuracy and reliability of such tests are still questionable [18]. 
  
Infection Type  IgM Result  IgG Result  IgM/IgG* Titre  
Acute Primary  + (convalescent)   >1 (convalescent)  
Acute Secondary  + (convalescent)   <1 (convalescent)  
 − (convalescent) + (convalescent), x4 increase 
in titre acute → convalescent  
 
Not Acute,  
Secondary  
− (convalescent)  + (convalescent), but no x4 
increase in titre 
 
Not Infected − (convalescent)  − (convalescent)   
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1.5 Current Estimates of Dengue Burden 
As of 2012, the World Health Organisation (WHO) listed dengue as the most important 
mosquito-borne viral infection worldwide. There are now more than 100 endemic countries 
(Figure 1.2) and an estimated 40% of the world’s population at risk of infection [4]. There 
has been a 30-fold increase in incidence over the past 50 years with an increasing number of 
countries reporting dengue cases for the first time [44], including in the Florida Keys in 
September 2009 [45], south-east France in 2010 [46], Madeira, Portugal in 2012 [47], and 
Tokyo, Japan in 2014 [48].  
 
Figure 1.2: Map showing countries at risk of dengue in 2013. Reproduced from [49]. 
Estimates of the global burden of dengue have ranged widely. Previously the WHO 
estimated that 2.5 billion people were at risk with 50 – 100 million infections occurring 
annually [2,50], while Beatty et al. estimated that 3.6 billion people were at risk with 34 
million DF cases and 2 million DHF cases each year [51]. The most recent estimates by Bhatt 
et al. using cartographic approaches estimated 390 million dengue infections per year (95% 
credible interval (CrI): 284 – 528), with 96 million (95% CrI: 67-136) apparent infections. This 
total estimate is more than three times the burden estimate previously quoted by the WHO 
[2,50]. 
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Accurate burden estimation is difficult, not only due to the aforementioned limitations 
associated with dengue diagnostics, but also due to differences in surveillance systems 
leading to underestimation of dengue incidence, the lack of standardised reporting 
procedures or diagnostic criteria, and the lack of integration between private and public 
sectors [52]. The WHO collates surveillance data from dengue affected countries via its 
DengueNet system, but the data are not always updated regularly and there can be 
inconsistencies with other sources (e.g. WHO regional offices or countries) of national and 
subnational data [53]. Previous studies have attempted to estimate the burden of dengue 
and associated economic costs in South East Asia and South America by calculating 
expansion factors from systematic literature reviews, collation of existing data, and 
population-based cohorts [54–57]. However, the lack of standardisation also affects the 
validity of expansion factors (calculated by dividing the cumulative incidence of dengue in 
cohort studies by that from passive data at both national and local levels) as estimates of 
underreporting. Due to the wide spectrum of clinical manifestations and the lack of routine 
laboratory testing, dengue is globally underreported and analyses of officially reported 
dengue numbers need to take this into account [58]. 
1.6 Novel Control Methods 
In their 2012 report the WHO called for the evaluation and integration of current 
interventions to achieve a 50% and 25% reduction in dengue mortality and morbidity 
respectively [44]. As previously mentioned, dengue virus is transmitted between humans 
primarily by the urban-adapted Aedes aegypti mosquito and increasingly by Aedes 
albopictus [3–5]. There are currently no commercially available antiviral drugs, and until the 
Sanofi dengue vaccine is rolled out in the majority of dengue endemic countries, or other 
dengue vaccine candidates are successfully developed [59–63], dengue prevention relies 
heavily on mosquito control [64]. Conventional vector control methods include draining of 
mosquito breeding-sites, larvicides, and biological control (Figure 1.3). Fumigation with 
insecticides is particularly common in cities; however it is costly and disruptive [2,64]. Since 
Aedes aegypti mosquitoes are daytime biters, bed nets, which are a particularly effective 
control measure against malaria are redundant. This makes novel control measures such as 
genetically modified (GM) and Wolbachia-infected mosquitoes even more important. 
 
Page 28 of 228 
 
 
Figure 1.3: New and existing vector control methods. Existing methods (top green region) and methods currently under development (bottom yellow 
region) are shown in the context of mosquito life cycle. Reproduced from Achee et al. [64]. 
Page 29 of 228 
 
1.6.1 Genetically Modified Mosquitoes 
Release of insects carrying a dominant lethal (RIDL) allele is similar to the traditional sterile 
insect technique (SIT) but in addition to GM males out-competing the wild type males, the 
male mosquitoes carry female-specific lethal genes. So GM males released into the wild will 
deliver specific female-acting transgenes into the wild population. The flightless gene results 
in the reduction of gene expression of a gene usually expressed in the flight muscle. 
Daughters of RIDL males are thus unable to fly and hence to mate or to find human hosts to 
feed on (Figure 1.4a). The late-acting lethal gene induces death in both male and female 
offspring of RIDL males either at the pupal or adult stage (Figure 1.4b). Thus both lethal 
genes will eventually result in a reduction in the wild type population and of female 
mosquitoes which are capable of transmitting the dengue virus [65,66]. Currently this RIDL 
technology has been successfully trialled in Malaysia by Oxitec Ltd. [67] and field trials have 
demonstrated an 80% and 81-95% suppression of the wild Ae. aegypti population in the 
Cayman Islands and Bahia, Brazil respectively [68,69].  
 
Figure 1.4: Release of insects carrying a dominant-lethal allele (RIDL).  Genetically modified males 
are released and mate with wild-type females. RIDL males carry a) a female-acting transgene. 
Daughters of the RIDL males carrying this transgene are flightless and thus unable to find human 
hosts, b) a late-acting lethal gene, which induces death in male and female offspring at the the pupal 
or at the adult stage. Reproduced in part from [65]. 
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1.6.2 Biological Control: Wolbachia 
The endosymbiotic bacterium Wolbachia pipientis naturally infects up to 65% of all insects. 
Wolbachia infects the gonads of their hosts resulting in trans-ovarial transmission to the 
next generation and causes reproductive changes in its host including feminisation, 
parthenogenesis, male killing, and sperm-egg incompatibility [70]. Although Wolbachia does 
not naturally infect Ae. aegypti mosquitoes, once introduced into a population by 
transinfection, the bacterium can spread rapidly due to its maternal transmission route. The 
three mechanisms currently being trialled for vector control via Wolbachia (Figure 1.5) are: 
a) the release of Wolbachia-infected males (similarly to SIT). The offspring of uninfected 
wild-type females and Wolbachia-infected males will die as embryos due to cytoplasmic 
incompatibility. If the native female mosquitoes harbour a different Wolbachia strain to that 
carried by the males, again any offspring will not be viable, b) the release of Wolbachia-
infected females that inhibit pathogen (i.e. dengue) growth. All offspring will carry the 
Wolbachia and exhibit dengue-resistant characteristics, and c) the release of females 
carrying the wMelPop strain of Wolbachia. This particular strain of Wolbachia shortens the 
lifespan of its insect host in addition to inhibiting viral replication in the mosquito. Reducing 
lifespan has a disproportionate impact on dengue transmission since only older insects 
transmit dengue [65]. Currently field trials are on-going in Australia to determine the 
capacity of Wolbachia infected mosquitoes to invade wild Ae. aegypti populations [65,71–
73]. If successful, this form of biological control could be highly cost-efficient and effective in 
the long-term given Wolbachia is self-propagating.  
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Figure 1.5: Summary of how the release of Wolbachia-infected mosquitoes affect the wild type 
population and subsequent offspring. Release of Wolbachia-infected a) males will lead to 
cytoplasmic incompatibility and embryonic death of all offspring with a wild-type female; b) females 
carrying the pathogen-blocking stain of Wolbachia will result in pathogen-resistant female offspring 
and both male and female offspring carrying Wolbachia from birth; c) females carrying the life-
shortening wMelPop strain of Wolbachia will lead to offspring with reduced lifespans that will not 
survive to transmit dengue. Reproduced in part from [65].  
 
1.6.3 Sustainability and Scalability of Novel Control Methods 
The two methods discussed – RIDL and Wolbachia control will require different numbers of 
mosquitoes to be released. With the RIDL method, multiple and numerous releases will be 
required over an indeterminate timeframe since the genetic modification cannot be passed 
on to any of the offspring. Therefore much like the SIT, island settings where elimination of 
mosquitoes is more feasible will likely benefit the most from this method. In other settings, 
constant releases may be needed in order to keep the native mosquito population 
supressed sufficiently [67,73]. In contrast, since Wolbachia infections are transmitted 
transovarially, in theory the bacteria should be able to establish itself in the native mosquito 
population without constant new releases. However this will be setting dependent since 
cytoplasmic incompatibility may lead to non-viable offspring. Additionally, after the local 
mosquito population has been eliminated, wild-type mosquitoes from a different area are 
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likely to invade the now empty niche which would require the re-release of Wolbachia-
carrying mosquitoes [70,74]. For both methods, the production of fit and competitive 
mosquitoes capable of out-competing their wild-type counterparts is crucial. Lab rearing of 
both RIDL and Wolbachia-carrying mosquitoes can quickly lead to in-breeding so the 
periodic modification or infection of wild-type mosquitoes will be essential in maintaining 
the fitness of the modified mosquitoes. Crucially, the release of any genetically or 
biologically modified organisms needs local community acceptance, so good communication 
and transparency will be vital in the implementation of such novel control methods [75,76]. 
1.6.4 Dengue Vaccine 
The recently licensed Sanofi Pasteur’s dengue vaccine (Dengvaxia®) is the first of the dengue 
vaccines in development (Figure 1.6) to have been licensed for use in a country [59]. 
Dengvaxia® is a tetravalent live-attenuated chimeric yellow fever-dengue (CYD) vaccine. 
Phase III trials have shown an overall reduction in dengue cases of 65%, an 81% reduction in 
hospitalised cases, and a 93% reduction in severe dengue cases [60,77]. However the 
vaccine is only licensed for use in children 9 years and older, with increased risk of 
hospitalised cases linked to the use of the vaccine in children under nine years of age [78]. 
Vaccine efficacy was also significantly lower in dengue naïve individuals [60,77]. However 
even under these limitations dengue vaccines can have beneficial individual-level and 
population-level effects by reducing susceptibility to infection given an infectious bite, or by  
reducing the probability of onward transmission from an infected vaccinated person to a 
mosquito. High vaccine coverage will also reduce overall transmission within a community. 
The Strategic Advisory Group of Experts (SAGE) on immunisation recently recommended 
introduction of the vaccine only in settings with high endemicity (>70% seroprevalence in 
target age group) and that the vaccine should not be given in low transmission settings 
(<50% seroprevalence in the target age group) [79].  
Although recent studies suggest that neutralising antibody titres correlate with protection 
from symptomatic infection [80], correlates of protection for an effective dengue vaccine 
are yet to be well established [81]. Given the importance of dengue immunogenicity at 
baseline prior to vaccine administration [60,61], it is vital to have robust baseline estimates 
of dengue transmission intensity and knowledge of prior dengue infections by age. 
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Figure 1.6: Summary of dengue vaccine candidates currently in development.  Reproduced from [82]. 
1GlaxoSmithKline and Walter Reed Army Institute Research. 2National Institute of Allergy and 
Infectious Diseases, US NIH: National Institutes of Health. NIAID licensed its strains to 
several developing country manufacturers on a non-exclusive basis. 3Both Butantan Institute and 
Panacea Biotech use NIAID vaccine formulation. 4US Navy Medical Research and Development. 
5Dengvaxia has been approved by Mexico, the Philippines and Brazil for 9 to 45 year olds living in 
dengue endemic areas. 
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1.7 Catalytic Models and Estimating the Force of Infection 
Transmission intensity or the force of infection (λ) is defined as the per capita rate that 
susceptible individuals acquire infection [83] and is an important indicator of the burden of 
dengue fever (or indeed any infectious disease), and a key parameter in dengue 
transmission dynamics [84]. Dengue is geographically highly heterogeneous in transmission 
intensity [85–87], so improved estimates of λ are of real value in informing the efficient 
implementation of control strategies and their subsequent evaluation and adaptation.  
The force of infection has been estimated from age-stratified case and serological data using 
catalytic models for many pathogens, most notably by Muench (1934) [83], Griffiths (1974) 
[84], Grenfell & Anderson (1985) [88], and Farrington (1990) [89]. Age-stratified data are 
important in terms of the epidemiology and transmission dynamics of infectious diseases as 
age-related changes can reveal temporal changes in the intensity of disease transmission 
within a population. Such data can generally be obtained from two sources [88]:  
1) Age-stratified case-notification data over a certain time-period.  
In countries where dengue fever is notifiable, patients at hospital with clinically 
diagnosed or laboratory confirmed dengue fever will be reported to the national 
surveillance system [90–94]. Hospital databases will also hold records of suspected 
or confirmed dengue.  
Limitations: Reporting bias with age. Cases involving young children are more likely 
to be reported than adults with the same disease. However, if notifications are 
representative of the true age-distribution class, under-reporting (if age-constant, i.e. 
age-independent) should not influence the use of proportional case reports. For 
dengue, since the majority of infections are asymptomatic, notification data will only 
detect severe cases requiring healthcare. It has been suggested that such data 
should be considered the incidence of secondary and heterotypic infections [95]. 
Access to healthcare may also bias the population that is detected by case 
notifications and this should be taken into account in developing countries where 
this may be more of an issue. Finally, the quality of such data will also be highly 
dependent on the country’s or region’s surveillance system and may not be 
generalizable [52].  
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2) Age-stratified seroprevalence surveys.  
These surveys (cohorts or cross-sectional) provide information on the proportion of 
the population that has been previously infected. If serum samples are drawn 
randomly from a population, rather than, for example: hospital outpatients, schools, 
or blood banks, seroprevalence data will provide a far more reliable source of data 
than case data as they can detect all past infections and will not be affected by 
biased reporting or surveillance systems.  
Limitations: In addition to the aforementioned problems associated with dengue 
diagnostics – as a measure of past exposure, serological data are sensitive to past 
changes in disease incidence and can vary as a result of chance variation and sample 
size. As monotypic dengue antibodies are thought to be life-long [13], the variability 
in antibody levels between older age groups will inevitably be small [96]. This may 
mask or change actual age-related changes in the data making accurate serological 
testing over a wide age range crucial. Additionally there will be issues associated 
with cross-reactivity between dengue serotypes and other flaviviruses [2,39]. 
Muench was the first to propose the use of ‘summation data’ in conjunction with a simple 
catalytic model to estimate the force of infection (λ) stating that limitations with notification 
data meant that estimations can only ever be approximations [83]. He used summation data 
to calculate the exposure rate that would effectively produce the sum of all effective 
exposures observed. He argued that by averaging the lifetime exposure rate in the same 
way that exposure rates are averaged and compared between epidemic and inter-epidemic 
years, different diseases and populations could be compared effectively [83,97]. His simple 
catalytic model assumes that the force of infection is constant i.e. both age and time 
independent. He applied this model to yellow fever data in Brazil, to compare whooping 
cough and chicken pox, and to estimate infection rates of tuberculosis [83,97]. Here he 
introduced the concept of how the effective exposure rate is based on the proportion of the 
population who may show traces of past infection. However the assumption of a constant 
force of infection only holds true if the population in question were homogeneous with 
respect to susceptibility, exposure to the pathogen, and if the infection was endemic with a 
constant incidence rate. Griffiths extended Muench’s simple catalytic model and suggested 
a catalytic linear infection model for measles notification data where the force of infection 
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was assumed to increase linearly with age between 0 – 10 years [84]. He also noted that 
95% of measles infections occur by 10 years of age, after which the force of infection 
decreases. Grenfell and Anderson further extended Muench’s and Griffith’s models using 
measles case notifications and serological data and developed a model where λ was 
modelled using a polynomial function, but allowed the data to determine the order of the 
polynomial to estimate an age-dependent force of infection assuming time-homogeneity 
[88]. Here the authors stressed that the key determinant of the type of model chosen 
should be the quality and type of data available. For case-notification data, quality is 
dependent on the surveillance system used and the associated inherent biases. For 
serological data, whether the samples are representative of the general population is a 
major limitation in addition to the time/age homogeneity that must be assumed since cross-
sectional serological surveys will only provide a picture of who was previously infected at 
one point in time [98]. 
Catalytic polynomial models allow us to examine the age-dependence of the force of 
infection and allow a fair degree of flexibility. However, although polynomials are sufficient 
to model the general characteristics of age-dependence, there are some aspects of λ that 
cannot be accurately described. For example, where seroprevalence may vary from age-to-
age due to diagnostic or sampling reasons, the non-monotonicity will result in negative 
values of λ. Furthermore, estimates of λ may increase unrealistically at older ages requiring 
λ to be estimated over certain age groups. Farrington thus imposed constraints, such as a 
positive λ, on a generalised non-linear model based on prior knowledge of the pathogens of 
interest (measles, mumps, and rubella) in order to mitigate these problems [89,99]. Finally, 
Keiding et al. developed a non-parametric model with a two-step process. The prevalence 
was first estimated using isotonic regression, then the force of infection was calculated by 
using a kernel smoother [100]. He further developed this model by replacing the kernel 
smoother with a spline-based model [101].  
It should be noted that all the catalytic models described above can be regarded as different 
types of survival analysis models if placed within a broader statistical context [102]. All have 
certain limitations. With cross-sectional seroprevalence data, models are being fitted to 
data from a specific time point giving limited ability to distinguish temporal changes in 
incidence of infection from age-related changes in exposure [97]. Importantly, age-stratified 
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data provide information on age and time-dependent changes in infectious disease 
dynamics. One is usually assumed to be constant over time in order to make conclusions 
about the other [103]. However in many infections, both factors will play a part in 
determining patterns of transmission within a population. Therefore age and time-
structured data - ideally age-stratified seroprevalence data at regular intervals are required 
to make stronger conclusions about the force of infection and gives more power to resolve 
age and time effects. Given the importance of age-related changes in the force of infection 
to the design of vaccination and disease control, it is crucial to collect finely age-stratified 
data.  
Although the main catalytic models introduced above assume that susceptible individuals 
can only be infected once in their lifetime, this condition does not hold for multi-strain 
pathogens like dengue where individuals can be infected sequentially with heterogeneous 
serotypes [20]. Ferguson et al. developed a multi-strain survival model to estimate strain-
specific forces of infection which allowed for both age and time-dependent changes in λ and 
assumed a level of varying susceptibility upon secondary infection dependent on prior 
infection history [104]. Many subsequent dengue models developed since are similar to 
Muench’s original model [83], or an adaptation of the multi-strain model by Ferguson et al. 
[104]. 
Dengue dynamics are difficult to disentangle due to the complex immunological responses 
infection can trigger. Infection with each of the four serotypes will result in protective 
immunity against the homologous strain but also a transient period of cross-protection 
against heterologous strains [105]. However as levels of antibodies decay, sub-neutralising 
antibody levels can then result in ADE upon secondary infection with a different serotype 
which may enhance transmission as well as the risk of disease [11,106,107]. This potentially 
needs to be accounted for in estimating forces of infection from serological data [104].  
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1.8 Thesis outline 
The aim of this thesis is to refine baseline estimates of dengue transmissibility from 
currently available data, and to use the methods developed to generate new estimates of 
the global burden of dengue infection and disease. This thesis is divided into 6 chapters. 
Following this introductory chapter: 
1) Chapter 2: in this chapter I collate age-stratified seroprevalence data from the 
literature and estimate the dengue transmission intensity as quantified by the force 
of infection ( )  and the basic reproduction number 0( )R  from non-serotype specific 
serological data. 
2) Chapter 3: following on from chapter 2, I estimate   and 0R  from serotype-specific 
PRNT data and ascertain whether non-serotype- and serotype-specific data can give 
comparable baseline estimates of dengue transmissibility. 
3) Chapter 4: in this chapter I collate age-stratified incidence or case-notification data 
from the literature and estimate   and 0R . I then compare estimates obtained 
from seroprevalence data to incidence data and assess whether the two types of 
data give similar estimates. 
4) Chapter 5: in this chapter I use the model developed in chapter 4 in conjunction with 
the force of infection estimates from chapters 2 and 3, and the probability of dengue 
occurrence data (University of Oxford) to calculate and map the burden of dengue 
disease globally. 
5) Chapter 6: a discussion chapter summarising the key findings of this thesis and 
placing them in the context of the challenges of dengue surveillance, control, and 
evaluation as a whole. 
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2 Estimating Dengue Transmission Intensity from Non-serotype 
Specific Seroprevalence Surveys 
Work in this chapter formed the basis of: Imai N, Dorigatti I, Cauchemez S, Ferguson 
NM (2015) Estimating Dengue Transmission Intensity from Sero-Prevalence Surveys in 
Multiple Countries. PLoS Negl Trop Dis 9(4): e0003719. doi: 10.1371/journal.pntd.0003719 
In this chapter I begin with collecting age-stratified seroprevalence data in the literature. 
The following chapter (chapter 3) also uses these collated data. Here, models are developed 
to estimate the force of infection from cross-sectional non-serotype specific seroprevalence 
surveys. 
2.1 Introduction 
Although recent estimates of the global distribution of dengue and the resulting disease 
burden have refined our understanding, estimates of global dengue distribution and 
transmission intensity (as quantified by either the force of infection    - the per capita rate 
at which susceptible individuals acquire infection, or the basic reproduction number, ( 0R )) 
remain ambiguous [108]. In particular, Bhatt et al.’s estimate of 390 million dengue 
infections per year is three times higher than previous official WHO estimates, with India 
accounting for 34% of that total [108]. Motivated by previous work on malaria, the Bhatt et 
al. analysis relied on correlating their geographic niche-modelling based estimates of 
dengue presence with burden estimates derived from serological surveys. While an 
improvement on previous approaches, the fact that dengue infection induces serotype-
specific neutralising immunity weakens the parallels with malaria, in that the maximum 
number of dengue infections an individual can experience is strictly limited (while a person 
can experience dozens of malaria infections in their lifetime). Here we argue that obtaining 
robust estimates of the geographic variation in average dengue transmission intensity – as 
quantified by 0R  (the average number of secondary cases resulting from the introduction of 
a single infectious individual into a large susceptible population [109]), of each serotype – is 
key to improving the reliability of burden estimates. In addition, a quantitative 
understanding of variation in transmission intensity is essential in assessing the likely impact 
of interventions such as vaccine [60,61] or novel vector control measures [70,74,110].  
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However, with no standardised diagnostic method, challenging clinical diagnosis (Box 1) and 
highly variable surveillance systems, there is no consistent way to estimate global dengue 
transmission [39,111,112]. Dengue transmission is geographically highly heterogeneous, 
even down to very fine spatial scales [87], however it can also be driven by temperature 
fluctuations at larger scales leading to similar patterns of transmission across wider regions 
[113]. Most model-based estimates of dengue transmission intensity and reproduction 
number have utilised case-notification data, which heavily depend on the quality of the 
surveillance system and the health infrastructure of the country in question [114–121]. 
Additionally, since the majority of dengue infections generate only mild symptoms, are 
asymptomatic, or are clinically diagnosed as a viral infection, even sensitive healthcare-
based surveillance systems substantially underestimate true rates of infection [122,123]. 
Serological data are therefore invaluable in quantifying dengue transmission, in being able 
to identify both symptomatic and asymptomatic past infections and thus quantify infection 
prevalence and incidence in the population as a whole. 
Here we utilise published age-stratified non-serotype specific seroprevalence surveys and 
estimate   and 0R for dengue in a variety of settings.  
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Box 2.1: Main issues associated with current diagnostic methods 
 Although highly accurate and sensitive, virus isolation and PCR can be time 
consuming and expensive and relies on sampling (and therefore detection) of 
symptomatic cases. 
 Routinely used serological methods - IgM and IgG ELISAs - are unable to differentiate 
between the 4 dengue serotypes and are affected by cross-reactivity with other 
flaviviruses (e.g. yellow fever or Japanese encephalitis).  
 IgG ELISAs are unable to differentiate between past, recent, and current infection [2].  
 IgM ELISAs can be confounded by false positives and are only useful for a limited 
time post-infection [124].  
 In secondary or later infections, serological diagnosis of the most recent infecting 
dengue serotype is difficult due to the presence of pre-existing cross-neutralising and 
cross-reactive antibodies [15,125].  
 Serological assay protocols (e.g. thresholds used to define seropositivity) are not 
standardised across laboratories [112]. 
 Laboratory capacity and general public health infrastructure and surveillance 
systems vary widely within and between countries. 
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2.2 Methods 
2.2.1 Literature Search 
We searched MEDLINE, EMBASE, and Web of Knowledge for publications reporting age-
stratified dengue serological surveys. Figure 2.1 describes the search process and search 
terms used. Studies published before 1980 were not included in the analysis as we were 
interested in contemporary dengue transmission. Studies reporting age-specific 
seroprevalence for at least 5 age groups were included and categorised according to the 
assay type used. Studies reporting fewer than 5 age groups were excluded as these studies 
tended to have wide age groups where the mean seroprevalence did not accurately reflect 
the variability in seroprevalence within that age group (i.e. variability in dengue 
transmission over time as a reflection of age). Data were extracted from published datasets 
where age-specific seroprevalence was tested by IgG enzyme-linked immunosorbent assays 
(ELISAs), inhibition ELISAs (IEs) or PRNTs (used in chapter 3). IgG and IE data are both non-
serotype specific and we refer to them interchangeably.  
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Figure 2.1: Flowchart describing the literature search process for dengue seroprevalence surveys. 
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2.2.2 Catalytic Models 
Data type: Single cross-sectional non-serotype specific surveys 
In the context of dengue, seroprevalence measures obtained with non-serotype specific 
assays such as IgG ELISAs only give an indication of whether an individual has ‘ever’ been 
infected and do not differentiate between infecting serotypes or identify the number of past 
infections. We assume that upon infection, individuals in age group i  move from being 
seronegative to seropositive. We denote the force of infection (also called the infection 
hazard) by  ; the proportions of the population of age a which are seronegative and 
seropositive as ( )ix a and ( )iz a , respectively (Figure 2.2). Since infection with one serotype 
only provides homologous immunity, a seropositive individual may still be susceptible to 
secondary heterotypic infection [15]. 
 
 
Figure 2.2: Compartmental model showing the flow of individuals in a catalytic model. 
 
Model A: Constant force of infection 
A simple catalytic model (model A) was fitted to the single cross-sectional IgG datasets. The 
model assumes a constant infection hazard  , with infection causing individuals of age a  to 
move from a seronegative ( )x a  to a seropositive ( )z a  state [109]. The proportion 
seropositive (IgG positive) in age group  i  at age a, ( )iz a  is given by: 
 ( ) 1 expiz a a   ,  (2.1) 
where   is the force of infection and a is the age in years. 
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Model B: Constant force of infection and antibody decay 
Since some datasets appeared to have declining seroprevalence with age, the constant force 
of infection model (model A) was extended by assuming that antibodies could decay with 
age at a rate   (Figure 2.3), moving people back to the seronegative class (model B).  
 
 
Figure 2.3: Compartmental model showing the flow of individuals in a catalytic model where 
individuals may lose seropositivity/antibodies. 
 
The proportion of IgG seropositive individuals in age group i  at age a  (in years) is then 
given by: 
(1 )
( ) .
dz
z z
da
z
 
  
  
  
 
 
(2.2) 
Assuming   and   are constant, integrating (2.2) gives: 
   
 
0 0 '
( ) 1 exp ' exp '' '
1 exp
a a a
a
z a da da da
a
    

 
 
         
      
 
           
  
 
 
(2.3) 
 
Data type: Yearly cross-sectional IgG ELISA surveys 
Model C: Time-varying force of infection with interannual variability 
Whenever yearly cross-sectional IgG data were available from the same location, a time-
varying catalytic model (model C) where the force of infection was allowed to vary over time 
was fitted to these data. Assuming the force of infection  has a constant component 0
and a time-varying component given by a sinusoidal function with periodicity T, amplitude  
and phase  : 
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.
( ) 1  si
0
n 2  
T
t
t    
   
     
   
 
. 
(2.4) 
Exposure was also allowed to change with age, by introducing a critical age critA  at which 
exposure levels change. Below that age, exposure is reduced or increased by a scaling factor 
S relative to individuals over that age. For individuals younger than the critical age 
( )crita A  the seroprevalence at age a  and time t  is given by: 
 
 
0
0
0
0
( , ) 1  exp 1  sin 2  
2   
1  exp    
2
 2  
a t u
z a t S du
T
t a
cos
TS T
S a
t
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T
   
 
 


 
    
               
     
                  
                

 
 
(2.5) 
 
For individuals aged equal to or above the critical age ( )crita A , seroprevalence is given by: 
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(2.6) 
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We estimated the force of infection ( 0 ), the periodicity (T ), amplitude ( ) and phase ( ) 
of dengue outbreaks, and the critical age ( critA ) and scale ( S ) at which exposure levels 
change.  
 
Estimation Procedure 
The constant force of infection (A), antibody decay (B), and time-varying force of infection 
models (C) were fitted to the IgG data from each available dataset using a Metropolis-
Hastings Markov Chain Monte-Carlo (MH MCMC) algorithm with a beta-binomial likelihood. 
Uniform priors were assigned to all parameters. We assumed that the probability of testing 
seropositive in each age group was beta-binomially distributed: 
 ~ , ,i i iX BetaBinomial N p   
where iN  is the total number of individuals in age group i , ip  is the probability of testing 
seropositive (or the proportion in that age group seropositive), and   represents over-
dispersion. The likelihood is given by: 
 
 
 
,
,
i i i i
i
i
N B X a N X b
L p
X B a b
   
  
 
, 
where B  is the beta function with standard arguments a  and b . We re-parameterised the 
beta distribution in terms of its mean ( m ) and variance ( v ):  /m a a b   and 
   
2
/ 1v ab a b a b    
 
 respectively. The over-dispersion parameter   was then 
defined as:  / 1v m m     . 
The beta arguments then become:  
 1/ 1a m    and   1 1/ 1b m    . 
Here we assign im p  from equations (2.1) and (2.3) for models A and B respectively, and 
equations (2.5) and (2.6) for model C, and estimate  . Substituting the above into the 
likelihood this becomes: 
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 
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. 
Ignoring the constant, the log-likelihood for one age group is: 
        
      
log 1/ 1 , 1 1/ 1
log 1/ 1 , 1 1/ 1
i i i i i i
i i
LnL p B X m N X m
B m m
 
 
      
   
 . 
So total log-likelihood across all age groups is: 
 
      
      
log 1/ 1 , 1 1/ 1
log 1/ 1 , 1 1/ 1
i i i i i
i
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B X m N X m
LnL p
B m m
 
 
     

   
   
, 
(2.7) 
where iX  is the number of individuals testing positive among those tested in age group i, 
iN  is the total number of individuals tested in age group i ,   represents the degree of 
over-dispersion, and m  is the predicted proportion of seropositive individuals in that age 
group. The predicted proportion of seropositive individuals in each age group is calculated 
by taking the average seroprevalence within each age group. For example for age group 5-9 
years, seroprevalence at each age 5, 6, 7 etc. would be computed and the mean value taken 
as the seroprevalence for that age group. 
Confidence Intervals around the Observed Seroprevalence 
Binomial proportion 95% confidence intervals (CI) were calculated for the reported 
seroprevalence in each age group i  by: 
1.96i
i
X
CI se
N
   , 
where 
    / 1 /i i i i
i
X N X N
se
N

 . 
Here iX  is the number of individuals testing positive among those tested in age group i  
and iN  is the total number of individuals tested in age group i . 
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2.2.3 Estimating the Basic Reproduction Number 
For each model, the strain-specific basic reproduction number 0iR  was estimated under 
two different assumptions: 
1) Tertiary and quaternary infections possible – here we can only analytically derive an 
expression for 0iR  in the case that there is no cross-immunity mediated interactions 
between serotypes. 
2) Individuals develop complete immunity to all dengue serotypes after secondary 
infection – in this case we can explore the different assumptions about cross-
immunity. 
Assumption 1: Tertiary and quaternary infection possible. 
When tertiary and quaternary infections are possible, we can only estimate 0iR   assuming 
there are no cross-immunity mediated interactions between serotypes. Following Ferguson 
et al. [104], the serotype–specific basic reproduction number under assumption 1 is given 
by: 
0
0
( ( ) / ) / ( ( )) 1
1 ( ') ( ', ) '
i i
i
i
d t dt t
R
f a z a t da
 



 
 , (2.8) 
where   is the reciprocal of the infectious period (1/6 days) [126,127], ( )f a  is the 
probability density function of the age distribution of the population and ( )iz a  is the 
proportion seropositive to serotype i at age a.  
For model C where the force of infection varies with time ( )t  is given by:  
0( ) 1  sin 2  
t
t
T
    
   
     
   
 
. 
(2.9) 
Assuming temporal changes in the force of infection are relatively small ( /d dt  ), for 
models A and B equation (2.8) reduces to: 
0
0
1
1 ( ') ( ') '
i
i
R
f a z a da


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(2.10) 
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Assuming that the serotypes are equally transmissible and equally prevalent (and thus that 
the force of infection for each serotype is a quarter of the overall force of infection for 
dengue when four serotypes are in circulation, ), the serotype-specific proportion of 
seropositive individuals of age a, ( )iz a , is given by equations (2.11)–(2.14) for models A – C 
respectively: 
Constant force of infection model (model A):   
( ) 1 exp
4
iz a a
 
   
 
 
 
(2.11) 
 
Antibody decay model (model B):   
4( ) 1 exp
4
4
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
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
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 
 
 
(2.12) 
Time-varying force of infection model (model C):  
For crita A :  
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(2.13) 
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For crita A : 
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Assumption 2: Complete immunity after secondary infection 
If only primary and secondary infections can occur, the assumption of no cross-immunity 
between serotypes can be relaxed. Following Ferguson et al.[104], the serotype–specific 
basic reproduction number for models A – C is then given by: 
0
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(2.15) 
Here ( , )x a t  is the proportion seronegative at age a  and time t , ji  is the relative 
susceptibility to infection of someone infected with serotype j  following infection with 
serotype i ,  and ji  is the relative infectiousness of someone infected with serotype j  
following infection with serotype i (relative to a primary infection), and other terms are as 
defined previously. We set ji 1  , and also set ji  = 1 since this parameter cannot be 
estimated from serological data alone. ( )t  is given in equation (2.9) for model C where 
the force of infection varies with time. Assuming temporal changes in the force of infection 
are relatively small ( /d dt  ), for models A-B, (2.15) reduces to: 
0
0
1
( ') ( ') ( ') '
i
ji ji jj i
R
f a x a z a da 



 
 
 
 
(2.16) 
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Expressions for ( )jz a  for models A and C are given in equations (2.17) and (2.18)-(2.19) 
respectively below: 
Constant force of infection model (model A):  
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(2.17) 
Time-varying force of infection model (model C):  
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For criticala A : 
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(2.19) 
We did not consider models combining both antibody decay (model B) and serotype 
interactions, as derivation of closed-form expressions for 0iR  proved intractable in this case.  
For all calculations, ( )f a  or the probability density function of the age distribution of the 
population was calculated from demography data corresponding to each study year – either 
from the United Nations population estimates [128], or where available the national census 
data of the corresponding study region. 
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2.3 Results 
Fifty-three studies reporting age-specific seroprevalence were identified from a total of 
15,525 potentially relevant papers (Figure 2.1). Of these, 38 used non-serotype specific 
assays including IgG and IEs. Only nine studies used PRNTs and five studies reported results 
from multiple assays. Excluding studies with less than 5 reported age groups from further 
analysis left a total of 30 surveys from 18 countries for IgG data, and 7 studies from 5 
countries for PRNT data. 28 (out of 30) surveys from 17 countries were cross-sectional IgG 
seroprevalence surveys from a single year. The remaining 2 (out of 30) surveys were 
conducted in Nicaragua and combined provided 7 years’ worth of cross-sectional non-
serotype specific data. Most IgG surveys identified were conducted in 2000 – 2010 (23/30), 
while most PRNT surveys were conducted in the 1990s (4/7). Although recent serosurveys 
used commercial diagnostics, many studies used in-house assays. Table 2.1 summarises the 
study and demographics of the datasets retained for analysis from the corresponding or 
closest year. All studies summarised in Table 2.1 were fitted using model A and B, and 
model C was also fitted to the two Nicaraguan datasets. Only an overall force of infection 
could be estimated from non-serotype specific IgG data. As expected, estimates of the force 
of infection varied widely between countries and, to a lesser extent, within countries. Table 
2.2 and Figure 2.4a show parameter estimates derived from the constant force of infection 
model (A), and Figure 2.5 show the model fits. The combined log-likelihood score for this 
model across the 28 datasets was -13206.8, while the combined log-likelihood score for the 
antibody decay model (model B) was -13086.8. Southeast Asian such as Vietnam and 
Thailand, had a higher force of infection compared with most sites in the Americas [6]. 
Corresponding estimates of 0iR  varied according to the assumptions made regarding host 
immunity (Figure 2.4b). Assuming that two heterologous infections are sufficient for 
complete immunity (Assumption 2) produced up to two-fold higher estimates of 0iR  
compared to when we assumed that quaternary infections are required for complete 
immunity (Assumption 1). However, 0iR  estimates under these two assumptions converge 
as the estimated force of infection decreases. 
The joint antibody decay rate (model B) was low when estimated across all non-serotype 
specific datasets at 0.020 (95% CrI: 0.014 – 0.030). Allowing for antibody decay slightly 
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increased the estimated force of infection for each dataset (Table 2.3). Of the non-serotype 
specific datasets examined, all 17 countries had more than one serotype in circulation in the 
past. Figure 2.6 shows model B fits.  
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Table 2.1: Summary of cross-sectional non-serotype specific datasets identified and associated demographics. 
^ Survey date not given, noted as ‘pre-year of publication’. ⁺All assays were IgG or HI ELISAs .⁻Cross-sectional surveys from multiple years (2001 – 2007).
Country Author Survey Year Region Assay Type⁺ # Serotypes  
circulating 
Participant 
Ages 
N Population size of 
study region 
(thousands) 
Rural/Urban % <15 
years 
old 
Models  
used 
Brazil Braga [129] 2005/06 Recife PanBio 4 5 - 65 2817 40 Urban 28 A and B 
Costa Rica Iturrino-Monge 
[130] 
2002/03 Puntarenas, San Jose PanBio 4 1 - 10 206 358/1373 Urban 31.5 A and B 
Dominican  
Republic 
Yamashiro [131] 2002 Santo Domingo Focus Tech 4 0 - 60 1209 1887 Urban 35 A and B 
El Salvador Hayes [132] 2000/01 Las Pampitas CDC NA 0 - 69 371 944 Rural 38 A and B 
French  
Polynesia 
Deparis [133] 1996 Teroma In-house 4 0 - 21 169 16 Urban 34 A and B 
India Padbidri [134] 1988/89 Andaman HI/N NA 0 - 40 2401 356 Rural 38 A and B 
Laos Vallée [135] 2006 Vientiane In-house 4 0 - 6 143 277 Urban 40 A and B 
 Hiscox [136]  2007/08 Khammouane HI 4 0 - 90 1708 337 Rural  A and B 
Mayotte Sissoko [137] 2006 Mayotte Focus Tech NA 2 - 55 1154 175 Whole island 41 A and B 
Mexico Brunkard [138] 2004 Matamoros PanBio 4 15 - 75 600 412 Urban 32 A and B 
 Ramos [139] 2005 Matamoros Quantitative 4 5 – 65 131 412 Urban  A and B 
Nicaragua⁻ Balmaseda [140] 2001-03 Managua IE 4 5 – 16 1971 2101 Urban 41 A and C 
 Balmaseda [30] 2004-07 Managua IE 4 2 - 9 14182 2101 Urban 38 A and C 
Pakistan Ali [141] Pre-2003^ Khyber  
Pakhtunkhawa 
Cortez NA 0 - 60 613 20000 Urban/rural 42 A and B 
 Mahmood [142]  2012 Lahore NovaTech NA 15 - 55 274 7566 Urban 35 A and B 
Papua  
New Guinea 
Senn [143] 2007/08 Madang  
Province 
PanBio NA 0 - 25 577 493 Urban/rural 39 A and B 
Peru Hayes [144]  1992 Loreto In-house  2 0 - 60 1608 9 Urban/Rural/Jungle 38 A and B 
 Reiskind [145]  1996 Santa Clara In-house 2 5 - 87 1225 2.4 Suburban 36 A and B 
Singapore Goh [146]  1984 National HI 4 0 - 40 425 2709 Urban 24 A and B 
 Yew [147] 2004 National PanBio 4 18 - 74 4152 2709 Urban 19 A and B 
 Yap [148] 2007 National PanBio 4 7 - 85 3939 2709 Urban 17 A and B 
Sri Lanka Malavige [149] Pre-2006^ Colombo district PanBio 4 6 – 18 313 2309 Urban 25 A and B 
 Tissera [150] 2008 Colombo City In-house  4 0 – 12 797 647 Urban 25 A and B 
 Tam [151] 2008 Colombo City In-house 4 0 - 12 797 647 Urban 25 A and B 
Thailand Perret [152] 2000 Bangkok In-house 4 5 – 12 283 6355 Urban 24 A and B 
 Tuntaprasart [153] 2000 Ratchaburi In-house 4 15 - 40 245 842 Urban 21 A and B 
USA Brunkard [138] 2004 Brownsville PanBio NA 15 – 75 600 139 Urban  A and B 
 Ramos [139] 2005 Brownsville Quantitative  NA 5 – 65 139 139 Urban 36 A and B 
Vietnam Bartley [154] 1996/97 Dong Thap Province PanBio 4 0 – 20 308 309 Urban/Rural 32 A and B 
 Thai [155] Pre-2005^ Binh Thuan Province MRL 4 7 - 14 961 1100 Rural 27 A and B 
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Figure 2.4: A) Force of infection and B) corresponding R0i estimates from constant force of infection 
model (model A) fitted to cross-sectional non-serotype specific datasets.  Posterior median and 95% 
credible intervals (CrI) shown. Assumption 1 = individuals can be infected four times, assumption 2 = 
individuals develop protective immunity after two infections. See end of chapter for figure 
references and ISO country abbreviations. 
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Figure 2.5: Model fits from the constant force of infection model (model A) fit to IgG data (points).  
95% exact confidence intervals around data points, posterior median (line) and 95% CrI (shaded 
area) shown. See end of chapter for figure references and ISO country abbreviations.
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Table 2.2: Summary estimates from the fit of cross-sectional non-serotype specific datasets using model A (constant force of infection). 
Country Author Force of Infection    Over-dispersion   0iR (95% CrI) LnL 
  (95% CrI) (95% CrI) Assumption 1  Assumption 2  
Brazil Braga et al.[129] 0.058 (0.050-0.080) 0.155 (0.116-0.346) 1.55 (1.47-1.80) 2.08 (1.90-2.70) -1056.2 
Costa Rica Iturrino-Monge et al.[130] 0.107 (0.086-0.197) 0.329 (0.264-0.555) 1.87 (1.68-2.73) 2.77 (2.35-4.72) -115.8 
Dominican Republic Yamashiro et al.[131] 0.117 (0.104-0.153) 0.087 (0.050-0.264) 1.84 (1.74-2.13) 2.67 (2.44-3.29) -229.9 
El Salvador Hayes et al. (2)[132] 0.099 (0.076-0.430) 0.443 (0.299-0.799) 1.82 (1.62-5.43) 2.67 (2.21-10.66) -47.6 
French Polynesia Deparis et al.[133] 0.304 (0.261-0.463) 0.044 (0.016-0.396) 3.73 (3.30-5.41) 6.90 (5.97-10.42) -51.6 
India Padbidri et al.[134] 0.002 (0.001-0.007) 0.010 (0.004-0.239) 1.01 (1.01-1.04) 1.01 (1.01-1.05) -336.4 
Laos Vallee et al.[135] 0.037 (0.030-0.076) 0.043 (0.018-0.231) 1.23 (1.18-1.48) 1.36 (1.28-1.87) -46.4 
 Hiscox et al.[136]  0.021 (0.019-0.026) 0.033 (0.022-0.126) 1.13 (1.12-1.16) 1.18 (1.16-1.23) -1093.7 
Mayotte Sissoko et al.[137] 0.010 (0.009-0.017) 0.056 (0.033-0.241) 1.06 (1.05-1.09) 1.07 (1.06-1.12) -544.6 
Mexico Brunkard et al.[138] 0.035 (0.031-0.047) 0.093 (0.061-0.300) 1.23 (1.21-1.32) 1.37 (1.32-1.55) -286.3 
 Ramos et al.[139] 0.037 (0.030-0.059) 0.133 (0.073-0.439) 1.24 (1.20-1.41) 1.40 (1.31-1.74) -78.2 
Pakistan Ali et al.[141] 0.007 (0.006-0.016) 0.063 (0.035-0.308) 1.05 (1.04-1.10) 1.05 (1.05-1.14) -302.0 
 Mahmood et al.[142]  0.033 (0.030-0.044) 0.040 (0.018-0.253) 1.22 (1.19-1.29) 1.34 (1.30-1.49) -174.7 
Papua New Guinea Senn et al.[143] 0.222 (0.175-0.357) 0.116 (0.053-0.521) 2.55 (2.19-3.58) 4.11 (3.39-6.15) -175.7 
Peru^ Hayes (1) et al.[144]  0.037 (0.034-0.048) 0.061 (0.042-0.189) 1.37 (1.34-1.51) 1.37 (1.34-1.51) -828.1 
 Reiskind et al.[145]  0.013 (0.013-0.016) 0.014 (0.007-0.083) 1.11 (1.11-1.14) 1.11 (1.11-1.14) -675.7 
Nicaragua* Balmaseda et al.[30,140] 0.218 (0.214 – 0.223) 0.016 (0.009 – 0.028) 3.22 (3.16 – 3.27) 6.42 (6.27 – 6.58) -8184.2 
Singapore Goh et al.[146]  0.055 (0.047-0.086) 0.229 (0.166-0.507) 1.43 (1.37-1.71) 1.80 (1.65-2.47) -143.4 
 Yew et al.[147] 0.023 (0.020-0.035) 0.147 (0.099-0.422) 1.21 (1.18-1.34) 1.33 (1.27-1.59) -2273.7 
 Yap et al.[148] 0.027 (0.025-0.033) 0.041 (0.027-0.146) 1.26 (1.25-1.33) 1.44 (1.40-1.57) -2084.4 
Sri Lanka Malavige et al.[149] 0.040 (0.037-0.053) 0.034 (0.018-0.139) 1.35 (1.31-1.47) 1.61 (1.54-1.88) -206.8 
 Tissera et al.[150] 0.134 (0.118-0.202) 0.160 (0.124-0.320) 2.24 (2.06-2.99) 3.69 (3.28-5.35) -509.7 
 Tam et al.[151] 0.128 (0.120-0.154) 0.026 (0.015-0.089) 2.17 (2.09-2.45) 3.53 (3.35-4.18) -504.8 
Thailand Perret et al.[152] 0.112 (0.092-0.166) 0.120 (0.050-0.607) 2.16 (1.91-2.91) 3.79 (3.08-5.98) -46.8 
 Tuntaprasart et al.[153] 0.137 (0.127-0.175) 0.038 (0.019-0.175) 2.43 (2.30-2.92) 4.26 (3.93-5.42) -175.0 
USA (Texas) Brunkard et al.[138] 0.010 (0.009-0.016) 0.086 (0.056-0.279) 1.08 (1.07-1.12) 1.10 (1.09-1.17) -381.9 
 Ramos et al.[139] 0.011 (0.009-0.026) 0.226 (0.149-0.578) 1.09 (1.07-1.21) 1.12 (1.08-1.32) -84.1 
Vietnam Bartley et al.[154] 0.142 (0.129-0.184) 0.088 (0.056-0.243) 2.12 (2.02-2.50) 3.36 (3.09-4.23) -147.0 
 Thai et al.[155] 0.112 (0.101-0.153) 0.093 (0.063-0.285) 2.02 (1.91-2.45) 3.19 (2.92-4.27) -606.3 
^Only 2 serotypes in circulation, calculation adjusted accordingly, i.e. assuming complete immunity upon secondary infection (assumption 2). Assumption 1: tertiary and quaternary infections 
possible, assumption 2: complete protection after secondary infection. 
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Figure 2.6: Model fits from the antibody decay model (model B) fit to IgG data (points). 95% exact CI 
around data points, posterior median (line) and 95% CrI (shaded area) shown. See end of chapter for 
figure references and ISO country abbreviations.
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Table 2.3: Summary estimates from the fit of cross-sectional non-serotype specific datasets using model B.  All the non-serotype specific datasets were 
fitted together using the antibody decay model (model B) to estimate an overall shared antibody decay rate.  
*Assumption 1: tertiary and quaternary infections possible. Global log-likelihood = -13086.8.
Country Author  (95% CrI)   (95% CrI)   (95% CrI) 
0iR  Assumption 1* 
LnL 
Brazil Braga et al.[129] 0.020 
(0.014 – 0.030) 
0.203 (0.161 – 0.267) 0.010 (0.001-0.039) 2.32 (2.07-2.60) -1063.0 
Costa Rica Iturrino-Monge et al.[130] 0.115 (0.072 – 0.178) 0.158 (0.046-0.375) 1.59 (1.36-1.95) -116.3 
Dominican Republic Yamashiro et al.[131] 0.186 (0.128 – 0.258) 0.164 (0.067-0.326) 1.89 (1.60-2.26) -306.3 
El Salvador Hayes et al. (1)[132] 0.702 (0.217 – 0.986) 0.150 (0.015-0.596) 5.11 (2.20-7.21) -332.2 
French Polynesia Deparis et al.[133] 0.356 (0.172 – 0.811) 0.131 (0.010-0.529) 2.93 (1.89-5.47) -41.6 
India Padbidri et al.[134] 0.002 (0.001 – 0.009) 0.007 (0.000-0.251) 1.01 (1.01-1.04) -42.2 
Laos Vallee et al.[135] 0.038 (0.021 – 0.068) 0.019 (0.001-0.134) 1.16 (1.09-1.30) -204.6 
 Hiscox et al.[136]  0.037 (0.028 – 0.053) 0.025 (0.006-0.108) 1.16 (1.13-1.22) -492.7 
Mayotte Sissoko et al.[137] 0.017 (0.010 – 0.031) 0.071 (0.019-0.288) 1.07 (1.04-1.12) -478.3 
Mexico Brunkard et al.[138] 0.098 (0.058 – 0.179) 0.058 (0.013-0.219) 1.47 (1.28-1.82) -537.9 
 Ramos et al.[139] 0.090 (0.049 – 0.187) 0.044 (0.001-0.288) 1.43 (1.23-1.88) -388.8 
Pakistan Ali et al.[141] 0.011 (0.007 – 0.021) 0.036 (0.003-0.245) 1.05 (1.03-1.10) -89.6 
 Mahmood et al.[142]  0.060 (0.041 – 0.097) 0.022 (0.001-0.200) 1.28 (1.19-1.43) -296.5 
Papua New Guinea Senn et al.[143] 0.451 (0.224 – 0.792) 0.053 (0.002-0.346) 3.11 (2.02-4.69) -172.9 
Peru Hayes (2) et al.[144]  0.065 (0.040 – 0.116) 0.149 (0.062-0.344) 1.58 (1.36-1.99) -951.6 
 Reiskind et al.[145]  0.022 (0.017 – 0.030) 0.018 (0.002-0.099) 1.20 (1.16-1.27) -692.9 
Singapore Goh et al.[146]  0.089 (0.046 – 0.185) 0.441 (0.219-0.709) 1.48 (1.24-2.04) -176.3 
 Yew et al.[147] 0.040 (0.019 – 0.091) 0.240 (0.099-0.532) 1.24 (1.12-1.56) -68.5 
 Yap et al.[148] 0. 051 (0.031 – 0.090) 0.167 (0.072-0.373) 1.32 (1.19-1.56) -2765.2 
Sri Lanka Malavige et al.[149] 0. 046 (0.036 – 0.060) 0.025 (0.001-0.113) 1.26 (1.20-1.35) -2767.6 
 Tissera et al.[150] 0. 144 (0.125 – 0.166) 0.006 (0.000-0.0345) 1.81 (1.67-1.96) -2440.3 
 Tam et al.[151] 0. 140 (0.127 – 0.160) 0.004 (0.000-0.025) 1.78 (1.65-1.93) -42.3 
Thailand Perret et al.[152] 0.414 (0.116 – 0.942) 0.139 (0.024-0.556) 3.96 (1.72-8.33) -288.1 
 Tuntaprasart et al.[153] 0. 157 (0.118 – 0.204) 0.033 (0.002-0.164) 1.96 (1.69-2.28) -71.9 
USA (Texas) Brunkard et al.[138] 0. 018 (0.011 – 0.030) 0.071 (0.017-0.258) 1.09 (1.06-1.15) -51.1 
 Ramos et al.[139] 0.020 (0.008 – 0.057) 0.215 (0.055-0.568) 1.10 (1.01-1.30) -19.8 
Vietnam Bartley et al.[154] 0.166 (0.117 – 0.232) 0.120 (0.036-0.293) 1.85 (1.57-2.21) -158.8 
 Thai et al.[155] 0.135 (0.105 – 0.176) 0.035 (0.005-0.164) 1.76 (1.58-2.01) -607.5 
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With age-structured serosurvey data from multiple sequential years (as was available for 
Nicaragua), it was possible to estimate temporal and age-specific changes in exposure 
[30,140] (Figure 2.7a). Model C which allowed for the force of infection to vary sinusoidally 
over time and to change at (fitted) age threshold was fitted to those data. Table 2.4 
summarises the estimated parameter values and Figure 2.8 show the model fits. We 
estimated that exposure increased in individuals over 3.9 years old (95% CrI: 2.7 – 5.4 years), 
with the estimated force of infection during the study period (2001 – 2007) being 0.323 
(95% CrI: 0.261 – 0.377) above 3.9 years and 0.174 (95% CrI: 0.118 – 0.280) below 3.9 years. 
These estimates represent the average total force of infection for all four serotypes in 
circulation. The force of infection was estimated to vary with a period of 8.8 years (95% CrI: 
1.3 – 12.5 years). Resulting estimates of 0iR  (Figure 2.7b) showed the same dependence on 
immunity assumptions as the point estimates derived from single serosurveys (Figure 2.4), 
but interestingly showed less temporal variation than the force of infection estimates 
(Figure 2.7a). 
Page 63 of 228 
 
 
Figure 2.7: Estimated time-varying A) serotype-specific force of infection in individuals under the 
threshold age and B) R0i derived by fitting the time-varying force of infection model (model C) to 
Nicaraguan data (2001 – 2007). Posterior median and 95% CrI shown. Assumption 1: individuals can 
be infected up to four times, assumption 2: individuals develop protective immunity after their 
second infection.  
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Table 2.4: Summary parameter estimates where the time-varying force of infection model (model C) 
was fitted to 7 years’ worth of cross-sectional data from Nicaragua.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Observed (points) and estimated (line) cross-sectional seroprevalence in Nicaragua from 
2001 to 2007 using the age-threshold model with time-varying force of infection (model C).  95% 
exact confidence intervals around data points, posterior median (line) and 95% CrI (shaded area) 
shown. 
  
Parameter Name Median Estimate (95% CrI) LnL 
Force of infection   0.323 (0.261 – 0.377) -7848 
Amplitude   0.360 (0.072 – 0.670) 
Phase   0.392 (0.015 – 0.990) 
Periodicity (yrs) T  8.8 (1.3 – 12.5) 
Scaling of for those under 
critical age threshold relative 
to those over that threshold 
S  0.54 (0.39 – 0.84) 
Critical age (yrs) threshold at 
which   assumed to change 
criticalA  3.9 (2.7 – 5.4) 
Over-dispersion    0.016 (0.009 – 0.028) 
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2.4 Discussion 
From a literature review, we selected 30 studies reporting age-structured seroprevalence 
data obtained with IgG/IE assays in 18 different locations from 1980 to 2010. From each 
dataset, we estimated dengue transmission intensity, quantified by λ and 0iR . Overall, our 
estimates highlight the highly heterogeneous nature of dengue transmission in both space 
and time. This analysis also highlights how the relationship between the force of infection 
and 0iR  is affected by underlying assumptions about serotype interactions and immunity. 
The majority of our estimates of 0iR  from 18 countries ranged from 1 – 4 (28 out of 28 and 
24 out of 28 from the constant force of infection model (model A) fitted to IgG datasets 
under assumption 1: individuals can be infected four times, and 2: individuals develop 
protective immunity after two infections, respectively).  
Dengue epidemiology differs between the Americas and Southeast Asia. Severe dengue 
predominantly affects children in Southeast Asia in contrast to the Americas where disease 
more often manifests in adults as the milder dengue fever [6]. However the changing 
demographics in Thailand (lower birth and death rates) have increased the average age of 
DHF suggesting that the epidemiology will continue to evolve [121]. However with the cross-
sectional data used in this analysis it is difficult to determine whether the higher force of 
infection in South East Asia is a reflection of the length of time dengue has been in 
circulation. The recent Phase III dengue vaccine trial conducted in several countries in Latin 
America showed that the forces of infection are highly heterogeneous across Latin America, 
with some countries comparable to South East Asia (Columbia and Honduras) and others 
having much lower forces of infection (Mexico and Puerto Rico) [77]. However, multiple 
cross-sectional surveys or cohort studies would be needed to estimate how forces of 
infection by age have changed over time. The low 0iR  estimated in the Indian subcontinent 
is probably due to the lack of datasets from this region and the spatial heterogeneity of 
transmission within that large region. The one serosurvey from India used in our study was 
conducted in Andaman, an island with a low population density where we estimated a very 
low force of infection. It is likely that the epidemiology of dengue on Andaman is not 
representative of dengue epidemiology on the mainland.  
Page 66 of 228 
 
Seroprevalence surveys have the benefit of not being affected by surveillance system 
sensitivity or case reporting rates, but still have several limitations (Box 1) [10,31]. A 
particular issue is the wide variation in the assays used between studies (Table 2.1). 
Optimally, one would assess the sensitivity of transmission intensity estimates to factors 
that varied between assays, such as the threshold used to define seronegativity. However, 
such an analysis requires access to the raw titer data which was not provided in any of the 
publications reviewed here. Additionally, seroprevalence surveys sometimes use serum 
samples collected for a different purpose and therefore may not be representative of the 
population. Six out of the 31 studies used such samples: from blood banks [131], ante-natal 
clinics [152], hospitals [143,146,156], or residual samples from a different study [154]. Use 
of convenience samples can increase the volume of serological data produced, but the 
potential biases such sampling introduces must be taken into account when analysing such 
data. Cross-reactivity with Japanese encephalitis and other flaviviruses such as zika virus can 
also be an issue with IgG assays. Of the studies included in this chapter, there were 6 
countries where Japanese encephalitis cases had occurred in the past (Laos, Sri Lanka, India, 
Vietnam, and Singapore). Table 2.5 summarises each author’s justification (where available) 
in their chosen assay in their study context. 
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Table 2.5: Justification of assay choice in each country where Japanese encephalitis (JE) cases had 
been previously reported. 
 
Although we can only estimate a total force of infection across all serotypes from non-
serotype specific data (such as surveys using IgG ELISA assays), such data are still sufficient 
for assessing heterogeneity in overall dengue transmission intensity between different 
populations. It is not possible to disentangle temporal from any age-dependent variation in 
exposure from single cross-sectional seroprevalence surveys, requiring broad assumptions 
to be made about such variation. Hence, for simplicity, we generally assumed constant 
transmission intensity over time when analysing single cross-sectional surveys. However, for 
Nicaragua [30,140], data from multiple sequentially conducted serosurveys were available, 
so we were able to estimate time and age-dependent changes in the force of infection. We 
found evidence of long term variation in transmission intensity over a timescale of 1-12 
Country Ref Justification 
Singapore Goh et al. 
Yew et al. 
Yap et al. 
[146–148] 
Although the PanBio ELISA can be cross-reactive with JE, the 
incidence of JE in Singapore is very low in comparison to dengue 
which is endemic. They therefore concluded that the impact of false 
positives on the observed dengue seroprevalence would be 
minimal. 
Sri Lanka Tam et al. 
[151] 
Specifically tested how the seropositivity against JE would affect 
dengue estimates using JE vaccination history as a proxy. They 
found no evidence for JE having an effect and conclude that the 
majority of past infections detected by the ELISA were dengue. 
 Malavige et al. 
[149] 
Cite the high specificity and sensitivity of the PanBio assay making it 
unlikely that JE was affecting the results, but go on to specify that 
false positives cannot be completely ruled out. 
 Tissera et al. 
[150] 
Surveyed in a known dengue area and so state that the impact of JE 
would be minimal. 
India Padbidri et al. 
[134] 
Tested samples in conjunction with neutralizing antibodies and so 
cross-reactivity with JE can be ruled out. 
Thailand Perret et al. 
[152] 
Tested all samples with IgM and IgG ELISAs for JE as well and 
excluded cross-reactivity in dengue positive samples by calculating 
the ratio between JE and dengue IgG antibody. 
 Tuntaprasart 
et al. [153] 
Conducted a post-outbreak survey and therefore contribution of JE 
is likely to be minimal. 
Laos Vallee et al. 
[135] 
Authors differentiate between recent JE and dengue infection. 
However they are unable to differentiate past infections. However 
they state that dengue infections appeared to be more frequent 
than JE. 
 Hiscox et al. 
[157] 
Authors categorized their results as: if a sample was positive for 
both JE and dengue this was considered flavivirus positive. If the 
sample produced a 2-fold higher titre to the homologous virus they 
were categorized as DENV positive or JEV positive only. 
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years, and that exposure levels changed with age, with children aged 4 or older having twice 
the exposure of those under that age. We suspect that this may be associated with school 
attendance, with children spending more time away from home leading to an increase in 
exposure if the majority of transmission is occurring outside the domestic environment 
[158]. This school-cohort effect has also been observed in Sri Lanka, conversely with a 
decrease in exposure, where Tam et al. estimated an age-varying force of infection of 0.154 
(95% CI: 0.132 – 0.177) for 0.5 – 6 year olds and 0.087 (95% CI: 0.020 – 0.154) for children 
aged 6 years and above also demonstrating the existence of different transmission 
environments [151]. 
In the next chapter (chapter 3) I compare the estimates obtained from IgG data to estimates 
derived from serotype-specific PRNT data and summarise the issues associated with cross-
sectional seroprevalence data and discuss the limitations of this analysis. In addition, a 
simple regression is used to explore the impact that potential environmental and 
demographic covariates have on the estimated force of infection. 
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ISO 3 letter code Country 
BRA Brazil 
CRI Costa Rica 
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PAK Pakistan 
PER Peru 
PNG Papua New Guinea 
PYF French Polynesia 
SGP Singapore 
SLV El Salvador 
THA Thailand 
USA United States of America 
VNM Vietnam 
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3 Estimating Dengue Transmission Intensity from Serotype-specific 
Seroprevalence Surveys and a Comparison of Data Types 
Work in this chapter formed the basis of: Imai N, Dorigatti I, Cauchemez S, Ferguson 
NM (2015) Estimating Dengue Transmission Intensity from Sero-Prevalence Surveys in 
Multiple Countries. PLoS Negl Trop Dis 9(4): e0003719. doi: 10.1371/journal.pntd.0003719 
In this chapter I use the cross-sectional serotype-specific PRNT data identified in chapter 2 
and apply a multistrain model to estimate the serotype-specific force of infection. Re-
analysing the PRNT data as non-serotype specific data allows us to compare how useful less 
expensive assays can be. I then summarise the limitations of analysing seroprevalence data. 
3.1 Introduction 
In the previous chapter (chapter 2) I analysed data from non-serotype specific IgG ELISAs 
used in less expensive cross-sectional surveys. In this chapter I use serotype-specific 
seroprevalence data from PRNTs, which are considered the current gold standard for non-
acute routine dengue serotyping (PCR for acute serotyping), to estimate strain-specific 
forces of infection. Due to the much lower costs, future seroprevalence studies are still 
likely to depend on IgM or IgG ELISAs rather than the more labour intensive PRNTs. Here I 
compare the estimates derived from IgG, IE and PRNT data to determine the usefulness of 
less expensive assays. 
3.2 Methods 
3.2.1 Literature Search 
The literature was searched for age-stratified seroprevalence surveys since 1980 and data 
were extracted from published datasets where age-specific seroprevalence was tested by 
PRNTs. The search process is described in detail in chapter 2.  
3.2.2 Catalytic Models 
Data type: Cross-sectional PRNT surveys 
Since dengue viruses exist as four distinct serotypes, individuals may be seropositive for one 
serotype but seronegative for the other three serotypes. For example an individual may 
have a primary infection with DENV-1 (DENV-1 seropositive), and then upon secondary 
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infection with e.g. DENV-2, that individual becomes DENV-2 seropositive, still remaining 
DENV-1 seropositive. In order to fit serotype-specific PRNT data, we applied the multi-strain 
catalytic model developed by Ferguson et al. [104]. Different model variants (model D1 – 
D4) were assessed as described below, which explored different assumptions on serotype 
interactions.  
Moreover, for comparison purposes, we fitted the same PRNT data to model A (constant 
force of infection model described in chapter 2), having defined individuals with PRNT titres 
below the detection limit for all four dengue serotypes as seronegative and individuals with 
at least one PRNT titre over the detection limit as seropositive. Since assays differed 
between surveys, here the detection limit also varied from study to study. The data were 
fitted to model A as described in chapter 2. 
Model D1 (no interaction): No interaction between circulating serotypes 
Here we assume complete serotype independence. We assumed absence of antibody-
dependent enhancement (ADE), no cross-protection, no change in susceptibility and no 
change in transmissibility following primary infection. 
Under these assumptions the proportion seronegative against all dengue serotypes, ( , )x a t  
is given by: 
 
0
0
,
1 sin 2
cos 2 cos 2
2
( , ) exp
exp
exp
a
jj
a
jj
i
jj
a t d
t
d
T
T t a t
a
T T
x a t    

    

    

   
  
     
       
    
          
               
          






  
  
  
Page 75 of 228 
 
The proportion seropositive against strain i only is given by: 
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, 
(3.1) 
where i  is the force of infection of strain i ,T  is the periodicity in years,   is the amplitude, 
  is the phase, t  is the chronological time in years and a  is the age in years. 
 
Models D2-D4: Assuming interaction between serotypes 
The following models assume interaction between serotypes mediated by cross-immunity. 
We define ij  to be susceptibility of an individual to infection with serotype j following 
infection with serotype i , relative to the susceptibility of an individual who has never been 
infected with dengue.  
Ferguson et al. [104] showed that the proportion of the population at age a  and time t , 
seropositive for strain i  and seronegative for each other serotype j  in circulation, ( )j i , 
( , )iw a t , is given by: 
0 0
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a
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w a t x a t a t a t d d
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, 
(3.2) 
where we assume that the force of infection is given by: 
( , ) 1 sin 2i i
t
a t
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(3.3) 
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Substituting the definition of the force of infection given in equation (3.3) into equation 
(3.2) we obtain: 
0
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, 
(3.4) 
where i  is the force of infection of strain i ,T  is the periodicity in years,   is the amplitude, 
  is the phase, t  is the chronological time in years and a  is the age in years. 
Finally, evaluating the integral between 0 and a gives: 
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(3.5) 
Here  ,x a t  is the proportion seronegative (completely unexposed to any strain of dengue), 
which is explicitly given by: 
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Model D2 (equal interaction): We assume that susceptibility enhancement-inhibition ij  is 
identical for all strain combinations. We estimate 5 parameters: a force of infection for each 
serotype i ( 1,...,4)i  and one susceptibility parameter ij   for all , 1,...,4i j  . 
Model D3 (primary interaction): We assume that susceptibility enhancement-inhibition is 
dependent only on the primary infecting strain ( )i  . We estimate 8 parameters: a force of 
infection for each serotype i  and a susceptibility enhancement-inhibition term for each 
primary infecting serotype i  . 
Model D4 (secondary interaction): We assume that susceptibility enhancement-inhibition is 
dependent only on the secondary infecting strain ( )j . We estimate 8 parameters: a force 
of infection for each serotype i and a susceptibility enhancement-inhibition term for each 
secondary infecting serotype j . 
 
Estimation Procedure 
Given a seroprevalence survey of N individuals at time 0t , the kN  individuals in each age 
class k can be classified into: xkn  the number unexposed (seronegative against any strain, 
PRNT < cut off defined in the study), ikn  the number monotypically exposed against 
serotype i  (PRNT for serotype i > cut off defined and PRNT < cut off defined in the study for 
the remaining serotypes), and ( –   )k xk i ikN n n   multi-typically exposed (PRNT > cut off 
defined in the study for 2 or more serotypes). The multinomial log-likelihood is then given 
by: 
 0 0
1
0 0
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xk k ik i k k xk ikm i i
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,  
(3.6) 
where the proportion seropositive and seronegative in each age group was calculated by 
taking the average seroprevalence within each age group. For example, for age group 5-9 
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years, seroprevalence at each age 5, 6, 7 etc. would be computed and the mean value taken 
as the seroprevalence for that age group.  
Models D1 – D4 were fitted to PRNT data using the MH-MCMC algorithm using the 
multinomial log-likelihood defined in equation (3.6). Since the available PRNT data are all 
cross-sectional seroprevalence surveys from a single year, we assume no seasonality and set 
0  . For the constant force of infection model (model A) fitted to the re-defined PRNT 
data a beta-binomial likelihood was defined as described previously (chapter 2). All models 
were fitted using the R Statistical Package (version 3.1.0) [159]. 
 
Deviance Information Criterion (DIC) 
Goodness of fit of each model variant was assessed using the DIC calculated by: 
ˆ 2D pD C DI   , 
where Dˆ  is the deviance at the posterior mean:  
 og |ˆ 2lD P data      . 
pD  is the effective number of parameters calculated as the difference between the 
deviance of the posterior mean  D  and the deviance at the posterior mean  Dˆ . 
  ˆpD D D  , 
where  2log |D P data      . 
 
3.2.3 Estimating the Basic Reproduction Number, R0 
For the PRNT data, since we were able to estimate serotype-specific forces of infection, we 
estimated strain-specific reproduction numbers ( 0iR ) as described by Ferguson et al. [104]. 
For the constant force of infection model (model A) fitted to PRNT data, methods are 
described in chapter 2. As in chapter 2, for each model we estimated 0iR  under two 
different assumptions: 
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1. Tertiary and quaternary infections possible – here we can only analytically derive an 
expression for 0iR  in the case that there are no cross-immunity mediated 
interactions between serotypes. 
2. Individuals develop complete immunity to all dengue serotypes after secondary 
infection – in this case we can explore different assumptions about cross-immunity.  
Assumption 1: Tertiary and quaternary infection possible. 
When tertiary and quaternary infections are possible, we can only estimate 0iR  assuming 
there are no cross-immunity mediated interactions between serotypes. Thus estimates 
cannot be derived for models D2-D4 (equal interaction, primary interaction, and secondary 
interaction models). 
Following Ferguson et al. [104], the serotype–specific basic reproduction number under 
assumption 1 is given by: 
0
0
( ( ) / ) / ( ( )) 1
1 ( ') ( ', ) '
i i
i
i
d t dt t
R
f a z a t da
 



 
 
, 
(3.7) 
where   is the reciprocal of the infectious period (1/6 days) [126,127], ( )f a  is the 
probability density function of the age distribution of the population and ( )iz a  is the 
proportion seropositive to serotype i at age a. Assuming temporal changes in the force of 
infection are relatively small ( /d dt  ), for model D1 equation (3.7) reduces to: 
0
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1 ( ') ( ') '
i
i
R
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 
   
The serotype-specific proportion of seropositive individuals of age a, ( )iz a , for model D1 
(no interaction) is given by: 
 ( ) 1 expi iz a a     (3.8) 
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Assumption 2: Complete immunity after secondary infection 
If only primary and secondary infections can occur, we can relax the assumption of no cross-
immunity between serotypes. Following Ferguson et al.[104], the serotype–specific basic 
reproduction number for the no interaction, equal interaction, primary interaction, and 
secondary interaction models (D1 – D4) is given by: 
0
0
( ( ) / ) / ( )) 1
( ') ( ', ) ( ', ) '
i i
i
ji ji jj i
d t dt t
R
f a x a t w a t da
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 
 
Here ( , )x a t  is the proportion seronegative at age a and time t and ji  is the relative 
infectiousness of someone infected with serotype j  following infection with serotype i
(relative to a primary infection), and other terms are as defined previously. We set ji  = 1 
since this parameter cannot be estimated from serological data alone. Assuming temporal 
changes in the force of infection are relatively small ( /d dt  ), this reduces to: 
0
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For model D1 (no interaction) we set ji 1  , while for models D2 (equal interaction), D3 
(primary interaction), and D4 (secondary interaction) we estimate the interaction 
parameters ji . For models D1 and D2-D4 the proportion of population seropositive for 
strain j only are given in equation (3.5).  
For all calculations, ( )f a  or the probability density function of the age distribution of the 
population was calculated from demography data corresponding to each study year – either 
from the UN population estimates [128], or where available the national census data of the 
corresponding study region. 
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3.2.4 Multiple Linear Regression 
A weighted regression analysis was used to explore the relationship between the   values 
(estimated from the constant force of infection model (model A) fitted to the non-serotype 
specific seroprevalence data in chapter 2, and the   values estimated from model A fit to 
the serotype-specific PRNT data re-categorised as IgG data) and a number of environmental 
and demographic covariates (equation (3.9)). 
0 1 2 max 3 4 5 6absLat T P N G U               , (3.9) 
where   is the force of infection, absLat  is the absolute latitude, maxT  is the average 
maximum temperature, P  is the population size of the study region, N  is the total number 
of individuals sampled, G  is the GDP per capita (USD), and U  is whether the study was 
conducted in an rural or urban area (0=rural, 1=urban). Data on each covariate was 
extracted from the source publication, United Nations estimates [128], or World Bank 
estimates [160]. The model was weighted according to the variance of the   estimates 
(weights = 1/variance of the posterior distribution). The model was fitted in the R Statistical 
Package (version 3.1.0) [159]. 
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3.3 Results 
3.3.1 Parameter Estimates 
Of the 53 studies reporting age-specific seroprevalence identified in chapter 2, only nine 
studies used PRNTs. Excluding studies with fewer than 5 reported age groups from further 
analysis left a total of 7 studies from 5 countries, conducted mostly in the 1990s (4 of 7). 
Table 3.1 summarises the study and demographics of the datasets retained for analysis from 
the corresponding or closest year. Model A (constant force of infection) and models D1 – D4 
(no interaction, equal interaction, primary interaction, and secondary interaction) were 
fitted to studies summarised in Table 3.1. 
PRNT data are serotype-specific, allowing us to estimate the serotype-specific force of 
infection ( i ) and basic reproduction number ( 0iR  ) for each serotype individually (Figure 
3.1). Estimates varied widely between different surveys, again highlighting the 
heterogeneity of dengue transmission. Within the same survey, serotype-specific 
differences in transmission intensity were apparent, demonstrating how a certain serotype 
may be more dominant at any one time point. For example, for model D2 (equal interaction), 
force of infection estimates for Haiti were 0.046 (95% CrI: 0.010 – 0.179) for DENV-1 but 
0.219 (95% CrI: 0.088 – 0.445) for DENV-4. 
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Table 3.1: Summary of PRNT surveys identified and associated demographics. 
^Number of serotypes known to have been in circulation.
Country Author Year Region Age Range 
(years) 
N Serotypes^ Population size 
of study region 
(thousands) 
Rural/Urban % Aged  
<15 yrs 
Models 
used 
Cuba Guzman et al.[161] 1983 Cerro 0 – 45 1295 2 125.5 Urban 26 A, D1 – D4 
 Guzman et al.[162] 1997/98 Santiago 0 - 95 1151 2 475.6 Urban 17.3 A, D1 – D4 
Haiti Halstead et al.[29] 1996/99 Port au Prince 6 – 14 210 4 2000 Urban 43 A, D1 – D4 
Indonesia Graham et al.[163] 1995 Yogyakarta 4 – 10 1837 4 421 Urban 34 A, D1 – D4 
Peru Morrison et al.[158] 1999 Iquitos 5 – 60+ 2524 2 350 Urban 34 A, D1 – D4 
Thailand Sangkawibha et al.[164] 1980 Rayong 0 - 10 1009 4 53 Suburban 39.4 A, D1 – D4 
Thailand Rodriguez-Barraquer et 
al.[165] 
2010 Rayong 6 - 19 1647 4 230 Urban 19.3 A, D1 – D4 
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Figure 3.1: Serotype-specific estimates of A) force of infection, λi, and B) R0i estimates derived from 
model D2 (equal interaction) fitted to the PRNT datasets. Posterior median and 95% CrI shown. See 
end of chapter for references and ISO country codes. 
 
Comparison of cross-protection or enhancement parameters under different assumptions 
allowed us to estimate the probable serotype causing primary and secondary infections. 
However, due to the wide credible interval of the estimated parameter, it was difficult to 
definitively determine the sequence of infections (Table 3.2 - Table 3.5).  
For all datasets, the model fit improved when we assumed some level of inter-serotype 
interaction, demonstrating that inter-serotype interactions play an important role in dengue 
dynamics. Figure 3.2 – Figure 3.5 show the model fits for each model variant and Table 3.6 
compares the DIC for each model variant. 
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Figure 3.2: Model fits from the multi-serotype no interaction model (D1) fit to PRNT data (points).  
95% exact confidence intervals around data points, posterior median (line) and 95% CrI (shaded 
area) shown. *Multitypic (right-most column) defined as multi-typically infected with more than one 
serotype. PRNT > cut-off point for ≥2 serotypes. [Ref] refers to ISO/reference list at end of chapter. 
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Table 3.2: Summary estimates of the strain-specific forces of infection (λ) and reproduction numbers (R0i) obtained from model D1 fitted to PRNT surveys 
assuming no inter-serotype interaction. *Assumption 1: individuals can have up to 4 infections, 2: individuals develop immunity after 2 infections. 
 Country Cuba Haiti Indonesia Peru Thailand  
 Author Guzman et al.[161] Guzman et al.[162] Halstead et al.[29] Graham et al.[163] Morrison et al.[158] Sangkawibha et 
al.[164] 
Rodriguez- 
Barraquer et al.[165] 
i  
 
DENV-1 
 
0.027  
(0.025 – 0.030) 
0.013 
(0.012 – 0.014) 
0.074  
(0.030 – 0.129) 
0.046  
(0.042 – 0.051) 
0.081  
(0.077 – 0.085) 
0.030  
(0.023 – 0.038) 
0.024  
(0.020 – 0.029) 
DENV-2 
 
0.013  
(0.012 – 0.014) 
0.005 
(0.004 – 0.006) 
0.146  
(0.094 – 0.204) 
0.058  
(0.053 – 0.063) 
0.073  
(0.069 – 0.077) 
0.082  
(0.072 – 0.093) 
0.041  
(0.036 – 0.045) 
DENV-3 
 
NA NA 0.103 
(0.055 – 0.159) 
0.011 
(0.008 – 0.014) 
NA 0.051 
(0.042 – 0.060) 
0.024 
(0.020 – 0.029) 
DENV-4 
 
NA NA 0.167 
(0.115 – 0.225) 
0.018 
(0.015 – 0.022) 
NA 0.047 
(0.038 – 0.056) 
0.029 
(0.024 – 0.033) 
ii
   0.040 
(0.038 – 0.043) 
0.018 
(0.017 – 0.020) 
0.494 
(0.434 – 0.561) 
0.134 
(0.127 – 0.141) 
0.154 
(0.148 – 0.160) 
0.209 
(0.196 – 0.224) 
0.118 
(0.112 – 0.124) 
0iR  
Assumption 1 
DENV-1 
 
1.93 
(1.84 – 2.02) 
1.41 
(1.37 – 1.2.02) 
2.97 
(1.74 – 4.53) 
2.46 
(2.30 – 2.63) 
3.70 
(3.54 – 3.86) 
1.79 
(1.58 – 2.03) 
2.10 
(1.87 – 2.36) 
DENV-2 
 
1.41 
(1.36 – 1.46) 
1.16 
(1.13 – 1.16) 
4.99 
(3.55 – 6.73) 
2.88 
(2.70 – 3.08) 
3.41 
(3.27 – 3.55) 
3.36 
(3.05 – 3.70) 
3.06 
(2.79 – 3.36) 
DENV-3 
 
NA NA 3.77 
(2.48 – 5.31) 
1.31 
(1.23 – 1.40) 
NA 2.40 
(2.15 – 2.68) 
2.10 
(1.87 – 2.35) 
DENV-4 
 
NA NA 5.59 
(4.10 – 7.33) 
1.52 
(1.42 – 1.63) 
NA 2.28 
(2.04 – 2.56) 
2.34 
(2.10 – 2.60) 
0iR  
Assumption 2 
DENV-1 
 
1.93 
(1.84 – 2.02) 
1.41 
(1.37 – 1.2.02) 
6.91 
(6.05 – 7.98) 
3.11 
(2.96 – 3.28) 
3.70 
(3.54 – 3.86) 
3.56 
(3.35 – 3.79) 
4.05 
(3.82 – 4.31) 
DENV-2 
 
1.41 
(1.36 – 1.46) 
1.16 
(1.13 – 1.16) 
7.80 
(6.70 – 9.15) 
3.45 
(3.28 – 3.64) 
3.41 
(3.27 – 3.55) 
4.42 
(4.13 – 4.74) 
4.64 
(4.37 – 4.94) 
DENV-3 
 
NA NA 7.20 
(6.26 – 8.35) 
2.59 
(2.48 – 2.71) 
NA 3.80 
(3.56 – 4.07) 
4.05 
(3.82 – 4.30) 
DENV-4 
 
NA NA 8.19 
(7.01 – 9.64) 
2.66 
(2.54 – 2.79) 
NA 3.75 
(3.52 – 4.01) 
4.17 
(3.93 – 4.43) 
 LnL -1631.9 -1091.3 -137.3 -2632.8 -2898.5 -1320.7 -1785.2 
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Figure 3.3: Model fits from the multi-serotype equal interaction model (D2) fit to PRNT data (points). 
95% exact confidence intervals around data points, posterior median (line) and 95% CrI (shaded 
area) shown. *Multitypic (right-most column) defined as multi-typically infected with more than one 
serotype. PRNT > cut-off point for ≥2 serotypes. [Ref] refers to ISO/reference list at end of chapter. 
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Table 3.3: Summary estimates of the force of infection (λ) and serotype-specific reproduction number (R0i) assuming inter-serotype interactions are equal 
for all serotype combinations. Model D2 (equal interaction) fitted to PRNT data. 
*φ is the interaction parameter describing susceptibility enhancement-inhibition estimated using model D2. 
 
 
 Country Cuba Haiti Indonesia Peru Thailand 
 Author Guzman et al.[161] Guzman et al.[162] Halstead et al.[29] Graham et al.[163] Morrison et al.[158] Sangkawibha et 
al.[164] 
Rodriguez- 
Barraquer et al.[165] 
i  
 
DENV-1 
 
0.027 
(0.024 – 0.030) 
0.013 
(0.012 – 0.015) 
0.046 
(0.010 – 0.179) 
0.042 
(0.037 – 0.047) 
0.062 
(0.057 – 0.068) 
0.021 
(0.015 – 0.029) 
0.012 
(0.012 – 0.016) 
DENV-2 
 
0.007 
(0.005 – 0.008) 
0.003 
(0.002 – 0.004) 
0.120 
(0.038 – 0.176) 
0.056 
(0.050 – 0.062) 
0.056 
(0.050 – 0.063) 
0.081 
(0.069 – 0.095) 
0.033 
(0.029 – 0.037) 
DENV-3 
 
NA NA 0.081 
(0.023 – 0.373) 
0.008 
(0.006 – 0.010) 
NA 0.041 
(0.033 – 0.051) 
0.012 
(0.009 – 0.016) 
DENV-4 
 
NA NA 0.219 
(0.088 – 0.445) 
0.013 
(0.011 – 0.017) 
NA 0.037 
(0.029 – 0.047) 
0.018 
(0.014 – 0.021) 
ii
   0.033 
(0.031 – 0.036) 
0.016 
(0.015 – 0.018) 
0.518 
(0.403 – 0.681) 
0.119 
(0.112 – 0.127) 
0.118 
(0.112 – 0.125) 
0.182 
(0.167 – 0.198) 
0.075 
(0.070 – 0.080) 
 *  1.350 
(0.691 – 2.024) 
0.128  
(0.005 – 0.519) 
0.475 
(0.107 – 0.994) 
1.100 
(0.898 – 1.330) 
0.898 
(0.697 – 1.120) 
1.199 
(0.935 – 1.493) 
5.561 
(4.728 – 6.530) 
0iR  
 
DENV-1 
 
1.89 
(1.75 – 2.07) 
1.50 
(1.43 – 1.56) 
10.15 
(6.75 – 28.65) 
3.23 
(2.99 – 3.51) 
3.67 
(3.38 – 3.99) 
3.54 
(3.21 – 3.94) 
2.49 
(2.29 – 2.71) 
DENV-2 
 
1.32 
(1.13 – 1.63) 
1.46 
(1.30 – 1.54) 
10.94 
(7.33 – 19.03) 
3.50 
(3.25 – 3.77) 
3.56 
(3.26 – 3.92) 
4.32 
(3.92 – 4.79) 
3.25 
(3.00 – 3.53) 
DENV-3 
 
NA NA 10.50 
(6.97 – 19.55) 
2.77 
(2.56 – 3.02) 
NA 3.76 
(3.40 – 4.18) 
2.49 
(2.29 – 2.71) 
DENV-4 
 
NA NA 11.81 
(7.83 – 19.57) 
2.84 
(2.62 – 3.09) 
NA 3.71 
(3.35 – 4.13) 
2.62 
(2.40 – 2.84) 
 LnL -1631.9 -1091.3 -137.3 -2632.8 -2885.9 -1320.7 -1785.2 
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Figure 3.4: Model fits from the multi-serotype primary interaction model (D3) fit to PRNT data 
(points).  95% exact confidence intervals around data points, posterior median (line) and 95% CrI 
(shaded area) shown. *Multitypic (right-most column) defined as multi-typically infected with more 
than one serotype. PRNT > cut-off point for ≥2 serotypes. [Ref] refers to ISO/reference list at end of 
chapter.
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Table 3.4: Summary estimates of the force of infection (λ) and serotype-specific reproduction number (R0i) assuming inter-serotype interactions are 
dependent only on the primary infecting serotype. Model D3 (primary interaction) fitted to PRNT data.
  Cuba  Haiti Indonesia Peru Thailand  
 Author Guzman et 
al.[161] 
Guzman et al.[162] Halstead et al.[29] Graham et al.[163] Morrison et al.[158] Sangkawibha et 
al.[164] 
Rodriguez- 
Barraquer et al.[165] 
i  
 
DENV-1 
 
0.028 
(0.026 – 0.031) 
0.013 
(0.012 - 0.015) 
0.116 
(0.013 – 0.312) 
0.036 
(0.027 – 0.048) 
0.026 
(0.022 – 0.030) 
0.014 
(0.008 – 0.026) 
0.018 
(0.002 – 0.034) 
DENV-2 
 
0.004 
(0.003 – 0.006) 
0.003 
(0.002 – 0.004) 
0.045 
(0.014 – 0.182) 
0.046 
(0.038 – 0.060) 
0.091 
(0.086 – 0.097) 
0.106 
(0.082 – 0.126) 
0.011 
(0.007 – 0.024) 
DENV-3 
 
NA NA 0.115 
(0.017 – 0.309) 
0.006 
(0.004 – 0.014) 
NA 0.028 
(0.019 – 0.046) 
0.021 
(0.004 – 0.035) 
DENV-4 
 
NA NA 0.126 
(0.032 – 0.317) 
0.029 
(0.016 – 0.041) 
NA 0.030 
(0.018 – 0.049) 
0.026 
(0.006 – 0.041) 
ii
   0.033 
(0.030 – 0.036) 
0.016 
(0.015 – 0.017) 
0.452 
(0.358 – 0.579) 
0.119 
(0.111 – 0.126) 
0.117 
(0.111 – 0.123) 
0.180 
(0.165 – 0.196) 
0.075 
(0.070 – 0.080) 
  
1   
4.188 
(2.167 – 6.716) 
0.361 
(0.018 – 1.414) 
1.785 
(0.244 – 12.465) 
0.596 
(0.038 – 1.670) 
0.011 
(0.000 – 0.053) 
0.397 
(0.018 – 1.641) 
9.434 
(0.202 – 19.264) 
2   
0.126 
(0.005 – 0.736) 
0.143 
(0.005 – 0.719) 
0.237 
(0.013 – 1.065) 
0.333 
(0.013 – 1.345) 
4.904 
(3.736 – 6.291) 
2.781 
(1.492 – 4.612) 
0.653 
(0.031 – 3.294) 
3   
NA NA 1.095 
(0.150 – 5.693) 
0.464 
(0.018 – 2.789) 
NA 0.473 
(0.029 – 1.526) 
11.475 
(1.227 – 19.503) 
4   
NA NA 0.510 
(0.052 – 2.011) 
4.277 
(1.804 – 7.217) 
NA 0.759 
(0.080 – 1.978) 
9.644 
(1.374 – 19.101) 
0iR  
DENV-1 
 
1.41 
(1.17 – 1.72) 
1.47 
(1.35 – 1.47) 
5.08 
(1.13 – 12.07) 
3.71 
(2.30 – 5.12) 
5.02 
(4.78 – 5.26) 
5.03 
(2.77 – 6.63) 
1.46 
(1.06 – 5.20) 
DENV-2 
 
2.02 
(1.61 – 2.19) 
1.45 
(1.23 – 1.54) 
11.94 
(7.10 – 17.58) 
4.43 
(2.88 – 5.25) 
1.43 
(1.20 – 1.72) 
2.48 
(1.49 – 3.79) 
5.03 
(3.74 – 5.62) 
DENV-3 
 
NA NA 7.17 
(2.47 – 13.78) 
3.59 
(1.34 – 5.17) 
NA 4.99 
(3.13 – 6.59) 
1.24 
(1.04 – 4.02) 
DENV-4 
 
NA NA 10.52 
(5.90 – 16.49) 
1.55 
(1.00 – 2.08) 
NA 4.25 
(2.57 – 6.29) 
1.45 
(1.08 – 4.05) 
 LnL -1625.4 1091.8 -136.7 -2629.1 -2804.8 -1316.3 -1779 
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Figure 3.5: Model fits from the multi-serotype secondary interaction model (D4) fit to PRNT data 
(points). 95% exact confidence intervals around data points, posterior median (line) and 95% CrI 
(shaded area) shown. Multitypic (right-most column) defined as multi-typically infected with more 
than one serotype. PRNT > cut-off point for ≥2 serotypes. [Ref] refers to ISO/reference list at end of 
chapter.
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Table 3.5: Summary estimates of the force of infection (λ) and serotype-specific reproduction number (R0i) assuming inter-serotype interactions are 
dependent only on the secondary infecting serotype. Model D4 (secondary interaction) fitted to PRNT data. 
 
 Country Cuba Haiti Indonesia Peru Thailand 
 Author Guzman et al.[161] Guzman et al.[162] Halstead et al.[29] Graham et al.[163] Morrison et al.[158] Sangkawibha et 
al.[164] 
Rodriguez-Barraquer 
et al.[165] 
i  
DENV-1 
 
0.028 
(0.026 – 0.031) 
0.013 
(0.012 – 0.015) 
0.035 
(0.008 – 0.174) 
0.044 
(0.033 – 0.053) 
0.026 
(0.022 – 0.030) 
0.017 
(0.011 – 0.026) 
0.013 
(0.009 – 0.018) 
DENV-2 
 
0.004 
(0.003 – 0.006) 
0.003 
(0.002 – 0.004) 
0.076 
(0.023 – 0.267) 
0.055 
(0.044 – 0.067) 
0.092 
(0.086 – 0.097) 
0.096 
(0.078 – 0.113) 
0.029 
(0.024 – 0.039) 
DENV-3 
 
NA NA 0.077 
(0.016 – 0.313) 
0.007 
(0.005 – 0.010) 
NA 0.035 
(0.023 – 0.048) 
0.013 
(0.009 – 0.019) 
DENV-4 
 
NA NA 0.208 
(0.056 – 0.401) 
0.013 
(0.010 – 0.017) 
NA 0.033 
(0.022 – 0.046) 
0.019 
(0.014 – 0.027) 
ii
   0.033 
(0.030 – 0.036) 
0.016 
(0.015 – 0.017) 
0.456 
(0.363 – 0.575) 
0.119 
(0.111 – 0.126) 
0.117 
(0.111 – 0.124) 
0.180 
(0.165 – 0.196) 
0.075 
(0.071 – 0.080) 
  
1  
0.125 
(0.005 – 0.699) 
0.142 
(0.005 – 0.705) 
1.061 
(0.026 – 8.135) 
0.558 
(0.021 – 2.443) 
4.909 
(3.735 – 6.313) 
3.030 
(0.138 – 8.914) 
5.287 
(0.343 – 9.690) 
2  
4.158 
(2.173 – 6.727) 
0.359 
(0.016 – 1.444) 
1.322 
(0.056 – 8.146) 
1.061 
(0.066 – 2.882) 
0.011 
(0.000 – 0.052) 
0.187 
(0.008 – 0.965) 
7.975 
(3.015 – 9.929) 
3  
NA NA 0.479 
(0.013 – 5.901) 
2.774 
(0.106 – 9.050) 
NA 1.793 
(0.100 – 5.862) 
4.838 
(0.319 – 9.715) 
4  
NA NA 0.372 
(0.014 – 3.571) 
0.912 
(0.038 – 4.090) 
NA 1.260 
(0.054 – 5.463) 
4.408 
(0.321 – 9.570) 
0iR  
 
DENV-1 
 
1.41 
(1.17 – 1.71) 
1.47 
(1.35 – 1.54) 
7.44 
(4.46 – 12.44) 
2.82 
(2.00 – 4.08) 
5.03 
(4.80 – 5.27) 
3.65 
(2.38 – 5.22) 
2.27 
(1.95 – 2.78) 
DENV-2 
 
2.02 
(1.63 – 2.19) 
1.45 
(1.24 – 1.53) 
9.04 
(5.42 – 14.24) 
3.39 
(2.39 – 4.63) 
1.43 
(1.20 – 1.73) 
3.10 
(2.32 – 3.95) 
3.46 
(2.84 – 3.93) 
DENV-3 
 
NA NA 8.01 
(3.86 – 13.77) 
1.99 
(1.07 – 3.47) 
NA 3.27 
(2.08 – 5.12) 
2.56 
(1.98 – 3.41) 
DENV-4 
 
NA NA 7.86 
(4.56 – 13.27) 
2.69 
(1.98 – 3.50) 
NA 3.42 
(2.43 – 5.17) 
2.33 
(1.97 – 2.98) 
 LnL -1625.4 -1091.8 -137.1 -2632.7 -2804.8 -1317.6 -1784.6 
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Table 3.6: DIC comparison of different model variants (A, D1-D4) for serotype-specific PRNT datasets. 
 
Interestingly, the serotype-specific estimates of the reproduction number did not scale 
linearly with the estimated values of the force of infection, although the relative order is 
maintained i.e. if 3 4  then 03 04R R . If one serotype dominates, as was the case in Haiti, 
changes in the force of infection of the other non-dominant serotypes marginally affect the 
estimates of the reproduction number of the non-dominating serotypes.  
In order to compare the estimates of dengue force of infection derived from IgG and PRNT 
assays, we also analysed the PRNT data ignoring strain-specificity (i.e. treating PRNT data as 
if it were IgG data), by categorising individuals as ‘seronegative’ if their PRNT titers were 
negative for all serotypes, or seropositive if they tested positive for at least one serotype. 
We used the same thresholds for seronegativity used by each source study. The resulting 
force of infection estimates generated using model A were consistent with the sum of the 
individual serotype-specific λ estimates obtained from the full PRNT datasets (Table 3.7 
summarises the parameter estimates and Figure 3.7 show the model fits). This consistency 
was highest when some level of inter-serotype interaction (cross-protection or 
enhancement) was allowed for (Figure 3.6). 
Author/Country/Ref Model Variant DIC 
 D1 
No 
interaction 
D2 
Equal 
interaction 
D3 
Primary 
interaction 
D4 
Secondary 
interaction 
Guzman/Cuba/[161] 3300 3300 3279 3283 
Guzman/Cuba/[162] 2223 2223 2221 2220 
Halstead/Haiti/[29] 278 278 277 275 
Graham/Indonesia/[163] 5300 5300 5294 5298 
Morrison/Peru/[158] 5819 5819 5632 5633 
Sangkawibha/Thailand/[164] 2657 2657 2648 2649 
Rodriguez-
Barraquer/Thailand/[165] 
3602 3602 3582 3597 
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Figure 3.6: Total force of infection (λ) estimates (for all 4 serotypes) derived from models A (constant 
force of infection), D1-D4 (no interaction, equal interaction, primary interaction, and secondary 
interaction models) fitted to PRNT datasets (treating PRNT data as IgG data). Models D2 – D4 allow 
for cross-protection between serotypes. Posterior median and 95% CrI shown. 
 
Table 3.7: Summary estimates where the constant force of infection model (A) was fitted to PRNT 
data  re-categorised into ‘seronegative’ (PRNT < cut-off for all serotypes) or ‘seropositive’ (PRNT > 
cut-off for at least one serotype). 
    
0iR  (95% CrI) 
 
Country Author   
(95% CrI) 
  
(95% CrI) 
Assumption 1 Assumption 2 LnL 
Cuba Guzman et al.[161] 0.040 
(0.032 – 0.073) 
0.184 
(0.136-0.424) 
1.52 
(1.40 – 2.14) 
1.52 
(1.40 – 2.14) 
-893 
 Guzman et al.[162] 0.014 
(0.012 – 0.021) 
0.176 
(0.137-0.337) 
1.14 
(1.12 – 1.23) 
1.14 
(1.12 – 1.23) 
-652 
Haiti Halstead et al.[29] 0.398 
(0.340 – 0.596) 
0.062 
(0.023-0.520) 
3.67 
(3.26 – 5.08) 
6.32 
(5.49 – 9.16) 
-22 
Indonesia Graham et al.[163] 0.120 
(0.107 – 0.170) 
0.074 
(0.047-0.272) 
1.89 
(1.79 – 2.32) 
2.81 
(2.59 – 3.77) 
-1234 
Peru Morrison et al.[158] 0.128 
(0.121 – 0.146) 
0.037 
(0.028-0.087) 
2.94 
(2.82 – 3.28) 
2.94 
(2.82 – 3.28) 
-10254 
Thailand Sangkawibha et 
al.[164] 
0.170 
(0.141 – 0.301) 
0.334 
(0.280-0.529) 
2.15 
(1.94 – 3.15) 
3.33 
(2.86 – 5.45) 
-581 
 Rodriguez- 
Barraquer et al.[165] 
0.076 
(0.069 – 0.097) 
0.097 
(0.073-0.216) 
1.81 
(1.73 – 2.09) 
2.77 
(2.56 – 3.50) 
-1071 
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Figure 3.7: Model A (constant force of infection) fit to PRNT data (points), having re-categorised 
them as ‘seropositive’ (PRNT > cut-off for at least one serotype) and ‘seronegative’ (PRNT < cut-off 
for all serotypes). 95% exact confidence intervals around data points, posterior median (line) and 
95% CrI (shaded area) shown. 
 
3.3.2 Regression Analysis 
Multiple regression analysis was conducted to explore the relationship between estimated 
dengue transmission intensity and the covariates summarised in Figure 3.8. Table 3.8 
summarises the analysis results. The multiple regression with all 6 predictors produced 
R2=0.37. The only predictor with strong evidence for an association with   was whether the 
study was conducted in an urban or rural setting, indicating that urban environments are 
associated with a higher force of infection. The distance from the equator (absolute 
latitude) and GDP per capita had weak evidence for a negative association with transmission 
intensity (Table 3.8). 
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Figure 3.8: Scatterplots showing the relationship between estimated force of infection, and 
demographic and environmental covariates. A) Absolute latitude, B) average maximum temperature, 
C) sample size, D) population size of study region, E) whether the study was conducted in an urban 
or rural setting, and F) GDP per capita (USD). Each point is an estimate for a single year. 
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Table 3.8: Weighted multiple regression results 
Variable Correlation with   Coefficients (95% CI) p-value 
Intercept - 5.33x10-2 
(-3.16x10-2 – 1.38x10-1) 
0.21 
Absolute latitude -0.14 -8.98x10-4 
(-1.88x10-3 – 8.15x10-5) 
0.07 
Average maximum temperature 0.20 -1.08x10-3 
(-4.44x10-3 – 2.28x10-3) 
0.52 
Sample size -0.29 -2.54x10-7 
(-1.09x10-5 – 1.04x10-5) 
0.96 
Population size of study region -0.16 -1.57x10-9 
(-4.31x10-9 – 1.17x10-9) 
0.25 
Urban/Rural^ 0.18 3.66x10-2 
(1.71x10-2 – 5.60x10-2) 
<0.001 
GDP per capita (USD) -0.23 -8.03x10-7 
(-1.64x10-6 – 3.56x10-8) 
0.06 
^coded as 1=urban, 0=rural.  
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3.4 Discussion 
In the first part of this discussion I will discuss the results of the PRNT data, and in the latter 
half discuss the results and limitations of serology data in general (chapter 2 and 3). 
From a literature review, we selected 7 studies reporting age-structured and serotype-
specific seroprevalence data obtained with PRNT assays from 5 countries between 1980 and 
2010. As in the previous chapter, from each dataset, we estimated dengue transmission 
intensity, quantified by the force of infection (λ) and the basic reproduction numbers ( 0iR ). 
Although we can only calculate a total force of infection across all serotypes from non-
serotype specific data (such as surveys using IgG ELISA assays), such data are still sufficient 
for assessing heterogeneity in overall dengue transmission intensity between different 
populations. However as demonstrated by the variable serotype specific i  estimated from 
the PRNT data, even within the same population, the dominant serotype in circulation 
changes over time [23,28,166]. Furthermore, we found that estimates of 0iR varied between 
serotypes, suggesting serotypes (or genotypes) differ in their intrinsic transmissibility 
[28,104,165]. These findings are in line with recent studies estimating type-specific 0iR  from 
10 endemic countries [167]. Therefore the assumption that all serotypes have identical i  
required to estimate serotype-specific transmission intensity from IgG data must be 
regarded as a crude simplification. However, we found that non-serotype specific data do 
yield an estimate of the total force of infection from all serotypes consistent with the sum of 
serotype-specific forces of infection able to be derived from PRNT data, particularly when 
analysis of the latter allowed for inter-serotype interaction (cross-protection or 
enhancement) [23]. 
Given the highly heterogeneous nature of dengue transmission, weighted multiple 
regression was conducted to explore the relationship between the estimated forces of 
infection and various potential predictors. Whether the study was conducted in an urban or 
rural environment was the only covariate to have a statistically significant association, with 
urban areas associated with a higher force of infection. Ideally we would have explored the 
associations using a meta-regression, allowing for the between trial variance with a random 
effects model. However since the outcome of interest (force of infection) was in itself 
calculated from a model, we could not calculate sampling variances from our data. 
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Our analysis has a number of additional limitations. First, in translating force of infection 
estimates into estimates of 0iR  we rely on a model which assumes exposure is due to 
endemic transmission, meaning all resulting 0iR estimates are by definition greater than 
one. Clearly this is less appropriate for settings with low seroprevalence such as Texas 
(chapter 2), where some or all of the seropositivity detected is due to imported cases rather 
than local transmission.  
Second, as in chapter 2 it is not possible to disentangle temporal from any age-dependent 
variation in exposure from single cross-sectional PRNT surveys, requiring broad assumptions 
to be made about such variation. Hence, for simplicity, we generally assumed constant 
transmission intensity over time when analysing single cross-sectional surveys. However we 
know from analysis of Nicaraguan data collected over 7 years (chapter 2) that there is long 
term variation in transmission intensity. Unfortunately PRNT data from the same site across 
multiple years were not available. Furthermore the majority of surveys analysed here were 
conducted in the 1990s hence the estimates may no longer be an accurate reflection of 
current dengue transmission dynamics. 
Third, estimates of transmission intensity (particularly 0iR ) are sensitive to assumptions 
about cross-protective immunity between serotypes – and most notably the extent to which 
tertiary and quaternary infections contribute to transmission.  While there is increasing 
evidence that tertiary and quaternary infections occur [25,28], there is little quantitative 
data on the infectiousness of such infections relative to primary and secondary infections. 
Consistent with published theory [166], our estimates of 0iR  were lower when we assumed 
tertiary and quaternary infections were as infectious as earlier infections (Assumption 1) 
than when we assumed complete immunity was acquired after secondary infection 
(Assumption 2). When one serotype had a very large force of infection relative to the other 
three serotypes (e.g. Haiti model 2: DENV-1 at 0.046 (95% CI: 0.010 – 0.179) compared to 
DENV-4 at 0.219 (95% CI: 0.088 – 0.445)), then regardless of the value of i  of the remaining 
serotypes, all 0iR  estimates were large and similar to each other. Thus it appears that the 
value of 0iR  is dominated by very large i  and changes in the other three i  play a minimal 
role. This uncertainty has relevance for planning interventions [23,26,105], since 0R  
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determines the coverage and effectiveness of vaccination or vector control measures 
required to achieve control of transmission [168]. The results from trials of the Sanofi live-
attenuated chimeric vaccine [60,61] make this issue more pressing, since reliable estimates 
of transmission intensity – and of the health burden due to dengue – will be important in 
strategic planning and resource allocation for vaccination in different contexts. 
Fourth, while PRNT assays are currently the gold standard for routine dengue serotyping, 
cross-reactivity means care must be taken when interpreting the results of serosurveys in 
areas where there is co-circulation of different flaviviruses or routine use of yellow fever or 
Japanese Encephalitis vaccine [20].  
Finally, our literature search highlighted that use of serological surveys as a tool to assess 
transmission remains rare for dengue, with publications of outbreak reports and notified 
case incidence data being much more common. Generally, published models estimating 
dengue transmission risk have therefore used notification data, the reliability of which 
therefore heavily depend on the quality of the surveillance system [169]. Gaining a better 
global picture of the variation in transmission will improve both estimates of the disease 
burden caused by dengue and assist in control planning. We would therefore advocate 
much more widespread and routine use of serological surveys as a surveillance tool which 
provides invaluable data for an immunising infection such as dengue. While PRNT data 
provide the maximum information, these chapters (chapters 2 and 3) shows that even the 
much less expensive ELISA-based assays would provide reasonable baseline estimates of 
overall transmission intensity.  
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3.6 ISO Abbreviations 
 
ISO 3 letter code Country 
CUB Cuba 
PER Peru 
HTI Haiti 
IDN Indonesia 
THA Thailand 
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4 Estimating Dengue Transmission Intensity from Case-notification 
Data from Multiple Countries 
 Work in this chapter formed the basis of: Imai N, Dorigatti I, Cauchemez S, Ferguson NM. 
Estimating Dengue Transmission Intensity from Case-notification Data from Multiple 
Countries. PLoS Negl Trop Dis 2016; 10: e0004833. 
In this chapter, I collate age-stratified case notification data from the literature and develop 
models to estimate the force of infection. Comparing these estimates to those obtained 
from seroprevalence data (chapters 2 and 3) shows that incidence data can be equally 
useful whilst also highlighting the limitations associated with such data. 
4.1 Introduction 
Dengue is the most widely distributed mosquito-borne viral infection, but assessment of its 
geographic variation in transmission remains challenging. Analysis based on mapping the 
probability of occurrence of dengue estimated dengue causes 390 million annual infections 
worldwide [108]. However, these estimates relied on assuming a direct linear correlation 
between probability of occurrence and incidence, rather than estimating transmission 
intensity as quantified by the force of infection or reproduction number. Here we develop 
methods to estimate transmission intensity from routine, age-stratified surveillance data on 
suspected dengue case incidence.   
All four serotypes of dengue virus (DENV-1, 2, 3, and 4) can cause dengue fever with the risk 
of severe dengue increasing with subsequent heterologous infections. Once infected, 
individuals develop long-lived protective homotypic immunity and short-lived heterotypic 
immunity [23,123]. Once antibody levels wane below the threshold required to provide 
protection ADE becomes a risk, leading to secondary heterologous infection having an 
enhanced risk of causing clinically apparent disease [4,20]. Hence while the majority of 
primary dengue infections are asymptomatic [170], secondary heterologous infection has 
been identified as a major risk factor for symptomatic and severe dengue [13,171,172]. 
Therefore the majority of cases seen in hospitals [122] or reported via surveillance systems 
[173] tend to be secondary infections.  
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In previous work, we estimated dengue transmission intensity from age-stratified 
seroprevalence data but highlighted the relative paucity of seroprevalence data compared 
with routine surveillance data on the incidence of suspected dengue [174]. This reflects 
dengue fever, DHF, and DSS being notifiable diseases in most countries [90–94]. Indeed, in 
many countries, incidence reports are the only type of data available. However the clinical 
diagnostic criteria vary and different countries have their own reporting standards [53]. The 
WHO collates surveillance data from dengue affected countries via its DengueNet system, 
but the data are not always updated regularly and there can be inconsistencies with other 
sources (e.g. WHO regional offices or countries) of national and subnational data [53].  
The lack of systematic data on dengue incidence, the lack of standardized reporting 
procedures or diagnostic criteria, and the lack of integration between private and public 
sectors makes accurate estimation of the true dengue burden difficult [52]. Previous studies 
have attempted to estimate the burden of dengue and associated economic costs in South 
East Asia and South America by calculating expansion factors from systematic literature 
reviews, collation of existing data, and population-based cohorts [52,54–57]. However, the 
lack of standardisation also affects the validity of expansion factors (calculated by dividing 
the cumulative incidence of dengue cohort studies by that from passive data at both 
national and local levels) as estimates of underreporting. Due to the wide spectrum of 
clinical manifestations and the lack of routine laboratory testing, dengue is globally 
underreported and analyses of officially reported dengue numbers need to take this into 
account [58]. 
While reported incidence levels cannot be relied upon to directly quantify disease burden, 
the age distribution of dengue cases provides more reliable information on dengue 
transmission intensity. Here we propose an approach for estimating average transmission 
intensity - as quantified by the force of infection or basic reproduction number ( 0R ) – from 
age-stratified incidence data. We compare estimates derived from seroprevalence and 
incidence data and assess the level of under-reporting of dengue disease. In addition, we 
estimate the relative contribution of primary to quaternary infections to the observed 
burden of dengue disease incidence. 
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4.2 Methods 
4.2.1 Literature Search 
Web of Knowledge and PubMed were searched for age-stratified incidence data since 1980 
as we were interested in contemporary dengue transmission and wanted to be consistent 
with our previous study (chapters 2 and 3) where we collated age-stratified seroprevalence 
data [174]. Search terms used were: ‘dengue’ and ‘age’ and (‘incidence’ or ‘cases’ or 
‘notifications’ or ‘notified cases’) with inclusion criteria mapped to subject headings. 
Additional web-based searches were performed to augment the primary literature search. 
Data were extracted from published datasets where authors reported age-stratified 
incidence data with corresponding population age-structure data.  
4.2.2 Estimating the Force of Infection and Reporting Rates 
We consider a population stratified into M age groups and denote aj  and aj+1 the lower and 
upper age bounds respectively of age group j  (j=0,…, M-1). Our model assumes perfect 
homotypic protection following infection with any serotype. Thus, an individual can 
experience a maximum of four dengue infections in their life (corresponding to the four 
dengue serotypes). Ideally, we would allow forces of infection to vary by serotype (DENV-1 
to DENV-4). However as serotype-specific data were not available, we assumed circulating 
serotypes were equally transmissible, i.e. had the same force of infection,  , which does 
not vary over time. The incidence of primary infections ( 1I ) for any one serotype for people 
in an age group j  is calculated as the integral of the probability of being seronegative to all 
four strains at age a  multiplied by four times the constant serotype-specific infection 
hazard,  , (since primary infection can occur with any of the four serotypes). Age a  spans 
the range 
1[ , ]j ja a  , as described by the bounds of integrations. Equations (4.1) - (4.4) give 
the incidence of primary to quaternary infections respectively when four serotypes are in 
circulation.  
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 The incidence of primary infections (  1I j ) is given by: 
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(4.1) 
The incidence of secondary infections (  2I j ) is given by: 
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(4.2) 
The incidence of tertiary infections (  3I j ) is given by: 
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(4.3) 
Finally the incidence of quaternary infections (  4I j ) is given by: 
   
 
1
1
1 1 1 1
1 1
3
4
2 3 4
2 3 4
3 3 2
4 1
4 3 3
3 3
4
2 3 4
4 6
j
j
j
j
j j j j
j j j j
j j j j j
a
a a
a
a
a a a a
a
a a a a
a a a a
a a a a
a a a a a
I j e e da
e e e e da
e e e e
e e e e e
 
   
   
    



   


   
  
 
   
   
    
 
   
        
              
         
     
 


1 12 4 4j j ja a ae e e
         
   
 
. 
(4.4) 
 
  
Page 107 of 228 
 
Total dengue infection incidence  T = 1 2 3 4I I I I    is, as expected: 
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 The average observed annual disease incidence rate per person in an age group is then 
given by a weighted sum of the primary to quaternary infection rates: 
 
 
  2 1 1 3 3 4
1
( ) ( ) ( ) ( )D j I j I j I j I j B
w j
          
, 
(4.5) 
where    1j jw j a a   is the width of the age group j ,   is the probability that a 
secondary infection results in a detected dengue case (=reporting rate), 1  is the probability 
that a primary infection is detected relative to a secondary infection, and 3  is the 
probability that a tertiary or quaternary infection is detected relative to a primary infection. 
Here B  is a baseline risk of disease used to represent any non-dengue related illnesses that 
are misdiagnosed as dengue, and is only estimated when fitting incidence where laboratory 
confirmation was lacking. Since we assumed that most symptomatic cases were secondary 
infections, we estimated the probability of detecting all other cases relative to secondary 
cases. We estimated these parameters using age-structured incidence data taking into 
account the age-structure of the population. Where fewer than 4 serotypes were in 
circulation, we changed the weighted sum of infection incidence accordingly as described 
below. 
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If there are fewer than four serotypes in circulation 
When there are fewer than four serotypes in circulation, the maximum number of infections 
an individual can acquire also changes accordingly. 
1) Only one serotype in circulation 
With only one serotype in circulation, individuals will only be infected once in their lifetime. 
Thus the incidence of primary infection in age group j  (with lower age bound aj  and upper 
age bound aj+1) 1( )I j is given by: 
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The incidence of disease in age group j  is then given by: 
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2) With two serotypes in circulation 
With two serotypes in circulation, individuals can have up to two infections in their lifetime. 
The incidence of primary infection in age group j  (with lower age bound aj  and upper age 
bound aj+1) 1( )I j  is given by: 
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and the incidence of secondary infection in age group j , 2 ( )I j is given by: 
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The incidence of disease in age group j  is then given by: 
 
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1
( ) ( )D j I j I j B
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    . 
3) With three serotypes in circulation 
With three serotypes in circulation, individuals can have a maximum of 3 infections.  
The incidence of primary infection in age group j  (with lower age bound aj  and upper age 
bound aj+1) 1( )I j  is given by: 
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The incidence of secondary infection in age group j , 2 ( )I j   is given by: 
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and the incidence of tertiary infection in age group j , 3( )I j  is given by: 
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The incidence of disease in age group j  is then given by: 
 
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Where population numbers were not available, the population age-structure closest to the 
survey population was used (taken from census data or from United Nations estimates 
[128]). We defined two model variants.  
Model 1A and 1B: assuming a single reporting rate across all ages 
For model 1 we assumed a single baseline reporting rate (  ) across all age groups and 
estimated 4 (or 5) parameters: i ,  ,  1 , 3  (and B). Where multiple years of incidence data 
were available from the same survey we fitted each model variant to individual years 
(model 1A), and to the cumulative incidence (model 1B). 
Models 2A and 2B: Assuming age-dependent reporting rates 
For model 2 we assumed an age-dependent reporting rate (
y  and o ) that changed at a 
certain age threshold thresholdA ;  
, if 
, if 
y threshold
o threshold
a a
a a
 

 
 
; 
that we estimated additionally to i , 1 , 3  (and B) for a total of 6 (or 7) parameters.  
A single value of 1  and 3  were estimated per country. Where incidence data were 
available for multiple years, we fitted each model variant to individual years (model 2A) and 
to the cumulative incidence (model 2B).  
When fitting to the cumulative incidence e.g. cumulative incidence over 10 years, we 
multiplied the estimated annual disease incidence by 10 to take into account the survey 
period.  
Estimation Procedure 
The expected number of cases per year in age-group j  ( jC ) is: 
j j jC n D   (4.6) 
where jn  is the population size of age group j .  
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We assumed that the number of cases reported in each age-group were Dirichlet-
multinomially (DMN) distributed, as we expected the overall distribution of cases would be 
more over-dispersed than what we would expect from a multinomial distribution [175]. The 
log-likelihood is given by: 
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(4.7) 
where   is the over-dispersion parameter characterising how different a DMN distribution 
is from the corresponding multinomial distribution (MN) with the same category 
probabilities (the larger the  , the greater the difference) and jy  is the observed number of 
cases in age class j . The probabilities ( )jp  are then calculated as the expected proportion 
of cases in one age group relative to the total number of cases across all age groups. 
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(4.8) 
We then assumed that the total number of cases across all ages ( N ) is Poisson distributed: 
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where   is the total expected number of cases across all age groups  jj C .  
The full log-likelihood is then: 
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(4.10) 
Finally, the average annual incidence rate per person can be calculated using equation (4.5). 
All models were fitted to the data using a MH MCMC algorithm using a Dirichlet-multinomial 
log-likelihood with uniform priors in version 3.1.0 of the R statistical language [159]. 
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4.2.3 Calculating the Basic Reproduction Number (R0i) 
We assumed dengue transmission was at endemic equilibrium and that the force of 
infection ( ) was constant in time. We additionally assumed that all serotypes in circulation 
were equally transmissible, i.e. had the same force of infection and basic reproduction 
number. We calculated a strain-specific basic reproduction number (R0i) from the single 
force of infection ( i ) estimated under two different assumptions about the number of 
infections required to acquire complete immunity. Under assumption 1, complete 
protection is acquired upon quaternary infection.  Under assumption 2, complete protection 
is reached after secondary infection (i.e. only primary and secondary infections are 
infectious). These assumptions match that of our previous work estimating the force of 
infection from serological data (chapters 2 and 3) and allowed us to compare the R0i 
estimates obtained from both types of data [174]. 
Assumption 1 – individuals can be infected 4 times, there is no cross-immunity between 
serotypes. The basic reproduction number for serotype i  is given by: 
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(4.11) 
where  f a  is the proportion of the population aged a .  iz a  is the proportion of 
population aged a  seropositive to serotype i and is calculated by: 
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(4.12) 
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



 
. 
(4.13) 
 
Assumption 2 – Complete immunity after secondary infection. 
If only primary and secondary infections can occur, we can relax the assumption of no cross-
immunity between serotypes. The basic reproduction number (the same for any serotype) is 
given by: 
       
0
0
1
1
iR
f a x a n z a da


   
 
, 
(4.14) 
where  f a  is the proportion of the population aged a , n  is the number of serotypes in 
circulation,  x a  is the proportion of the population seronegative at age a  calculated by: 
   expx a a  , and  iz a  is the proportion of the population seropositive for serotype 
i  at age a  calculated by: 
     
   
   
1 exp / exp 1 /
exp 1 / exp /
exp 1 / exp
iz a a n n a n
n a n n a n
n a n a
 
 
 
           
      
      
 
. 
(4.15) 
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Integrating between ages ja  and 1ja  : 
       
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(4.16) 
 
4.2.4 Comparing Force of Infection Estimates by Data Type  
We used weighted regression to assess how comparable force of infection estimates 
obtained from incidence data  inc  were with those derived from serological data  sero . 
We compared force of infection estimates from seroprevalence data described previously 
[174] and from 4 additional seroprevalence datasets (summarised in Table 4.3. Estimated as 
described in chapter 1, model A) with the estimates we derived from incidence data. 
Location- and time-matched incidence and serology data were not available, so we matched 
datasets by country, region, and survey year (within 5 years of each other). Since 
seroprevalence data represent all past infections, we compared force of infection estimates 
with those obtained from cumulative incidence data (models 1B and 2B) rather than yearly 
incidence data (Table 4.1). We used the deming regression (a weighted regression) method 
described by Ripley and Thompson [176] which explicitly accounts for measurement errors 
in both force of infection estimates from seroprevalence data (y-axis) and incidence data (x-
axis) to estimate the maximum likelihood estimation (MLE) line. Confidence intervals for the 
regression line were estimated using the jackknife estimate of the variance-covariance 
matrix between the estimated intercept and slope of the regression. The areas of the 
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symbols on the plots are proportional to the point weights, which correspond to the 
reciprocal of the variance of the error term in the linear regression. The larger circles 
indicate greater weight, i.e. smaller error. This was implemented using the deming package 
in R [177]. 
 
4.2.5 Multiple Linear Regression 
A weighted regression analysis was used to explore the relationship between the   values 
(estimated using the single reporting rate model fitted to cumulative incidence data (1B) 
where possible) and a number of environmental and demographic covariates (equation 
(4.17)). 
0 1 2 max 3 4 5 6 7absLat T P N G U Lab                  (4.17) 
where   is the force of infection, absLat  is the absolute latitude, maxT  is the average 
maximum temperature, P  is the population size of the study region, N  is the total number 
of individuals sampled, G  is the GDP per capita (USD), U  is whether the study was 
conducted in an rural or urban area (0=rural, 1=urban, 3=both), and Lab  is whether the 
cases were laboratory confirmed as dengue (0=no, 1=yes). Data on each covariate was 
extracted from the source publication, United Nations estimates [128], or World Bank 
estimates [160]. The model was weighted according to the variance of the   estimates 
(weights = 1/variance of the posterior distribution) and fitted in the R Statistical Package 
(version 3.1.0) [159]. 
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Table 4.1: Incidence datasets matched to closest serology datasets by region, year, or country 
*Although not cumulative incidence, these datasets were retained for analysis as they matched the corresponding seroprevalence surveys exactly by year 
and region. ^The two datasets reported DHF cases only; we therefore assumed all observed cases were due to secondary infections.
 
Incidence Datasets Serology Datasets 
Country  Author Survey Year Region Diagnosis Ref Author 
Survey 
Year 
Region Ref 
Brazil Penna 2001/06 Amazon Clinical [178] Silva-Nunez 2004 
Ramal do Granada 
(Acre State Amazon) 
[179] 
Brazil Cordeiro 2002/06 Pernambuco (Recife) Lab confirmed [180] Braga 2005/06 Recife (NE) [129] 
Brazil Cardoso 2000/09 Vitoria (~Rio) Lab confirmed [181] Lima 1998 Sao Paulo [92] 
Brazil Cordeiro 1995/01 
Pernambuco 
(Recife) 
Lab confirmed [180] Fernando 1996 
Paco do Lumiar, Sao Jose de Ribamar,  
Estado do Maranho 
[182] 
Laos Anker 2000/06 National Clinical [183] Vallee 2006 Vientiane [135] 
Nicaragua Hammond 1999/01 Leon Clinical/Lab [184] Balmaseda 2001/06 Managua [30] 
Singapore Anker 1999/05 National Clinical/Lab [183] Yew 2004 National [147] 
Singapore Ler 2000/07 National Lab confirmed [185] Yap 2007 National [148] 
Taiwan Lin 2003/09 Kaohsiung City Lab confirmed [186] Shu 
1997-
1998 
Liuchiu Hsiang [35] 
Thailand Thai MoH* 2000 Bangkok^ Lab confirmed [187] Perret 2000 Bangkok [152] 
Thailand Thai MoH* 2000 Ratchaburi^ Lab confirmed [187] Tuntaprasart 2000 Ratchaburi [153] 
Thailand Thai MoH* 2010 Rayong Lab confirmed [187] 
Rodriguez-
Barraquer 
2010 Rayong [188] 
Vietnam Cuong 1998/09 Hanoi Lab confirmed [189] Bartley 
1996-
1997 
Dong Thap [154] 
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4.3 Results 
4.3.1 Literature Search 
We identified 23 papers reporting incidence data. Figure 4.1 describes the search process 
and Table 4.2 summarises the studies identified. Seven papers reported age-stratified 
incidence data from multiple years, one paper reported data where the number of 
serotypes in circulation had changed over the survey years, 6 papers reported cumulative 
age-stratified incidence data, 8 papers reported age-stratified incidence data from a single 
year, and 2 papers reported age-stratified incidence data from multiple countries.  
 
Figure 4.1: Flowchart describing the literature search process for age-stratified incidence data. 
 
When considering each year separately, the identified studies provided a total of 96 
datasets from 13 countries.  The years included ranged from 1978 – 2011. The dataset 
reporting incidence data from 1978 was included since data were presented for the 11-year 
time period of 1978 – 1988 [190]. Of the 23 papers, 10 reported dengue incidence at the 
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national level and only 2 studies reported cases detected via active as well as passive 
surveillance. Three additional surveys were obtained from the Ministry of Health in Thailand 
[187] that reported age-specific incidence from Bangkok (2000), Ratchaburi (2000), and 
Rayong (2010) giving a total of 99 datasets from 13 countries. 
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Table 4.2: Summary of cross-sectional incidence datasets identified and associated demographics. *with active surveillance. 
Country Survey 
Year 
Region Diagnosis # serotypes in 
circulation 
Age range 
sampled 
Number surveyed Population  
size of study region  
Urban/Rural Ref 
Brazil 1995-2001 Pernambuco State Lab confirmed 2 0 - 80+ 8355325 8.5M Urban/Rural [191] 
 2002-2006 Pernambuco State Lab confirmed 3 0 - 80+ 8355325 8.5M Urban/Rural [191] 
 2000-2009 Vitoria Lab confirmed 3 0 - 80+ 292304 0.28M–0.32M Urban/Rural [181] 
 2001-2006 Amazon Clinical 4 0 - 70 3478916 23.6M Rural/Urban [178] 
Cambodia 2006-2008 Kampong Chan Province Lab confirmed* 4 0 - 20 804943 90000 Urban/Rural [192] 
 2006-2007 Kampong Chan Lab confirmed 4 0-14 14493 90000 Urban/Rural [193] 
China 1978-1988 Guangzhou Clinical 4 0 - 71+ 69671492 11.64M Urban [190] 
 1989-1999 Guangzhou Clinical 4 0 - 71+ 68990737 11.64M Urban [190] 
 2000-2009 Guangzhou Clinical 4 0 - 71+ 39489838 11.64M Urban [190] 
 2005-2011 Guangdong Clinical 4 0 - 80+ 88918687 104.3M Urban [90] 
Laos 2000-2006 National Clinical/Lab 4 0 - 15+ 4980938 5.4M Urban/Rural [183] 
 2010 Savannakhet Province Clinical 4 0 - 40+ 4879056 0.83M Urban [194] 
 2010 National Clinical 4 0 - 40+ 6388648 6.5M Urban/Rural [195] 
Nicaragua 1999-2001 Leon Lab confirmed 3 0 - 55 359723 0.39M Urban [184] 
Philippines 1998-2005 National Clinical/Lab 4 0 - 15+ 71661584 77.7M Urban/Rural [183] 
Puerto Rico 2006 Patillas Lab confirmed 4 0 - 40+ 16741 20200 Urban [196] 
 2007 National Lab confirmed 4 0 - 70+ 3823678 3.8M Urban/Rural [197] 
 2010 National Lab confirmed 4 0 - 70+ 3717885 3.7M Urban/Rural [173] 
 1994 National Lab confirmed 3 0 - 75+ 3525248 3.5M Urban/Rural [198] 
 1995-1997 National Lab confirmed 3 0 - 75+ 3525248 3.5M Urban/Rural [198] 
Singapore 1999-2005 National Clinical/Lab 4 0 - 15+ 2617012 4M Urban [183] 
 2005 National Lab confirmed 4 0 - 80 3447129 4.3M Urban [199] 
 2005 National Lab confirmed 4 0 - 55+ 4265809 4.3M Urban [185] 
 2007 National Lab confirmed 4 1 - 55+ 4588466 4.6M Urban [185] 
Sri Lanka 1997 National Clinical 4 0 - 65 17337179 17.3M Urban/Rural [200] 
 1996-2005 National Clinical 4 0 - 15+ 17706365 17.3M Urban/Rural [183] 
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Table 4.2 continued 
 
 
Table 4.3: Summary parameter estimates from four extra seroprevalence datasets 
Country Survey 
Year 
Region Diagnosis # serotypes in 
circulation 
Age range 
sampled 
Number surveyed Population  
size of study region  
Urban/Rural Ref 
Taiwan 2003-2009 Kaohsiung City Lab confirmed 4 0 - 74+ 10555563 1.5M Urban [186] 
Thailand 2000-2010 National Clinical 4 0-65+ 796686 66.4M Urban/Rural [201] 
 2006-2007 Ratchaburi Lab confirmed 4 0-14 6381 38208 Urban [193] 
 2000 Bangkok Lab confirmed 4 0-65 5054 6355144 Urban [187] 
 2000 Ratchaburi Lab confirmed 4 0-65 1371 791217 Urban [187] 
 2010 Rayong Lab confirmed 4 0-72 1059 616916 Urban [187] 
Vietnam 1998-2009 Hanoi Lab confirmed 4 0 - 80 6346088 6.5M Urban [189] 
Yemen 2010 Hadramout Lab confirmed 3 0 - 55+ 797049 0.7M Urban/Rural [202] 
Country Author Region Urban/Rural   force of infection 
(95% CrI) 
 over-dispersion 
(95% CrI) 
0iR Assumption 1 
(95% CrI) 
0iR Assumption 2 
(95% CrI) 
Ref 
Brazil Fernando Paco do Lumiar 
Sao Jose de Ribamar 
Estado do Maranho 
Urban 0.013 (0.011-0.021) 0.070 (0.044-0.270) 1.09 (1.08-1.15) 1.12 (1.10-1.21) [182] 
Brazil da Silva-Nunes Amazon Rural 0.008 (0.007-0.017) 0.026 (0.009-0.319) 1.05 (1.05-1.12) 1.06 (1.05-1.16) [203] 
Brazil Lima Campinas Urban 0.007 (0.006-0.016) 0.111 (0.079-0.319) 1.05 (1.04-1.11) 1.06 (1.05-1.15) [204] 
Taiwan Shu Liuchiu Hsiang Urban 0.026 (0.023-0.037) 0.157 (0.112-0.380) 1.24 (1.21-1.34) 1.38 (1.32-1.60) [35] 
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4.3.2 Additional Seroprevalence Surveys 
In addition to the seroprevalence surveys identified in chapters 2 and 3, the force of 
infection was estimated from four more surveys from Brazil and Taiwan to correspond to 
the incidence datasets identified here. Parameter estimates are given in Table 4.3, and 
model fits are shown in Figure 4.2. 
 
Figure 4.2: Model fits from non-serotype specific constant force of infection model (A) fitted to the 
extra seroprevalence datasets (as described previously [174] and chapter 2. Datasets described in 
Table 4.3). 95% exact confidence intervals around data points, posterior median (line) and 95% CrI 
(shaded area) shown. 
 
4.3.3 Parameter Estimates 
As expected, force of infection estimates varied widely between countries, with less 
variation seen within countries. Figure 4.3 and Figure 4.4 show the distribution of the total 
force of infection ( total ) grouped by country (calculated by multiplying the serotype-
specific force of infection by the number of serotypes in circulation) from models 1A (single 
reporting rate,  , fitted to yearly incidence data) and 2A (age-dependent reporting rate, y  
and o , fitted to yearly incidence data) respectively. Individual estimates are given in Table 
4.4 - Table 4.5 and the model fits are shown in Figure 4.5 – Figure 4.29. 
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Figure 4.3: Total force of infection and corresponding R0i estimates from models 1A (single reporting 
rate) fitted to yearly incidence data grouped by country. Each point represents the posterior median 
estimate and the error bars the 95% CrI. The box represents the country-specific central estimate 
calculated by taking the mean values of the MCMC output for each country (the line and limits of the 
box represents the posterior median and 95% CrI respectively). 
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Figure 4.4:  Total force of infection and corresponding R0i estimates from models 2A (age-dependent 
reporting rate) fitted to yearly incidence data grouped by country. Each point represents the 
posterior median estimate and the error bars the 95% CrI. The box represents the country-specific 
central estimate calculated by taking the mean values of the MCMC output for each country (the line 
and limits of the box represents the posterior median and 95% CrI respectively). 
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Table 4.4: Summary parameter estimates from model 1 fitted to yearly incidence data (model 1A). 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections.  
Author [Ref] Year Country i  (95% CrI)   (95% CrI) B  (95% CrI)   (95% CrI)  1  (95% CrI)  3  (95% CrI) tot (95% CrI) 0iR * (95% CrI) LnL 
          1 2  
Cordeiro 
[191] 
1995 Brazil 0.014 
(0.011-0.023) 
0.261 
(0.211-0.804) 
NA 0.012(0.008-
0.067) 
0.023 
(0.014-0.060) 
0.541 
(0.282-0.980) 
0.028 
(0.023-0.046) 
1.40 
(1.32-1.69) 
1.40 
(1.32-1.69) 
-17854 
 1996 0.019 
(0.016-0.030) 
0.390  
(0.338-0.810) 
NA 0.010 
(0.007-0.053) 
0.039 
(0.033-0.059) 
1.63 
(1.53-2.01) 
1.63 
(1.53-2.01) 
-40383 
 1997 0.018 
(0.014-0.027) 
0.610 
(0.530-0.948) 
NA 0.009 
(0.006-0.047) 
0.035 
(0.031-0.054) 
1.57 
(1.48-1.90) 
1.57 
(1.48-1.90) 
-57709 
 1998 0.020 
(0.018-0.027) 
0.883 
(0.800-0.994) 
NA 0.005 
(0.003-0.029) 
0.039 
(0.037-0.054) 
1.63 
(1.59-1.90) 
1.63 
(1.59-1.90) 
-93278 
 1999 0.020 
(0.018-0.028) 
0.572 
(0.20-0.844) 
NA 0.005 
(0.003-0.025) 
0.040 
(0.036-0.055) 
1.64 
(1.58-1.92) 
1.64 
(1.58-1.92) 
-64112 
 2000 0.019 
(0.017-0.026) 
0.452 
(0.407-0.719) 
NA 0.006 
(0.004-0.033) 
0.038 
(0.034-0.052) 
1.64 
(1.56-1.89) 
1.64 
(1.56-1.89) 
-50580 
 2001 0.018 
(0.016-0.026) 
0.289 
(0.257-0.515) 
NA 0.002 
(0.001-0.009) 
0.036 
(0.032-0.052) 
1.60 
(1.52-1.90) 
1.60 
(1.52-1.90) 
-31022 
 2002 0.024 
(0.023-0.031) 
0.962 
(0.928-0.999) 
NA 0.044 
(0.029-0.157) 
0.071 
(0.068-0.094) 
1.81 
(1.78-2.11) 
2.18 
(2.13-2.68) 
-
209223 
 2003 0.012 
(0.010-0.016) 
0.382 
(0.339-0.709) 
NA 0.008 
(0.005-0.035) 
0.035 
(0.031-0.049) 
1.37 
(1.32-1.53) 
1.48 
(1.41-1.73) 
-47533 
 2004 0.014 
(0.013-0.019) 
0.075 
(0.069-0.128) 
NA 0.006 
(0.003-0.032) 
0.043 
(0.038-0.056) 
1.46 
(1.41-1.63) 
1.63 
(1.55-1.88) 
-11581 
 2005 0.012 
(0.011-0.017) 
0.173 
(0.157-0.312) 
NA 0.007 
(0.004-0.035) 
0.037 
(0.033-0.051) 
1.40 
(1.35-1.56) 
1.53 
(1.46-1.78) 
-23548 
 2006 0.014 
(0.013-0.021) 
0.214 
(0.192-0.339) 
NA 0.009 
(0.006-0.048) 
0.042 
(0.038-0.062) 
1.46 
(1.41-1.70) 
1.62 
(1.54-1.99) 
-34400 
Penna 
[178] 
2001 0.006 
(0.005-0.015) 
0.457 
(0.333-0.947) 
0.007 
(0.003-0.238) 
0.022 
(0.010-0.332) 
0.023 
(0.018-0.059) 
1.16 
(1.13-1.44) 
1.24 
(1.18-1.80) 
-14639 
 2002 0.005 
(0.004-0.095) 
0.304 
(0.192-0.851) 
0.006 
(0.003-0.713) 
0.022 
(0.008-0.411) 
0.022 
(0.017-0.381) 
1.15 
(1.12-4.55) 
1.22 
(1.16-8.78) 
-9046 
 2003 0.006 
(0.004-0.179) 
0.348 
(0.228-0.864) 
0.007 
(0.003-0.817) 
0.024 
(0.010-0.451) 
0.022 
(0.017-0.715) 
1.16 
(1.12-8.28) 
1.23 
(1.17-16.66) 
-10371 
 2004 0.005 
(0.003-0.673) 
0.214 
(0.103-0.857) 
0.007 
(0.003-0.905) 
0.036 
(0.014-0.598) 
0.019 
(0.013-2.691) 
1.14 
(1.09-
31.46) 
1.19 
(1.12-63.04) 
-5540 
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Table 4.4 continued (2/5).  
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after 2 infections. 
Author [Ref] Year Country i  (95% CrI)   (95% CrI) B  (95% CrI)   (95% CrI)  1  (95% CrI)  3  (95% CrI) tot (95% CrI) 0iR * (95% CrI) LnL 
          1 2  
Penna 
[178] 
2005 Brazil 0.005 
(0.004-0.020) 
0.298 
(0.196-0.883) 
0.007 
(0.003-0.408) 
0.032 
(0.014-0.384) 
0.023 
(0.014-0.060) 
0.541 
(0.282-0.980) 
0.021 
(0.016-0.082) 
1.15 
(1.11-1.62) 
1.22 
(1.15-2.21) 
-8556 
 2006 0.005 
(0.004-0.014) 
0.325 
(0.237-0.854) 
0.004 
(0.002-0.206) 
0.013 
(0.005-0.280) 
0.019 
(0.015-0.058) 
1.13 
(1.10-1.42) 
1.19 
(1.14-1.77) 
-7823 
Vong 
[192] 
2006 Cambodia 0.084 
(0.078-0.104) 
0.190 
(0.183-0.201) 
NA 0.014 
(0.011-0.030) 
0.128 
(0.097-0.286) 
0.506 
(0.506-0.977) 
0.335 
(0.311-0.414) 
2.27 
(2.16-2.67) 
4.19 
(3.85-5.42) 
-20854 
 2007 0.071 
(0.067-0.082) 
0.964 
(0.928-0.999) 
NA 0.006 
(0.004-0.012) 
0.285 
(0.269-0.330) 
2.03 
(1.97-2.24) 
3.48 
(3.28-4.11) 
-110705 
 2008 0.062 
(0.057-0.077) 
0.303 
(0.292-0.327) 
NA 0.015 
(0.012-0.032) 
0.248 
(0.228-0.309) 
1.87 
(1.79-2.14) 
3.00 
(2.77-3.81) 
-34280 
Wichmann 
[193] 
2006 0.037 
(0.022-0.191) 
0.353 
(0.251-0.946) 
NA 0.209 
(0.081-0.937) 
0.146 
(0.087-0.765) 
1.32 
(1.18-3.78) 
1.54 
(1.26-12.89) 
-31 
 2007 0.078 
(0.066-0.176) 
0.899 
(0.852-0.995) 
NA 0.158 
(0.047-0.833) 
0.313 
(0.264-0.705) 
1.73 
(1.60-2.98) 
2.57 
(2.23-5.80) 
-543 
Anker 
[183] 
2000 Laos 0.004 
(0.001-0.043) 
0.049 
(0.023-0.898) 
NA 0.179 
(0.066-0.909) 
0.268 
(0.175-0.706) 
0.575 
(0.328-0.981) 
0.015 
(0.004-0.172) 
1.16 
(1.04-2.75) 
1.23 
(1.04-3.93) 
-1051 
 2001 0.007 
(0.001-0.051) 
0.078 
(0.047-0.903) 
NA 0.165 
(0.058-0.906) 
0.026 
(0.006-0.205) 
1.24 
(1.05-2.76) 
1.39 
(1.07-4.04) 
-3630 
 2002 0.013 
(0.006-0.070) 
0.135 
(0.099-0.855) 
NA 0.223 
(0.075-0.915) 
0.050 
(0.026-0.282) 
1.53 
(1.27-3.74) 
1.97 
(1.45-5.63) 
-8186 
 2003 0.015 
(0.008-0.098) 
0.179 
(0.125-0.810) 
NA 0.278 
(0.135-0.936) 
0.059 
(0.032-0.392) 
1.56 
(1.30-4.41) 
2.00 
(1.51-7.81) 
-17292 
 2004 0.010 
(0.003-0.061) 
0.050 
(0.035-0.810) 
NA 0.153 
(0.047-0.869) 
0.040 
(0.013-0.242) 
1.35 
(1.12-2.92) 
1.59 
(1.16-4.43) 
-3280 
 2005 0.009 
(0.002-0.073) 
0.092 
(0.054-0.922) 
NA 0.195 
(0.081-0.903) 
0.034 
(0.010-0.294) 
1.28 
(1.08-3.11) 
1.47 
(1.11-4.91) 
-5243 
 2006 0.009 
(0.003-0.067) 
0.093 
(0.059-0.877) 
NA 0.201 
(0.052-0.897) 
0.036 
(0.012-0.267) 
1.33 
(1.10-3.20) 
1.56 
(1.14-5.00) 
-5948 
Khampapongpane 
[195] 
2010 0.013 
(0.007-0.401) 
0.115 
(0.064-0.484) 
0.095 
(0.033-0.932) 
0.075 
(0.041-0.460) 
0.052 
(0.029-1.603) 
1.37 
(1.21-15.5) 
1.64 
(1.32-30.5) 
-33953 
Prasith 
[194] 
2010 0.022 
(0.010-0.791) 
0.092 
(0.057-0.647) 
0.336 
(0.099-0.970) 
0.377 
(0.211-0.935) 
0.086 
(0.039-3.164) 
1.70 
(1.30-27.8) 
2.39 
(1.50-55.1) 
-22762 
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Table 4.4 continued (3/5)  
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
Author [Ref] Year Country i  (95% CrI)   (95% CrI) B  (95% CrI)   (95% CrI)  1  (95% CrI)  3  (95% CrI) tot (95% CrI) 0iR  * (95% CrI) LnL 
          1 2  
Anker 
[183] 
1998 Philippines 0.019 
(0.001-0.065) 
0.034 
(0.025-0.930) 
NA 0.274 
(0.106-0.930) 
0.178 
(0.059-0.831) 
0.532 
(0.269-0.977) 
0.077 
(0.003-0.262) 
1.71 
(1.03-3.20) 
2.25 
(1.03-4.90) 
-33865 
 1999 0.028 
(0.021-0.088) 
0.006 
(0.005-0.014) 
NA 0.195 
(0.066-0.901) 
0.113 
(0.085-0.351) 
2.09 
(1.82-4.07) 
2.89 
(2.46-6.77) 
-9156 
 2001 0.023 
(0.012-0.086) 
0.018 
(0.013-0.666) 
NA 0.278 
(0.109-0.937) 
0.094 
(0.048-0.343) 
1.96 
(1.48-4.21) 
2.71 
(1.87-7.02) 
-23843 
 2002 0.025 
(0.016-0.077) 
0.015 
(0.011-0.184) 
NA 0.330 
(0.167-0.936) 
0.101 
(0.062-0.308) 
2.03 
(1.64-3.78) 
2.81 
(2.17-5.67) 
-16213 
 2003 0.019 
(0.001-0.067) 
0.032 
(0.023-0.860) 
NA 0.398 
(0.223-0.946) 
0.077 
(0.004-0.267) 
1.89 
(1.04-3.94) 
2.68 
(1.05-5.95) 
-28567 
 2004 0.023 
(0.011-0.086) 
0.016 
(0.015-0.755) 
NA 0.275 
(0.113-0.942) 
0.093 
(0.045-0.345) 
1.92 
(1.45-4.09) 
2.63 
(1.80-6.79) 
-22020 
 2005 0.018 
(0.002-0.069) 
0.030 
(0.021-0.842) 
NA 0.269 
(0.111-0.919) 
0.071 
(0.008-0.277) 
1.65 
(1.07-3.29) 
2.14 
(1.10-5.09) 
-32194 
Rigau-Perez 
[198] 
1994 Puerto Rico 0.022 
(0.020-0.028) 
0.355  
(0.314-0.490) 
NA 0.005 
(0.003-0.018) 
0.391 
(0.272-0.860) 
0.634 
(0.403-0.986) 
0.067 
(0.061-0.085) 
1.91 
(1.83-2.20) 
2.35 
(2.21-2.82) 
-50388 
 1995 0.020 
(0.017-0.026) 
0.033 
(0.029-0.355) 
NA 0.007 
(0.003-0.129) 
0.059 
(0.051-0.079) 
1.73 
(1.63-2.02) 
2.05 
(1.89-2.52) 
-3062 
 1996 0.019 
(0.016-0.026) 
0.030 
(0.026-0.358) 
NA 0.009 
(0.004-0.161) 
0.058 
(0.048-0.079) 
1.71 
(1.58-2.01) 
2.01 
(1.82-2.51) 
-2697 
 1997 0.020 
(0.018-0.027) 
0.035 
(0.031-0.528) 
NA 0.006 
(0.003-0.149) 
0.061 
(0.053-0.082) 
1.76 
(1.65-2.05) 
2.10 
(1.92-2.58) 
-3370 
Ramos 
[196] 
2006 0.017 
(0.013-0.039) 
0.369 
(0.307-0.807) 
NA 0.043 
(0.018-0.444) 
0.069 
(0.050-0.155) 
1.62 
(1.44-2.70) 
2.29 
(1.82-5.44) 
-203 
Sharp 
[173] 
2010 0.015 
(0.011-0.026) 
0.165 
(0.140-0.746) 
NA 0.029 
(0.020-0.106) 
0.061 
(0.044-0.106) 
1.70 
(1.48-2.34) 
2.46 
(1.92-4.14) 
-24291 
Tomashek 
[197] 
2007 0.010 
(0.006-0.020) 
0.053 
(0.043-0.379) 
NA 0.025 
(0.018-0.080) 
0.040 
(0.025-0.081) 
1.39 
(1.23-1.86) 
1.71 
(1.37-2.83) 
-7042 
Anker 
[183] 
1999 Singapore 0.004 
(0.002-0.041) 
0.133 
(0.053-0.912) 
NA 0.161 
(0.050-0.919) 
0.052 
(0.032-0.141) 
0.520 
(0.259-0.976) 
0.014 
(0.006-0.166) 
1.16 
(1.07-3.13) 
1.23 
(1.09-4.99) 
-521 
 2000 0.013 
(0.004-0.055) 
0.023 
(0.020-0.894) 
NA 0.217 
(0.082-0.942) 
0.051 
(0.015-0.220) 
1.71 
(1.19-4.76) 
2.46 
(1.29-8.36) 
-362 
 2001 0.016 
(0.009-0.064) 
0.061 
(0.057-0.591) 
NA 0.289 
(0.098-0.955) 
0.064 
(0.04-0.255) 
2.00 
(1.48-6.20) 
3.23 
(1.93-11.86) 
-940 
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Table 4.4 continued (4/5). *Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author 
[Ref] 
Year Country i  (95% CrI)   (95% CrI) B  (95% CrI)   (95% CrI)  1  (95% CrI)  3  (95% CrI) tot (95% CrI) 
0iR * (95% CrI) 
LnL 
          1 2  
Anker 
[183] 
2002 Singapore 0.009 
(0.003-0.062) 
0.125 
(0.090-0.919) 
NA 0.229 
(0.068-0.945) 
0.052 
(0.032-0.141) 
0.520 
(0.259-0.976) 
0.034 
(0.013-0.248) 
1.44 
(1.16-5.02) 
1.83 
(1.24-9.20) 
-1506 
 2003 0.010 
(0.004-0.058) 
0.140 
(0.106-0.855) 
NA 0.246 
(0.082-0.953) 
0.039 
(0.017-0.233) 
1.50 
(1.21-4.75) 
1.96 
(1.34-8.60) 
-1859 
 2004 0.010 
(0.006-0.050) 
0.345 
(0.260-0.915) 
NA 0.247 
(0.086-0.942) 
0.038 
(0.023-0.200) 
1.46 
(1.26-3.67) 
1.85 
(1.44-6.09) 
-4135 
 2005 0.016 
(0.009-0.072) 
0.293 
(0.258-0.822) 
NA 0.280 
(0.090-0.951) 
0.065 
(0.038-0.288) 
1.94 
(1.51-6.30) 
3.01 
(1.99-12.20) 
-6857 
Koh 
[199] 
2005 0.011 
(0.009-0.014) 
0.267 
(0.250-0.470) 
NA 0.007 
(0.005-0.034) 
0.043 
(0.038-0.058) 
1.43 
(1.37-1.59) 
1.80 
(1.66-2.20) 
-20559 
Ler 
[185] 
2005 0.012 
(0.011-0.016) 
0.265 
(0.250-0.369) 
NA 0.006 
(0.003-0.041) 
0.047 
(0.043-0.065) 
1.47 
(1.42-1.68) 
1.91 
(1.79-2.43) 
-25085 
 2007 0.005 
(0.004-0.008) 
0.337 
(0.276-0.872) 
NA 0.005 
(0.003-0.033) 
0.019 
(0.015-0.033) 
1.18 
(1.14-1.32) 
1.27 
(1.19-1.56) 
-14719 
Anker 
[183] 
1996 Sri Lanka 0.033 
(0.020-0.105) 
0.004 
(0.003-0.500) 
NA 0.336 
(0.168-0.943) 
0.216 
(0.155-0.575) 
0.617 
(0.373-0.979) 
0.133 
(0.081-0.419) 
2.99 
(2.15-7.33) 
4.98 
(3.38-12.70) 
-1139 
 1997 0.027 
(0.015-0.099) 
0.002 
(0.002-0.443) 
NA 0.235 
(0.071-0.929) 
0.108 
(0.060-0.395) 
2.35 
(1.72-5.94) 
3.58 
(2.40-10.96) 
-810 
 1998 0.034 
(0.023-0.113) 
0.003 
(0.002-0.355) 
NA 0.197 
(0.059-0.920) 
0.135 
(0.093-0.453) 
2.58 
(2.07-6.08) 
3.89 
(3.01-11.53) 
-989 
 1999 0.024 
(0.010-0.098) 
0.004 
(0.003-0.684) 
NA 0.233 
(0.082-0.920) 
0.097 
(0.040-0.392) 
2.16 
(1.45-5.58) 
3.19 
(1.83-10.18) 
-1174 
 2000 0.021 
(0.008-0.099) 
0.008 
(0.006-0.739) 
NA 0.225 
(0.079-0.924) 
0.084 
(0.033-0.395) 
2.09 
(1.39-6.34) 
3.16 
(1.70-11.82) 
-2302 
 2001 0.018 
(0.004-0.079) 
0.012 
(0.009-0.801) 
NA 0.286 
(0.128-0.948) 
0.071 
(0.017-0.315) 
1.98 
(1.20-5.75) 
3.03 
(1.31-9.55) 
-2218 
 2002 0.002 
(0.000-0.057) 
0.049 
(0.011-0.913) 
NA 0.134 
(0.043-0.882) 
0.008 
(0.002-0.226) 
1.10 
(1.02-4.12) 
1.13 
(1.02-6.93) 
-2262 
 2003 0.002 
(0.000-0.060) 
0.025 
(0.006-0.806) 
NA 0.137 
(0.047-0.929) 
0.009 
(0.001-0.242) 
1.10 
(1.01-4.42) 
1.14 
(1.01-7.54) 
-1215 
 2004 0.008 
(0.001-0.065) 
0.019 
(0.013-0.905) 
NA 0.176  
(0.064-0.923) 
0.030 
(0.002-0.259) 
1.37 
(1.03-4.69) 
1.66 
(1.03-8.06) 
-2864 
 2005 0.007 
(0.000-0.067) 
0.006 
(0.004-0.673) 
NA 0.156 
(0.056-0.898) 
0.028 
(0.002-0.269) 
1.33 
(1.02-4.56) 
1.57 
(1.02-7.72) 
-881 
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Table 4.4 continued (5/5). ^All cases reported = DHF, we have assumed that all cases were due to secondary cases and fixed γ₁ and γ₃ = 0. 
Author [Ref] Year Country i  (95% CrI)   (95% CrI) B  (95% CrI)   (95% CrI)  1  (95% CrI)  3  (95% CrI) tot (95% CrI) 0iR * (95% CrI) LnL 
          1 2  
Kulatilaka 
[200] 
2010 Sri 
Lanka 
0.066 
(0.056-0.369) 
0.001 
(0.001-0.001) 
0.083 
(0.058-0.539) 
0.009 
(0.006-0.052) 
0.216 
(0.155-0.575) 
0.617 
(0.373-0.979) 
0.265 
(0.226-1.478) 
3.66 
(3.18-26.65) 
7.46 
(6.22-85.19) 
-1565 
Limkittikul 
[201] 
2000 Thailand 0.055 
(0.049-0.199) 
0.012 
(0.009-0.016) 
0.060 
(0.032-0.686) 
0.033 
(0.018-0.213) 
0.009 
(0.005-0.040) 
0.505 
(0.263-0.978) 
0.221 
(0.195-0.795) 
3.37 
(3.04-11.67) 
6.44 
(5.67-23.65) 
-29875 
 2001 0.050 
(0.045-0.094) 
0.089 
(0.071-0.121) 
0.062 
(0.033-0.213) 
0.033 
(0.019-0.153) 
0.201 
(0.178-0.377) 
3.14 
(2.86-5.58) 
5.92 
(5.25-11.26) 
-
225605 
 2002 0.052 
(0.044-0.246) 
0.068 
(0.036-0.103) 
0.091 
(0.042-0.884) 
0.051 
(0.027-0.244) 
0.207 
(0.177-0.984) 
3.45 
(3.01-17.10) 
6.87 
(5.80-35.60) 
-
188228 
 2003 0.049 
(0.041-0.229) 
0.032 
(0.018-0.058) 
0.132 
(0.051-0.825) 
0.053 
(0.027-0.238) 
0.196 
(0.165-0.915) 
3.33 
(2.88-16.32) 
6.62 
(5.50-34.43) 
-
107289 
 2004 0.044 
(0.038-0.231) 
0.023 
(0.011-0.036) 
0.094 
(0.040-0.918) 
0.045 
(0.023-0.232) 
0.177 
(0.151-0.923) 
3.05 
(2.68-16.59) 
5.94 
(5.01-34.97) 
-66730 
 2005 0.042 
(0.036-0.179) 
0.026 
(0.016-0.043) 
0.103 
(0.045-0.691) 
0.038 
(0.020-0.204) 
0.168 
(0.144-0.715) 
2.95 
(2.62-12.81) 
5.70 
(4.86-27.29) 
-79945 
 2006 0.042 
(0.035-0.207) 
0.026 
(0.015-0.045) 
0.115 
(0.047-0.747) 
0.053 
(0.028-0.223) 
0.166 
(0.140-0.829) 
2.97 
(2.59-15.33) 
5.76 
(4.79-32.31) 
-80484 
 2007 0.041 
(0.036-0.154) 
0.048 
(0.034-0.065) 
0.056 
(0.029-0.569) 
0.035 
(0.020-0.193) 
0.163 
(0.144-0.616) 
2.96 
(2.68-11.34) 
5.76 
(5.04-23.94) 
-
112810 
 2008 0.037 
(0.034-0.059) 
0.076 
(0.066-0.091) 
0.031 
(0.018-0.318) 
0.016 
(0.009-0.106)  
0.147 
(0.135-0.236) 
2.74 
(2.57-4.19) 
5.21 
(4.78-8.74) 
-
159451 
 2009 0.036 
(0.033-0.179) 
0.042 
(0.022-0.058) 
0.061 
(0.029-0.900) 
0.024 
(0.012-0.172) 
0.146 
(0.131-0.715) 
2.76 
(2.53-13.70) 
5.26 
(4.68-28.46) 
-
103220 
 2010 0.034 
(0.032-0.045) 
0.101 
(0.092-0.119) 
0.027 
(0.016-0.086) 
0.009 
(0.005-0.052) 
0.136 
(0.127-0.179) 
2.67 
(2.54-3.38) 
5.07 
(4.71-6.88) 
-
215302 
Wichmann 
[193] 
2006 0.039 
(0.025-0.156) 
0.380 
(0.284-0.961) 
NA 0.164 
(0.060-0.904) 
0.156 
(0.099-0.623) 
1.34 
(1.20-3.02) 
1.60 
(1.31-8.59) 
-31 
 2007 0.070 
(0.045-0.186) 
0.617 
(0.551-0.954) 
NA 0.232 
(0.108-0.908) 
0.282 
(0.181-0.743) 
1.75 
(1.44-3.92) 
2.76 
(1.85-12.38) 
-114 
Bangkok^ 
[187] 
2000 0.047 
(0.044-0.055) 
0.055 
(0.054-0.058) 
NA 0.013 
(0.010-0.030) 
0 0 0.188 
(0.175-0.219) 
3.31 
(3.11-3.84) 
7.19 
(6.59-8.69) 
-11467 
Ratchaburi^ 
[187] 
2000 0.050 
(0.048-0.058) 
0.108 
(0.106-0.114) 
NA 0.012  
(0.009-0.034) 
0 0 0.202 
(0.192-0.232) 
3.37 
(3.23-3.82) 
6.60 
(6.25-7.66) 
-2810 
Rayong 
[187] 
2010 0.025 
(0.024-0.027) 
0.114 
(0.112-0.122) 
NA 0.001 
(0.001-0.002) 
0.009 
(0.005-0.040) 
0.505 
(0.263-0.978) 
0.099 
(0.097-0.107) 
1.99 
(1.96-2.09) 
3.25 
(3.16-3.50) 
-4128 
Ghouth 
[202] 
2010 Yemen 0.006 
(0.003-0.018) 
0.159 
(0.109-0.902) 
NA 0.083 
(0.048-0.446) 
0.233 
(0.088-0.943) 
0.501 
(0.244-0.977) 
0.019 
(0.008-0.055) 
1.16 
(1.07-1.49) 
1.19 
(1.07-1.67) 
-1792 
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Table 4.5: Summary parameter estimates from model 2 fitted to yearly incidence data (model 2A). 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
  
Author 
[Ref] 
Year Country i (95%CrI) y (95%CrI) o (95%CrI) 
B
(95%CrI) 
 
thresholdA
(95%CrI) 
  (95%CrI) 
 1
(95%CrI) 
 3
(95%CrI) 
tot (95%CrI) 0iR * (95%CrI) LnL 
            1 2  
Cordeiro 
[191] 
1995 Brazil 0.013 
(0.008-0.026) 
0.281 
(0.163-0.944) 
0.312 
(0.183-0.939) 
NA 65 
(20-80) 
0.009 
(0.004-0.052) 
0.038 
(0.027-
0.072) 
0.553 
(0.284-
0.983) 
0.026 
(0.017-0.052) 
1.36 
(1.23-1.79) 
1.36 
(1.23-1.79) 
-17854 
 1996 0.016 
(0.013-0.030) 
0.478 
(0.364-0.947) 
0.382 
(0.283-0.934) 
NA 65 
(50-80) 
0.010 
(0.006-0.058) 
0.032 
(0.025-0.059) 
1.51 
(1.39-2.02) 
1.51 
(1.39-2.02) 
-40383 
 1997 0.016 
(0.014-0.028) 
0.667 
(0.516-0.979) 
0.519 
(0.400-0.938) 
NA 65 
(50-80) 
0.008 
(0.005-0.046) 
0.032 
(0.027-0.056) 
1.51 
(1.43-1.95) 
1.51 
(1.43-1.95) 
-57709 
 1998 0.021 
(0.019-0.028) 
0.718 
(0.560-0.988) 
0.826 
(0.659-0.990) 
NA 35 
(20-80) 
0.006 
(0.003-0.040) 
0.041 
(0.038-0.056) 
1.67 
(1.61-1.94) 
1.67 
(1.61-1.94) 
-93277 
 1999 0.017 
(0.015-0.027) 
0.661 
(0.558-0.972) 
0.487 
(0.390-0.929) 
NA 65 
(65-80) 
0.003 
(0.002-0.022) 
0.035 
(0.030-0.053) 
1.55 
(1.47-1.89) 
1.55 
(1.47-1.89) 
-64111 
 2000 0.017 
(0.014-0.026) 
0.494 
(0.423-0.953) 
0.458 
(0.352-0.949) 
NA 65 
(50-80) 
0.004 
(0.003-0.028) 
0.035 
(0.029-0.052) 
1.57 
(1.47-1.90) 
1.57 
(1.47-1.90) 
-50580 
 2001 0.015 
(0.011-0.025) 
0.362 
(0.281-0.951) 
0.369 
(0.264-0.940) 
NA 65 
(50-80) 
0.005 
(0.003-0.029) 
0.029 
(0.022-0.049) 
1.48 
(1.34-1.85) 
1.48 
(1.34-1.85) 
-31021 
 2002 0.024 
(0.023-0.031) 
0.952 
(0.906-0.999) 
0.683 
(0.386-0.993) 
NA 80 
(65-80) 
0.044 
(0.029-0.177) 
0.071 
(0.068-0.094) 
1.81 
(1.77-2.12) 
2.18 
(2.11-2.69) 
-
209223 
 2003 0.011 
(0.009-0.017) 
0.450 
(0.366-0.962) 
0.419 
(0.333-0.956) 
NA 65 
(35-80) 
0.008 
(0.004-0.045) 
0.032 
(0.027-0.050) 
1.34 
(1.28-1.55) 
1.44 
(1.35-1.76) 
-47533 
 2004 0.014 
(0.013-0.019) 
0.076 
(0.069-0.366) 
0.398 
(0.102-0.967) 
NA 80 
(80-80) 
0.005 
(0.003-0.039) 
0.041 
(0.038-0.056) 
1.45 
(1.40-1.63) 
1.60 
(1.54-1.89) 
-11581 
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Table 4.5 continued (2/8).  
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
Author 
[Ref] 
Year Country i (95%CrI) y (95%CrI) o (95%CrI) 
B (95%CrI) 
thresholdA
(95%CrI) 
  
(95%CrI) 
 1
(95%CrI) 
 3
(95%CrI) 
tot
(95%CrI) 
0iR * (95%CI) 
LnL 
            1 2  
Cordeiro 
[191] 
2005 Brazil 0.012 
(0.010-0.018) 
0.180 
(0.156-0.741) 
0.288 
(0.168-0.961) 
NA 80 
(65-80) 
0.007 
(0.004-
0.040) 
0.038 
(0.027-
0.072) 
0.553 
(0.284-
0.983) 
0.036 
(0.031-
0.053) 
1.38 
(1.32-1.59) 
1.50 
(1.41-1.82) 
-23548 
 2006 0.014 
(0.012-0.022) 
0.215 
(0.189-0.806) 
0.290 
(0.201-0.946) 
NA 80 
(50-80) 
0.009 
(0.006-
0.054) 
0.042 
(0.036-
0.066) 
1.45 
(1.39-1.76) 
1.61 
(1.51-2.09) 
-34400 
Penna 
[178] 
2001 0.007 
(0.0052-0.081) 
0.277 
(0.093-0.922) 
0.473 
(0.288-0.971) 
0.020 
(0.005-0.883) 
70 
(50-90) 
0.047 
(0.015-
0.671) 
0.027 
(0.019-
0.226) 
1.19 
(1.13-7.75) 
1.30 
(1.19-8.57) 
-14641 
 2002 0.006 
(0.004-0.076) 
0.239 
(0.047-0.879) 
0.397 
(0.216-0.948) 
0.011 
(0.003-0.907) 
70 
(50-90) 
0.046 
(0.012-
0.704) 
0.024 
(0.016-
0.362) 
1.17 
(1.11-5.81) 
1.25 
(1.15-7.72) 
-9048 
 2003 0.006 
(0.004-0.074) 
0.219 
(0.047-0.861) 
0.415 
(0.246-0.953) 
0.020 
(0.004-0.939) 
70 
(50-90) 
0.059 
(0.016-
0.680) 
0.026 
(0.017-
0.295) 
1.18 
(1.12-5.03) 
1.27 
(1.16-7.05) 
-10374 
 2004 0.005 
(0.003-0.076) 
0.169 
(0.049-0.841) 
0.340 
(0.170-0.954) 
0.009 
(0.002-0.809) 
70 
(50-90) 
0.048 
(0.017-
0.675) 
0.021 
(0.013-
0.305) 
1.15 
(1.09-5.62) 
1.21 
(1.12-7.33) 
-5541 
 2005 0.006 
(0.004-0.077) 
0.204 
(0.052-0.851) 
0.396 
(0.214-0.956) 
0.014 
(0.004-0.910) 
70 
(50-90) 
0.062 
(0.021-
0.705) 
0.024 
(0.016-
0.311) 
1.17 
(1.11-3.68) 
1.26 
(1.15-7.83) 
-8558 
 2006 0.005 
(0.004-0.016) 
0.279 
(0.137-0.853) 
0.409 
(0.237-0.951) 
0.006 
(0.002-0.538) 
70 
(50-90) 
0.023 
(0.007-
0.423) 
0.020 
(0.014-
0.063) 
1.14 
(1.10-7.28) 
1.20 
(1.13-14.59) 
-7825 
Vong  
[192] 
2006 Cambodia 0.077 
(0.069-0.127) 
0.190 
(0.177-0.221) 
0.097 
(0.055-0.798) 
NA 
 
16 
(15-21) 
0.011 
(0.008-
0.027) 
0.141 
(0.108-
0.369) 
0.601 
(0.368-
0.980) 
0.309 
(0.276-
0.507) 
2.15 
(2.00-3.20) 
3.82 
(3.37-7.03) 
-20853 
 2007 0.068 
(0.065-0.080) 
0.955 
(0.912-0.999) 
0.307 
(0.159-0.947) 
NA 20 
(19-21) 
0.004 
(0.003-
0.010) 
0.274 
(0.259-
0.318) 
1.98 
(1.92-2.19) 
3.33 
(3.15-3.94) 
-
110702 
 2008 0.046 
(0.042-0.058) 
0.344 
(0.326-0.424) 
0.042 
(0.030-0.123) 
NA 18 
(18-18) 
0.005 
(0.004-
0.012) 
0.184 
(0.167-
0.233) 
1.61 
(1.54-1.81) 
2.27 
(2.10-2.82) 
-34269 
Page 131 of 228 
 
Table 4.5 continued (3/8). 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
Author 
[Ref] 
Year Country i
(95%CrI) 
y
(95%CrI) 
o
(95%CrI) 
B
(95%CrI) 
thresholdA  
(95%CrI) 
  
(95%CrI) 
 1
(95%CrI) 
 3
(95%CrI) 
tot
(95%CrI) 0i
R * (95%CrI) 
LnL 
            1 2  
Wichmann 
[193] 
2006 Cambodia 0.041 
(0.023-
0.254) 
0.317 
(0.229-
0.927) 
0.545 
(0.303-
0.980) 
NA 10 
(10-15) 
0.228 
(0.094-
0.937) 
0.141 
(0.108-
0.369) 
0.601 
(0.368-
0.980) 
0.164 
(0.092-
0.905) 
1.36 
(1.19-5.51) 
1.65 
(1.28-7.28) 
-31 
 2007 0.078 
(0.065-
0.187) 
0.880 
(0.814-
0.993) 
0.637 
(0.351-
0.986) 
NA 15 
(10-15) 
0.158 
(0.049-
0.886) 
0.314 
(0.261-
0.747) 
1.73 
(1.59-3.12) 
2.58 
(2.22-6.16) 
-543 
Anker 
[183] 
2000 Laos 0.001 
(0.001-
0.156) 
0.368 
(0.082-
0.948) 
0.269 
(0.1089-
0.941) 
NA 15 
(15-15) 
0.206 
(0.076-
0.909) 
0.115 
(0.062-
0.461) 
0.496 
(0.261-
0.975) 
0.006 
(0.003-
0.623) 
1.06 
(1.03-6.23) 
1.07 
(1.03-11.03) 
-1052 
 2001 0.004 
(0.002-
0.171) 
0.263 
(0.016-
0.958) 
0.243 
(0.112-
0.938) 
NA 15 
(15-15) 
0.227 
(0.086-
0.918) 
0.017 
(0.008-
0.685) 
1.16 
(1.07-6.55) 
1.23 
(1.09-13.88) 
-3631 
 2002 0.019 
(0.007-
0.146) 
0.120 
(0.046-
0.929) 
0.243 
(0.164-
0.917) 
NA 15 
(15-15) 
0.234 
(0.089-
0.919) 
0.076 
(0.029-
0.584) 
1.81 
(1.30-6.13) 
2.48 
(1.52-10.86) 
-8186 
 2003 0.023 
(0.008-
0.123) 
0.135 
(0.072-
0.950) 
0.379 
(0.248-
0.965) 
NA 15 
(15-15) 
0.248 
(0.108-
0.926) 
0.092 
(0.033-
0.492) 
1.88 
(1.32-5.26) 
2.54 
(1.54-10.10) 
-17292 
 2004 0.007 
(0.002-
0.177) 
0.152 
(0.014-
0.957) 
0.229 
(0.100-
0.922) 
NA 15 
(15-15) 
0.221 
(0.080-
0.928) 
0.028 
(0.008-
0.706) 
1.24 
(1.07-6.53) 
1.40 
(1.09-14.37) 
-3281 
 2005 0.045 
(0.004-
0.162) 
0.026 
(0.019-
0.954) 
0.303 
(0.148-
0.956) 
NA 15 
(15-15) 
0.233 
(0.091-
0.923) 
0.179 
(0.018-
0.648) 
2.35 
(1.14-5.63) 
3.29 
(1.22-11.94) 
-5243 
 2006 0.045 
(0.006-
0.167) 
0.030 
(0.020-
0.935) 
0.292 
(0.126-
0.944) 
NA 15 
(15-15) 
0.225 
(0.088-
0.929) 
0.180 
(0.026-
0.669) 
2.54 
(1.23-6.44) 
3.65 
(1.37-13.88) 
-5948 
Khampapongpane 
[195] 
2010 0.019 
(0.009-
0.161) 
0.092 
(0.040-
0.658) 
0.229 
(0.140-
0.895) 
0.110 
(0.031-
0.869) 
40 
(30-40) 
0.085 
(0.040-
0.573) 
0.075 
(0.034-
0.605) 
1.54 
(1.24-9.00) 
1.97 
(1.39-10.81) 
-33953 
Prasith 
[194] 
2010 0.043 
(0.016-
0.281) 
0.068 
(0.045-
0.524) 
0.346 
(0.171-
0.957) 
0.358 
(0.137-
0.962) 
80 
(15-80) 
0.357 
(0.189-
0.942) 
0.172 
(0.066-
0.713) 
2.51 
(1.52-5.42) 
4.13 
(1.98-6.62) 
-22762 
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Table 4.5 continued (4/8) 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
Author 
[Ref] 
Year Country i
(95%CrI) 
y
(95%CrI) 
o
(95%CrI) 
B
(95%CrI) 
thresholdA
(95%CrI) 
  
(95%CrI) 
 1
(95%CrI) 
 3
(95%CrI) 
tot
(95%CrI) 0i
R * (95%CrI) 
LnL 
            1 2  
Anker 
[183] 
  
1998 Philippines 0.006 
(0.002-
0.127) 
0.196 
(0.017-
0.965) 
0.097 
(0.041-
0.870) 
NA 15 
(15-15) 
0.278 
(0.102-
0.924) 
0.082 
(0.048-
0.225) 
0.323 
(0.140-
0.954) 
0.022 
(0.010-
0.508) 
1.20 
(1.09-5.05) 
1.32 
(1.12-9.40) 
-33864 
 1999 0.060 
(0.001-
0.147) 
0.004 
(0.003-
0.933) 
0.111 
(0.036-
0.857) 
NA 15 
(15-15) 
0.351 
(0.159-
0.941) 
0.239 
(0.005-
0.587) 
3.17 
(1.04-6.01) 
4.80 
(1.05-11.80) 
-9157 
 2001 0.002 
(0.001-
0.066) 
0.601 
(0.340-
0.981) 
0.099 
(0.055-
0.652) 
NA 15 
(15-15) 
0.252 
(0.095-
0.929) 
0.008 
(0.005-
0.264) 
1.07 
(1.05-3.54) 
1.10 
(1.06-5.54) 
-23843 
 2002 0.002 
(0.001-
0.124) 
0.507 
(0.127-
0.970) 
0.116 
(0.043-
0.818) 
NA 15 
(15-15) 
0.348 
(0.177-
0.936) 
0.007 
(0.004-
0.496) 
1.07 
(1.04-5.15) 
1.09 
(1.05-8.55) 
-16213 
 2003 0.011 
(0.003-
0.135) 
0.093 
(0.012-
0.941) 
0.060 
(0.030-
0.810) 
NA 15 
(15-15) 
0.373 
(0.188-
0.937) 
0.044 
(0.012-
0.540) 
1.49 
(1.13-6.34) 
1.92 
(1.19-10.80) 
-28567 
 2004 0.002 
(0.001-
0.125) 
0.432 
(0.158-
0.974) 
0.083 
(0.036-
0.789) 
NA 15 
(15-15) 
0.266 
(0.101-
0.941) 
0.009 
(0.005-
0.501) 
1.08 
(1.05-5.39) 
1.11 
(1.06-10.03) 
-22019 
 2005 0.057 
(0.004-
0.141) 
0.012 
(0.009-
0.938) 
0.170 
(0.070-
0.874) 
NA 15 
(15-15) 
0.354 
(0.173-
0.958) 
0.226 
(0.016-
0.566) 
2.92 
(1.14-5.48) 
4.32 
(1.21-10.57) 
-32194 
Rigau-Perez 
[198] 
1994 Puerto 
Rico 
0.022 
(0.018-
0.029) 
0.438 
(0.376-
0.894) 
0.517 
(0.400-
0.962) 
NA 55 
(25-99) 
0.003 
(0.002-
0.016) 
0.198 
(0.098-
0.648) 
0.539 
(0.299-
0.979) 
0.066 
(0.053-
0.087) 
1.90 
(1.70-2.23) 
2.33 
(2.00-2.89) 
-50387 
 1995 0.019 
(0.017-
0.027) 
0.040 
(0.034-
0.636) 
0.403 
(0.139-
0.972) 
NA 85 
(85-85) 
0.007 
(0.003-
0.159) 
0.058 
(0.051-
0.080) 
1.73 
(1.62-2.02) 
2.05 
(1.87-2.53) 
-3062 
 1996 0.018 
(0.010-
0.026) 
0.037 
(0.032-
0.846) 
0.397 
(0.151-
0.960) 
NA 85 
(75-85) 
0.011 
(0.005-
0.285) 
0.055 
(0.030-
0.077) 
1.67 
(1.34-1.98) 
1.96 
(1.44-2.46) 
-2697 
 1997 0.020 
(0.015-
0.029) 
0.042 
(0.036-
0.831) 
0.359 
(0.109-
0.973) 
NA 85 
(75-85) 
0.010 
(0.004-
0.235) 
0.061 
(0.046-
0.087) 
1.75 
(1.56-2.14) 
2.09 
(1.78-2.72) 
-3371 
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Table 4.5 continued (5/8) 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
 
Author 
[Ref] 
Year Country i
(95%CrI) 
y
(95%CrI) 
o
(95%CrI) 
B
(95%CrI) 
thresholdA
(95%CrI) 
  
(95%CrI) 
 1
(95%CrI) 
 3
(95%CrI) 
tot
(95%CrI) 0i
R * (95%CrI) 
LnL 
            1 2  
Ramos 
[196] 
2006 Puerto 
Rico 
0.017 
(0.013-
0.042) 
0.441 
(0.351-
0.930) 
0.470 
(0.327-
0.959) 
NA 40 
(30-61) 
0.038 
(0.014-
0.450) 
0.198 
(0.098-
0.648) 
0.539 
(0.299-
0.979) 
0.069 
(0.050-
0.170) 
1.62 
(1.43-2.92) 
2.29 
(1.81-6.17) 
-203 
Sharp 
[173] 
2010 0.015 
(0.009-
0.030) 
0.195 
(0.158-
0.943) 
0.276 
(0.194-
0.940) 
NA 60 
(20-81) 
0.020 
(0.012-
0.076) 
0.061 
(0.035-
0.119) 
1.69 
(1.38-2.56) 
2.45 
(1.68-4.69) 
-24289 
Tomashek 
[197] 
2007 0.010 
(0.003-
0.022) 
0.066 
(0.051-
0.936) 
0.240 
(0.096-
0.947) 
NA 70 
(30-85) 
0.023 
(0.015-
0.075) 
0.039 
(0.011-
0.087) 
1.37 
(1.10-1.93) 
1.67 
(1.14-3.01) 
-7042 
Anker 
[183] 
1999 Singapore 0.003 
(0.001-
0.124) 
0.312 
(0.025-
0.954) 
0.307 
(0.135-
0.936) 
NA 15 
(15-15) 
0.231 
(0.065-
0.954) 
0.042 
(0.023-
0.131) 
0.505 
(0.258-
0.971) 
0.010 
(0.006-
0.496) 
1.11 
(1.07-7.32) 
1.16 
(1.08-14.52) 
-521 
 2000 0.003 
(0.001-
0.169) 
0.321 
(0.012-
0.970) 
0.171 
(0.064-
0.928) 
NA 15 
(15-15) 
0.264 
(0.107-
0.951) 
0.010 
(0.005-
0.675) 
1.13 
(1.06-12.55) 
1.18 
(1.07-14.64) 
-362 
 2001 0.010 
(0.003-
0.124) 
0.146 
(0.027-
0.955) 
0.178 
(0.079-
0.938) 
NA 15 
(15-15) 
0.320 
(0.124-
0.958) 
0.041 
(0.013-
0.496) 
1.59 
(1.16-7.13) 
2.20 
(1.24-12.77) 
-940 
 2002 0.008 
(0.003-
0.104) 
0.197 
(0.035-
0.962) 
0.282 
(0.145-
0.951) 
NA 15 
(15-15) 
0.288 
(0.099-
0.956) 
0.032 
(0.013-
0.417) 
1.42 
(1.16-8.00) 
1.77 
(1.24-14.23) 
-1506 
 2003 0.014 
(0.005-
0.105) 
0.135 
(0.043-
0.946) 
0.265 
(0.150-
0.948) 
NA 15 
(15-15) 
0.314 
(0.116-
0.960) 
0.055 
(0.018-
0.421) 
1.75 
(1.22-8.03) 
2.53 
(1.35-16.24) 
-1859 
 2004 0.016 
(0.007-
0.078) 
0.233 
(0.104-
0.937) 
0.432 
(0.318-
0.961) 
NA 15 
(15-15) 
0.298 
(0.096-
0.959) 
0.062 
(0.029-
0.310) 
1.77 
(1.34-5.15) 
2.52 
(1.60-9.25) 
-4135 
 2005 0.023 
(0.011-
0.082) 
0.241 
(0.132-
0.947) 
0.372 
(0.288-
0.944) 
NA 15 
(15-15) 
0.299 
(0.106-
0.950) 
0.092 
(0.044-
0.328) 
2.42 
(1.61-7.12) 
4.09 
(2.22-14.06) 
-6857 
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Table 4.5 continued (6/8). 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
 
Author 
[Ref] 
Year Country i
(95%CrI) 
y
(95%CrI) 
o
(95%CrI) 
B
(95%CrI) 
thresholdA
(95%CrI) 
  
(95%CrI) 
 1
(95%CrI) 
 3
(95%CrI) 
tot
(95%CrI) 0i
R * (95%CrI) 
LnL 
            1 2  
Koh 
[199] 
2005 Singapore 0.011 
(0.009-
0.016) 
0.266 
(0.238-
0.768) 
0.361 
(0.278-
0.945) 
NA 65 
(55-85) 
0.007 
(0.004-
0.036) 
0.042 
(0.023-
0.131) 
0.505 
(0.258-
0.971) 
0.043 
(0.035-
0.064) 
1.43 
(1.34-1.66) 
1.80 
(1.60-2.37) 
-20559 
Ler 
[185] 
2005 0.012 
(0.010-
0.017) 
0.268 
(0.250-
0.734) 
0.342 
(0.256-
0.961) 
NA 81 
(55-81) 
0.006 
(0.003-
0.056) 
0.047 
(0.041-
0.068) 
1.47 
(1.41-1.72) 
1.91 
(1.76-2.54) 
-25085 
 2007 0.004 
(0.003-
0.009) 
0.390 
(0.280-
0.952) 
0.463 
(0.294-
0.959) 
NA 81 
(45-81) 
0.005 
(0.002-
0.034) 
0.017 
(0.013-
0.036) 
1.16 
(1.12-1.36) 
1.24 
(1.16-1.64) 
-14719 
Anker 
[183] 
1996 Sri Lanka 0.001 
(0.001-
0.028) 
0.424 
(0.015-
0.969) 
0.087 
(0.032-
0.854) 
NA 15 
(15-15) 
0.338 
(0.163-
0.947) 
0.091 
(0.066-
0.216) 
0.529 
(0.286-
0.975) 
0.004 
(0.002-
0.140) 
1.05 
(1.02-2.81) 
1.05 
(1.03-5.12) 
-1139 
 1997 0.001 
(0.000-
0.093) 
0.535 
(0.221-
0.978) 
0.125 
(0.054-
0.789) 
NA 15 
(15-15) 
0.229 
(0.072-
0.918) 
0.002 
(0.001-
0.174) 
1.02 
(1.01-4.17) 
1.02 
(1.01-7.27) 
-810 
 1998 0.001 
(0.000-
0.024) 
0.381 
(0.002-
0.971) 
0.113 
(0.047-
0.846) 
NA 15 
(15-15) 
0.287 
(0.105-
0.947 
0.003 
(0.002-
0.125) 
1.03 
(1.02-3.73) 
1.03 
(1.02-5.56) 
-990 
 1999 0.001 
(0.000-
0.026) 
0.260 
(0.002-
0.962) 
0.170 
(0.067-
0.922) 
NA 15 
(15-15) 
0.308 
(0.115-
0.956) 
0.005 
(0.002-
0.103) 
1.05 
(1.02-2.54) 
1.06 
(1.02-5.02) 
-1175 
 2000 0.084 
(0.001-
0.103) 
0.005 
(0.003-
0.951) 
0.198 
(0.063-
0.933) 
NA 15 
(15-15) 
0.330 
(0.133-
0.943) 
0.334 
(0.004-
0.151) 
5.53 
(1.05-2.74) 
9.91 
(1.06-5.53) 
-2302 
 2001 0.002 
(0.001-
0.031) 
0.288 
(0.005-
0.968) 
0.150 
(0.045-
0.918) 
NA 15 
(15-15) 
0.321 
(0.147-
0.936) 
0.009 
(0.004-
0.150) 
1.10 
(1.04-2.40) 
1.14 
(1.05-5.98) 
-2218 
 2002 0.002 
(0.001-
0.075) 
0.160 
(0.004-
0.964) 
0.284 
(0.121-
0.948) 
NA 15 
(15-15) 
0.256 
(0.092-
0.942) 
0.010 
(0.003-
0.270) 
1.11 
(1.03-6.22) 
1.15 
(1.04-12.97) 
-2263 
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Table 4.5 continued (7/8). 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
 
Author 
[Ref] 
Year Country i
(95%CrI) 
y
(95%CrI) 
o
(95%CrI) 
B
(95%CrI) 
thresholdA
(95%CrI) 
  
(95%CrI) 
 1
(95%CrI) 
 3
(95%CrI) 
tot
(95%CrI) 0i
R *(95%CrI) 
LnL 
            1 2  
Anker  
[183] 
2003 Sri Lanka 0.001 
(0.000-
0.055) 
0.463 
(0.152-
0.970) 
0.269 
(0.116-
0.908) 
NA 15 
(15-15) 
0.205 
(0.069-
0.909) 
0.091 
(0.066-
0.216) 
0.529 
(0.286-
0.975) 
0.002 
(0.001-
0.218) 
1.03 
(1.01-6.45) 
1.03 
(1.02-13.2) 
-1215 
 2004 0.003 
(0.001-
0.059) 
0.162 
(0.005-
0.957) 
0.228 
(0.083-
0.948) 
NA 15 
(15-15) 
0.301 
(0.105-
0.957) 
0.011 
(0.004-
0.240) 
1.13 
(1.04-6.74) 
1.18 
(1.05-14.23) 
-2865 
 2005 0.001 
(0.000-
0.086) 
0.428 
(0.098-
0.962) 
0.246 
(0.107-
0.899) 
NA 15 
(15-15) 
0.188 
(0.057-
0.936) 
0.002 
(0.001-
0.324) 
1.02 
(1.01-7.22) 
1.02 
(1.01-15.06) 
-882 
Kulatilaka 
[200] 
2010 0.066 
(0.058-
0.128) 
0.001 
(0.001-
0.002) 
0.459 
(0.216-
0.979) 
0.079 
(0.058-
0.507) 
65 
(65-65) 
0.010 
(0.006-
0.057) 
0.266 
(0.230-
0.467) 
3.67 
(3.23-7.54) 
7.48 
(6.36-14.43) 
-1566 
Limkittikul 
[201] 
2000 Thailand 0.060 
(0.051-
0.439) 
0.009 
(0.004-
0.016) 
0.457 
(0.173-
0.974) 
0.127 
(0.040-
0.901) 
80 
(80-80) 
0.056 
(0.025-
0.280) 
0.008 
(0.004-
0.036) 
0.466 
(0.235-
0.972) 
0.240 
(0.204-
0.758) 
3.61 
(3.16-8.14) 
6.99 
(5.95-16.47) 
-29877 
 2001 0.049 
(0.043-
0.080) 
0.099 
(0.087-
0.127) 
0.322 
(0.122-
0.960) 
0.043 
(0.025-
0.148) 
80 
(65-80) 
0.027 
(0.016-
0.133) 
0.194 
(0.173-
0.319) 
3.06 
(2.79-4.75) 
5.73 
(5.10-9.50) 
-225604 
 2002 0.051 
(0.044-
0.275) 
0.070 
(0.050-
0.104) 
0.354 
(0.124-
0.963) 
0.084 
(0.039-
0.447) 
80 
(65-80) 
0.049 
(0.027-
0.231) 
0.203 
(0.174-
0.901) 
3.38 
(2.97-19.26) 
6.71 
(5.70-39.95) 
-188228 
 2003 0.063 
(0.044-
0.458) 
0.015 
(0.010-
0.058) 
0.451 
(0.189-
0.970) 
0.429 
(0.098-
0.965) 
80 
(80-80) 
0.088 
(0.048-
0.294) 
0.253 
(0.175-
0.831) 
4.21 
(3.01-14.14) 
8.72 
(5.83-27.66) 
-107291 
 2004 0.041 
(0.037-
0.073) 
0.030 
(0.026-
0.039) 
0.385 
(0.133-
0.962) 
0.036 
(0.019-
0.281) 
80 
(80-80) 
0.025 
(0.016-
0.134) 
0.163 
(0.146-
0.291) 
2.86 
(2.62-4.86) 
5.45 
(4.85-10.22) 
-66728 
 2005 0.040 
(0.036-
0.271) 
0.032 
(0.021-
0.044) 
0.391 
(0.132-
0.970) 
0.059 
(0.029-
0.910) 
80 
(80-80) 
0.029 
(0.016-
0.202) 
0.161 
(0.143-
0.308) 
2.86 
(2.60-4.53) 
5.46 
(4.81-10.86) 
-79944 
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Table 4.5 continued (8/8). 
*Assumption1 = 4 infection, assumption 2 = 2 infections. ^All cases reported = DHF, we have assumed that all cases were due to secondary cases and fixed γ₁ and γ₃ = 0.
Author 
[Ref] 
Year Country i
(95%CrI) 
y
(95%CrI) 
o
(95%CrI) 
B
(95%CrI) 
thresholdA
(95%CrI) 
  
(95%CrI) 
 1
(95%CrI) 
 3
(95%CrI) 
tot
(95%CrI) 0i
R  (95%CrI)* 
LnL 
            1 2  
Limkittikul 
[201] 
2006 Thailand 0.041 
(0.035-
0.267) 
0.028 
(0.019-
0.046) 
0.409 
(0.158-
0.970) 
0.094 
(0.034-
0.670) 
80 
(80-80) 
0.046 
(0.026-
0.207) 
0.008 
(0.004-
0.036) 
0.466 
(0.235-
0.972) 
0.164 
(0.141-
0.680) 
2.94 
(2.61-10.1) 
5.68 
(4.84-19.90) 
-80483 
 2007 0.039 
(0.035-
0.062) 
0.054 
(0.046-
0.067) 
0.323 
(0.114-
0.956) 
0.034 
(0.018-
0.133) 
80 
(65-80) 
0.025 
(0.016-
0.120) 
0.157 
(0.140-
0.247) 
2.86 
(2.62-4.32) 
5.51 
(4.88-9.04) 
-
112810 
 2008 0.036 
(0.034-
0.050) 
0.077 
(0.071-
0.092) 
0.367 
(0.136-
0.973) 
0.028 
(0.015-
0.097) 
80 
(65-80) 
0.014 
(0.009-
0.071) 
0.145 
(0.134-
0.198) 
2.72 
(2.56-3.54) 
5.16 
(4.74-7.22) 
-
159451 
 2009 0.036 
(0.032-
0.071) 
0.043 
(0.033-
0.059) 
0.347 
(0.105-
0.966) 
0.053 
(0.027-
0.227) 
80 
(80-80) 
0.021 
(0.012-
0.117) 
0.144 
(0.130-
0.284) 
2.73 
(2.53-5.13) 
5.19 
(4.66-10.87) 
-
103220 
 2010 0.033 
(0.031-
0.044) 
0.103 
(0.093-
0.124) 
0.284 
(0.109-
0.961) 
0.028 
(0.016-
0.145) 
80 
(65-80) 
0.009 
(0.005-
0.053) 
0.134 
(0.125-
0.176) 
2.65 
(2.51-3.33) 
5.01 
(4.64-6.75) 
-
215303 
Wichmann 
[193] 
2006 0.045 
(0.026-
0.164) 
0.340 
(0.259-
0.933) 
0.573 
(0.344-
0.981) 
NA 10 
(10-15) 
0.184 
(0.067-
0.897) 
0.179 
(0.105-
0.654) 
1.40 
(1.22-3.17) 
1.74 
(1.34-9.44) 
-31 
 2007 0.073 
(0.049-
0.177) 
0.603 
(0.529-
0.956) 
0.600 
(0.376-
0.984) 
NA 15 
(10-15) 
0.241 
(0.100-
0.919) 
0.292 
(0.196-
0.707) 
1.79 
(1.49-3.70) 
2.87 
(1.97-11.33) 
-114 
Bangkok^ 
[186] 
2000 0.047 
(0.044-
0.055) 
0.055 
(0.054-
0.058) 
0.508 
(0.248-
0.974) 
NA 98 
(98-98) 
0.013 
(0.010-
0.032) 
0 0 0.188 
(0.175-
0.219) 
3.30 
(3.10-3.83) 
7.17 
(6.57-8.68) 
-11467 
Ratchaburi^ 
[186] 
2000 0.050 
(0.048-
0.058) 
0.109 
(0.106-
0.114) 
0.502 
(0.247-
0.974) 
NA 98 
(98-98) 
0.012 
(0.009-
0.031) 
0 0 0.202 
(0.191-
0.232) 
3.37 
(3.22-3.82) 
6.59 
(6.23-7.66) 
-2810 
Rayong 
[186] 
2010 0.019 
(0.018-
0.022) 
0.156 
(0.147-
0.187) 
0.074 
(0.069-
0.088) 
NA 28 
(28-31) 
0.000 
(0.000-
0.001) 
0.008 
(0.004-
0.036) 
0.466 
(0.235-
0.972) 
0.077 
(0.072-
0.089) 
1.73 
(1.68-1.87) 
2.56 
(2.44-2.93) 
-4115 
Ghouth 
[202] 
2010 Yemen 0.005 
(0.002-
0.021) 
0.201 
(0.112-
0.947) 
0.384 
(0.172-
0.973) 
NA 80 
(55-80) 
0.090 
(0.049-
0.463) 
0.222 
(0.090-
0.931) 
0.491 
(0.248-
0.980) 
0.015 
(0.007-
0.063) 
1.13 
(1.06-1.57) 
1.15 
(1.06-1.78) 
-1792 
Page 137 of 228 
 
 
Figure 4.5: Model fits of models 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to yearly incidence data from Brazil (Cordeiro et al. [191]). 95% exact confidence intervals shown 
around data points, posterior median (line) and 95% credible interval (shaded area) shown. 
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Figure 4.6: Model fits of models 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to yearly incidence data from Brazil (Penna et al. [178]). 95% exact confidence intervals shown 
around data points, posterior median (line) and 95% credible interval (shaded area) shown. 
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Figure 4.7: Model fits of models 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to yearly incidence data from Cambodia (Vong et al. [192] and Wichmann et al. [193]).  
95% exact confidence interval around data points, posterior median (line) and 95% credible interval 
(shaded area) shown. 
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Figure 4.8: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to yearly incidence data from Laos (Anker et al., [183] Prasith et al., [194] and Khampapongpane et al. 
[195]). 95% exact confidence interval around data points, posterior median (line), and 95% credible 
interval (shaded area) shown. 
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Figure 4.9: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to yearly incidence data from the Philippines (Anker et al. [183]). 95% exact confidence intervals 
around data points, posterior median (line), and 95% credible intervals (shaded area) shown. 
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Figure 4.10: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to yearly incidence data from Puerto Rico (Rigau-Perez et al., [198] Ramos et al., [196] Tomashek et 
al., [197] and Sharp et al. [173]). 95% exact confidence intervals around data points, posterior 
median (line), and 95% credible interval (shaded area) shown. 
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Figure 4.11: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to yearly incidence data from Singapore (Anker et al., [183] Koh et al., [199] and Ler et al. [185]). 
95% exact confidence intervals around data points, posterior median (line), and 95% credible 
interval (shaded area) shown. 
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Figure 4.12: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to yearly incidence data from Sri Lanka (Anker et al. [183]). 95% exact confidence interval around 
data points, posterior median (line), and 95% credible interval (shaded area) shown. 
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Figure 4.13: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to yearly incidence data from Thailand (Limkittikul et al. [201]). 95% exact confidence intervals 
around data points, posterior median (line), and 95% credible interval (shaded area) shown. 
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Figure 4.14: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to yearly incidence data from Thailand (Wichmann et al., [193] and data from Bangkok, Ratchaburi, 
and Rayong [187]). 95% exact confidence intervals around data points, posterior median (line), and 
95% credible interval (shaded area) shown. 
 
 
Figure 4.15: Model fits from model 1 (single reporting rate) and 2 (age-dependent reporting rate) 
fitted to yearly incidence data from Yemen (Ghouth et al. [202]). 95% exact confidence intervals 
around data points, posterior median (line), and 95% credible intervals (shaded area) shown. 
Page 147 of 228 
 
Figure 4.16 and Figure 4.17 show the distribution of the total force of infection ( total ) 
grouped by country (calculated by multiplying the serotype-specific force of infection by the 
number of serotypes in circulation) from models 1B (single reporting rate,  , fitted to 
cumulative incidence data) and 2B (age-dependent reporting rate, y  and o , fitted to 
cumulative incidence data) respectively. Individual estimates are given in Table 4.6 and 
Table 4.7 and the model fits are shown in Figure 4.18 – Figure 4.29. 
 
 
Figure 4.16: Total force of infection and corresponding R0i estimates from model 1B (single reporting 
rate) fitted to cumulative incidence data grouped by country. Each dot represents the posterior 
median estimate and the error bars the 95% CrI. The box represents the country-specific central 
estimate calculated by taking the mean values of the MCMC output for each country (the line and 
limits of the box represent the posterior median and 95% CrI respectively).  
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Figure 4.17:  Total force of infection and corresponding R0i estimates from model 2B (age-dependent 
reporting rate) fitted to cumulative incidence data grouped by country. Each dot represents the 
posterior median estimate and the error bars the 95% CrI. The box represents the country-specific 
central estimate calculated by taking the mean values of the MCMC output for each country (the line 
and limits of the box represent the posterior median and 95% CrI respectively) 
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Table 4.6: Summary parameter estimates from model 1 fitted to cumulative incidence data where available by country (single reporting rate, model 1B). 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
  
Author [Ref] Year Country i (95% CrI)  (95%CrI) B (95%CrI)  (95%CrI)  1 (95%CrI)  3 (95%CrI) tot (95%CrI) 0iR (95%CrI)* LnL 
          1 2  
Cordeiro 
[191] 
1995/01 Brazil 0.016 
(0.013-0.024) 
0.546 
(0.468-0.956) 
NA 0.008 
(0.005-0.041) 
0.034 
(0.018-0.144) 
0.496 
(0.268-0.976) 
0.033 
(0.026-0.047) 
1.52 
(1.40-1.77) 
1.52 
(1.40-1.77) 
-355182 
 2002/06 0.012 
(0.011-0.018) 
0.479 
(0.432-0.791) 
NA 0.006 
(0.004-0.036) 
0.037 
(0.033-0.053) 
1.40 
(1.35-1.58) 
1.53 
(1.46-1.81) 
-326485 
Cardoso 
[181] 
2000/09 0.012 
(0.012-0.015) 
0.078 
(0.073-0.103) 
NA 0.002 
(0.001-0.008) 
0.037 
(0.035-0.045) 
1.44 
(1.40-1.54) 
1.59 
(1.53-1.75) 
-4333 
Penna 
[178] 
2001/06 0.005 
(0.003-0.011) 
0.373 
(0.251-0.901) 
0.005 
(0.003-0.076) 
0.025 
(0.011-0.244) 
0.019 
(0.014-0.043) 
1.13 
(1.10-1.31) 
1.18 
(1.13-1.53) 
-55909 
Vong 
[192] 
2006/08 Cambodia 0.069 
(0.067-0.077) 
0.180 
(0.173-0.189) 
NA 0.003 
(0.002-0.007) 
0.037 
(0.015-0.229) 
0.383 
(0.170-0.961) 
0.277 
(0.266-0.308) 
2.00 
(1.95-2.14) 
3.37 
(3.24-3.80) 
-55933 
Wichmann 
[193] 
2006/07 0.027 
(0.016-0.163) 
0.263 
(0.150-0.946) 
NA 0.159 
(0.058-0.896) 
0.107 
(0.062-0.652) 
1.22 
(1.13-3.16) 
1.34 
(1.17-9.37) 
-30 
Luo 
[190] 
1978/88 China 0.018 
(0.014-0.235) 
0.000 
(0.000-0.001) 
0.399 
(0.237-0.741) 
0.002 
(0.001-0.023) 
0.046 
(0.020-0.366) 
0.514 
(0.255-0.970) 
0.071 
(0.056-0.941) 
1.82 
(1.62-2.72) 
2.83 
(2.28-5.76) 
-12911 
 1989/99 0.011 
(0.009-0.019) 
0.000 
(0.000-0.001) 
0.062 
(0.021-0.645) 
0.003 
(0.001-0.028) 
0.042 
(0.037-0.077) 
1.44 
(1.38-1.90) 
1.84 
(1.69-3.05) 
-12430 
 2000/09 0.012 
(0.005-0.081) 
0.000 
(0.000-0.006) 
0.243 
(0.084-0.560) 
0.055 
(0.034-0.269) 
0.049 
(0.022-0.352) 
1.53 
(1.22-5.72) 
2.05 
(1.34-11.45) 
-4413 
Guo 
[90] 
2005/11 0.004 
(0.003-0.010) 
0.000 
(0.000-0.005) 
0.006 
(0.002-0.099) 
0.028 
(0.018-0.104) 
0.018 
(0.011-0.040) 
1.15 
(1.09-1.36) 
1.22 
(1.12-1.63) 
-3459 
Anker 
[183] 
2000/06 Laos 0.011 
(0.006-0.042) 
0.102 
(0.074-0.372) 
NA 0.177 
(0.062-0.909) 
0.201 
(0.073-0.917) 
0.530 
(0.259-0.978) 
0.043 
(0.024-0.168) 
1.40 
(1.22-2.50) 
1.71 
(1.36-3.55) 
-45133 
Khampapongpane 
[195] 
2010 0.013 
(0.006-0.049) 
0.150 
(0.076-0.744) 
0.060 
(0.022-0.860) 
0.065 
(0.034-0.382) 
0.053 
(0.026-0.197) 
1.38 
(1.18-2.49) 
1.64 
(1.28-4.07) 
-33953 
Prasith 
[194] 
2010 0.018 
(0.009-0.082) 
0.139 
(0.082-0.469) 
0.164 
(0.059-0.934) 
0.297 
(0.162-0.937) 
0.072 
(0.038-0.328) 
1.57 
(1.29-4.04) 
2.10 
(1.49-6.92) 
-22762 
Hammond 
[184] 
1999/01 Nicaragua 0.021 
(0.005-0.035) 
0.026 
(0.021-0.858) 
NA 0.014 
(0.009-0.058) 
0.489 
(0.258-0.969) 
0.506 
(0.239-0.979) 
0.062 
(0.016-0.104) 
1.46 
(1.11-1.81) 
1.62 
(1.13-2.18) 
-1182 
Anker 
[183] 
1998-2005 Philippines 0.022 
(0.011-0.059) 
0.116 
(0.089-0.860) 
NA 0.265 
(0.119-0.938) 
0.316 
(0.137-0.932) 
0.460 
(0.225-0.967) 
0.086 
(0.043-0.237) 
1.86 
(1.43-3.21) 
2.53 
(1.76-4.82) 
-166118 
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Table 4.6 continued (2/2) 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
 
Author [Ref] Year Country i (95% CrI)  (95%CrI) B (95%CrI)  (95%CI)  1 (95%CrI)  3 (95%CrI) tot
(95%CrI) 
0iR (95%CrI)* LnL 
          1 2  
Rigau-Perez 
[198] 
1994 Puerto Rico 0.022 
(0.021-0.028) 
0.350 
(0.304-0.496) 
NA 0.005 
(0.003-0.019) 
0.408 
(0.282-0.904) 
0.656 
(0.416-0.987) 
0.067 
(0.062-0.085) 
1.92 
(1.83-2.20) 
2.36 
(2.22-2.83) 
-50388 
 1995/97  0.020 
(0.017-0.026) 
0.032 
(0.028-0.389) 
NA 0.006 
(0.003-0.143) 
  0.060 
(0.052-0.079) 
1.74 
(1.64-2.01) 
2.07 
(1.91-2.51) 
-9112 
Ramos 
[196]  
2006  0.017 
(0.013-0.043) 
0.364 
(0.300-0.804) 
NA 0.043 
(0.018-0.422) 
  0.070 
(0.051-0.170) 
1.64 
(1.44-2.93) 
2.32 
(1.83-5.20) 
-203 
Sharp 
[173] 
2010  0.015 
(0.011-0.028) 
0.160 
(0.134-0.504) 
NA 0.028 
(0.020-0.094) 
  0.062 
(0.046-0.111) 
1.71 
(1.50-2.43) 
2.48 
(1.97-4.37) 
-24291 
Tomashek 
[173] 
2007  0.010 
(0.005-0.020) 
0.053 
(0.044-0.699) 
NA 0.025 
(0.018-0.075) 
  0.040 
(0.021-0.079) 
1.38 
(1.20-1.83) 
1.69 
(1.30-2.75) 
-7042 
Anker 
[183] 
1999/05 Singapore 0.016 
(0.009-0.069) 
0.136 
(0.114-0.631) 
NA 0.328 
(0.112-0.956) 
0.047 
(0.020-0.444) 
0.488 
(0.229-0.974) 
0.062 
(0.035-0.275) 
1.86 
(1.45-5.50) 
2.78 
(1.86-10.03) 
-16182 
Koh 
[199] 
2005 0.011 
(0.009-0.014) 
0.268 
(0.251-0.527) 
NA 0.008 
(0.005-0.039) 
0.043 
(0.037-0.057) 
1.42 
(1.35-1.58) 
1.79 
(1.63-2.18) 
-20559 
Ler 
[185] 
2005/07 0.009 
(0.008-0.013) 
0.243 
(0.223-0.779) 
NA 0.006 
(0.003-0.050) 
0.037 
(0.031-0.052) 
1.36 
(1.30-1.53) 
1.64 
(1.51-2.06) 
-40149 
Anker 
[183] 
1996/05 Sri Lanka 0.019 
(0.013-0.079) 
0.070 
(0.057-0.356) 
NA 0.197 
(0.060-0.928) 
0.179 
(0.093-0.645) 
0.458 
(0.228-0.970) 
0.075 
(0.053-0.315) 
1.95 
(1.65-5.24) 
2.89 
(2.28-9.10) 
-16555 
Kulatilaka 
[200] 
2010 0.059 
(0.050-0.090) 
0.001 
(0.001-0.001) 
0.059 
(0.044-0.105) 
0.008 
(0.005-0.029) 
0.236 
(0.201-0.361) 
3.31 
(2.89-4.94) 
6.55 
(5.49-10.74) 
-1565 
Lin 
[186] 
2003/09 Taiwan 0.001 
(0.000-0.004) 
0.123 
(0.033-0.889) 
NA 0.010 
(0.007-0.053) 
0.034 
(0.019-0.399) 
0.508 
(0.253-0.980) 
0.002 
(0.001-0.015) 
1.02 
(1.01-1.15) 
1.02 
(1.01-1.21) 
-4241 
Limkittikul 
[201] 
200./10 Thailand 0.041 
(0.037-0.058) 
0.057 
(0.052-0.069) 
0.034 
(0.021-0.142) 
0.017 
(0.011-0.083) 
0.018 
(0.008-0.073) 
0.514 
(0.254-0.973) 
0.163 
(0.149-0.231) 
2.88 
(2.68-3.91) 
5.48 
(4.99-7.97) 
-1387845 
Wichmann 
[193] 
2006/07 0.058 
(0.037-0.198) 
0.470 
(0.411-0.945) 
NA 0.191 
(0.075-0.909) 
0.231 
(0.147-0.493) 
1.56 
(1.33-4.10) 
2.19 
(1.58-9.13) 
-146 
Cuong 
[189] 
1998/09 Vietnam 0.015 
(0.014-0.019) 
0.024 
(0.022-0.044) 
NA 0.010 
(0.007-0.031) 
0.039 
(0.016-0.682) 
0.496 
(0.253-0.971) 
0.061 
(0.055-0.076) 
1.54 
(1.48-1.69) 
2.06 
(1.92-2.42) 
-58901 
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Table 4.7: Summary parameter estimates from model 2 fitted to cumulative incidence data by country  (age-dependent reporting rate, model 2B). 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
Author [Ref] Country Year i
(95%CrI) 
y
(95%CrI) 
o
(95%CrI) 
B  
(95%CrI) 
thresholdA  
(95%CrI) 

(95%CrI) 
 1
(95%CrI) 
 3
(95%CrI) 
tot
(95%CrI) 
0iR (95%CrI)* LnL 
            1 2  
Cordeiro 
[191] 
Brazil 1995/01 0.018 
(0.014-
0.030) 
0.481 
(0.341-
0.943) 
0.460 
(0.369-
0.942) 
NA 65 
(20-79) 
0.007 
(0.004-
0.044) 
0.047 
(0.024-
0.193) 
0.491 
(0.258-
0.970) 
0.036 
(0.029-0.059) 
1.57 
(1.45-2.00) 
1.57 
(1.45-2.00) 
-355181 
 2002/06 0.012 
(0.010-
0.018) 
0.514 
(0.449-
0.966) 
0.494 
(0.368-
0.946) 
NA 65 
(50-79) 
0.006 
(0.004-
0.035) 
0.035 
(0.029-0.053) 
1.37 
(1.30-1.58) 
1.48 
(1.38-1.81) 
-326485 
Cardoso 
[181] 
2000/09 0.012 
(0.011-
0.015) 
0.078 
(0.072-
0.134) 
0.342 
(0.093-
0.973) 
NA 90 
(90-90) 
0.002 
(0.001-
0.008) 
 
0.037 
(0.034-0.045) 
1.43 
(1.40-1.54) 
1.58 
(1.53-1.76) 
-4333 
Penna 
[178] 
2001/06 0.006 
(0.004-
0.177) 
0.225 
(0.033-
0.910) 
0.403 
(0.222-
0.968) 
0.014 
(0.003-
0.820) 
70 
(30-90) 
0.045 
(0.017-
0.536) 
0.024 
(0.016-0.708) 
1.17 
(1.11-8.19) 
1.25 
(1.15-16.48) 
-55911 
Vong 
[192] 
Cambodia 2006/08 0.066 
(0.064-
0.073) 
0.183 
(0.177-
0.193) 
0.049 
(0.029-
0.216) 
NA 19 
(19-21) 
0.002 
(0.001-
0.005) 
0.033 
(0.015-
0.197) 
0.425 
(0.197-
0.966) 
0.265 
(0.256-0.292) 
1.94 
(1.91-2.07) 
3.22 
(3.10-3.58) 
-55927 
Wichmann 
[193] 
2006/07 0.030 
(0.016-
0.185) 
0.235 
(0.136-
0.931) 
0.495 
(0.272-
0.969) 
NA 15 
(10-15) 
0.183 
(0.068-
0.889) 
0.119 
(0.064-0.739) 
1.25 
(1.13-3.63) 
1.40 
(1.18-7.02) 
-31 
Luo 
[190] 
China 1978/88 0.017 
(0.014-
0.073) 
0.001 
(0.000-
0.001) 
0.491 
(0.245-
0.976) 
0.378 
(0.217-
0.748) 
90 
(90-90) 
0.002 
(0.001-
0.024) 
0.049 
(0.021-
0.394) 
0.522 
(0.262-
0.979) 
0.070 
(0.054-0.191) 
 
1.80 
(1.60-3.17) 
2.79 
(2.22-6.83) 
-12911 
 1989/99 0.011 
(0.009-
0.024) 
0.001 
(0.000-
0.001) 
0.511 
(0.254-
0.979) 
0.071 
(0.023-
0.701) 
90 
(90-90) 
0.003 
(0.001-
0.031) 
0.042 
(0.037-0.097) 
1.44 
(1.38-2.19) 
1.84 
(1.69-3.91) 
-12430 
 2000/09 0.012 
(0.005-
0.084) 
0.001 
(0.00-
0.008) 
0.498 
(0.242-
0.978) 
0.199 
(0.060-
0.552) 
90 
(90-90) 
0.052 
(0.033-
0.256) 
0.047 
(0.020-0.357) 
1.50 
(1.20-10.71) 
1.98 
(1.30-12.43) 
-4413 
Guo 
[90] 
2005/11 0.004 
(0.003-
0.010) 
0.001 
(0.00-
0.007) 
0.471 
(0.219-
0.973) 
0.007 
(0.002-
0.117) 
90 
(90-90) 
0.029 
(0.019-
0.104) 
0.018 
(0.011-0.039) 
1.15 
(1.09-1.35) 
1.22 
(1.12-1.61) 
-3459 
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Table 4.7 continued (2/3). 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
 
Author [Ref] Country Year i
(95%CrI) 
y
(95%CrI) 
o
(95%CrI) 
B  
(95%CrI) 
thresholdA
(95%CrI) 

(95%CrI) 
 1
(95%CrI) 
 3
(95%CrI) 
tot
(95%CrI) 
0iR (95%CrI)* LnL 
            1 2  
Anker 
[183] 
Laos 2000/06 0.016 
(0.003-
0.150) 
0.079 
(0.024-
0.949) 
0.331 
(0.176-
0.955) 
NA 15 
(15-15) 
0.204 
(0.074-
0.908) 
0.171 
(0.070-
0.828) 
0.476 
(0.248-
0.972) 
0.063 
(0.010-
0.601) 
1.59 
(1.09-
5.86) 
2.05 
(1.13-
11.58) 
-45134 
Khampapong
pane 
[195] 
2010 0.014 
(0.006-
0.095) 
0.117 
(0.060) 
0.234 
(0.137-
0.885) 
0.059 
(0.023-
0.582) 
40 
(20-40) 
0.070 
(0.034-
0.432) 
0.057 
(0.024-
0.380) 
1.41 
(1.17-
4.06) 
1.70 
(1.26-
7.51) 
-33953 
Prasith 
[194] 
2010 0.025 
(0.012-
0.173) 
0.097 
(0.061-
0.435) 
0.451 
(0.236-
0.969) 
0.260 
(0.097-
0.937) 
80 
(40-80) 
0.340 
(0.188-
0.929) 
0.098 
(0.047-
0.692) 
1.81 
(1.36-
7.41) 
2.63 
(1.64-
12.71) 
-22762 
Hammond 
[184] 
Nicaragua 1999/01 0.014 
(0.002-
0.034) 
0.038 
(0.023-
0.937) 
0.398 
(0.131-
0.959) 
NA 
 
55 
(39-55) 
0.016 
(0.010-
0.059) 
0.451 
(0.227-
0.971) 
0.502 
(0.264-
0.975) 
0.043 
(0.005-
0.103) 
1.31 
(1.04-
1.80) 
1.40 
(1.04-
2.16) 
-1183 
Anker 
[183] 
Philippines 1998-
2005 
0.010 
(0.006-
0.096) 
0.253 
(0.094-
0.943) 
0.170 
(0.117-
0.788) 
NA 15 
(15-15) 
0.301 
(0.132-
0.930) 
0.186 
(0.105-
0.829) 
0.443 
(0.207-
0.968) 
0.042 
(0.024-
0.385) 
1.41 
(1.23-
4.40) 
1.73 
(1.38-
7.35) 
-166118 
Rigau-Perez 
[198] 
Puerto Rico 1994 0.022 
(0.017-
0.029) 
0.456 
(0.377-
0.920) 
0.514 
(0.413-
0.967) 
NA 55 
(25-99) 
0.003 
(0.002-
0.015) 
0.165 
(0.080-
0.658) 
0.565 
(0.313-
0.977) 
0.065 
(0.052-
0.087) 
1.89 
(1.68-
2.24) 
2.31 
(1.97-
2.90) 
-50387 
 1995/97 0.020 
(0.016-
0.027) 
0.040 
(0.035-
0.841) 
0.368 
(0.127-
0.969) 
NA 85 
(75-85) 
0.008 
(0.003-
0.212) 
0.059 
(0.047-
0.080) 
1.73 
(1.56-
2.03) 
2.05 
(1.78-
2.54) 
-9113 
Ramos 
[196] 
2006 0.017 
(0.013-
0.039) 
0.454 
(0.364-
0.917) 
0.470 
(0.317-
0.957) 
NA 40 
(30-61) 
0.038 
(0.014-
0.395) 
0.069 
(0.051-
0.156) 
1.63 
(1.44-
2.71) 
2.31 
(1.84-
5.49) 
-203 
Sharp 
[173] 
2010 0.016 
(0.009-
0.030) 
0.193 
(0.158-
0.942) 
0.274 
(0.194-
0.939) 
NA 60 
(20-81) 
0.019 
(0.011-
0.078) 
0.062 
(0.038-
0.120) 
1.71 
(1.41-
2.57) 
2.50 
(1.75-
4.73) 
-24289 
Tomashek 
[197] 
2007 0.010 
(0.003-
0.022) 
0.070 
(0.052-
0.916) 
0.217 
(0.091-
0.935) 
NA 60 
(30-85) 
0.022 
(0.015-
0.080) 
0.039 
(0.010-
0.087) 
1.38 
(1.09-
1.93) 
1.68 
(1.12-
3.01) 
-7041 
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Table 4.7 continued (3/3). 
*Assumption 1: individuals can be infected up to four times. Assumption 2: individuals are immune after two infections. 
Author [Ref] Country Year i
(95%CrI) 
y
(95%CrI) 
o
(95%CrI) 
B  
(95%CrI) 
thresholdA
(95%CrI) 

(95%CrI) 
 1
(95%CI) 
 3
(95%CI) 
tot
(95%CI) 
0iR (95%CI)* LnL 
            1 2  
Anker 
[183] 
Singapore 1999/05 0.011 
(0.005-
0.108) 
0.201 
(0.053-
0.942) 
0.249 
(0.151-
0.942) 
NA 15 
(15-15) 
0.300 
(0.117-
0.952) 
0.052 
(0.022-
0.398) 
0.535 
(0.275-
0.970) 
0.044 
(0.020-
0.431) 
1.58 
(1.24-
8.19) 
2.14 
(1.40-
16.10) 
-16182 
Koh 
[199] 
2005 0.010 
(0.008-
0.016) 
0.267 
(0.238-
0.869) 
0.375 
(0.279-
0.919) 
NA 65 
(55-85) 
0.008 
(0.005-
0.047) 
0.042 
(0.031-
0.063) 
1.41 
(1.30-
1.65) 
1.75 
(1.51-
2.35) 
-20560 
Ler 
[185] 
2005/07 0.009 
(0.007-
0.014) 
0.242 
(0.214-
0.814) 
0.350 
(0.252-
0.945) 
NA 80 
(55-80) 
0.006 
(0.003-
0.062) 
0.036 
(0.027-
0.057) 
1.36 
(1.26-
1.59) 
1.63 
(1.43-
2.20) 
-40150 
Anker 
[183] 
Sri Lanka 1996/05 0.001 
(0.000-
0.188) 
0.165 
(0.003-
0.953) 
0.115 
(0.036-
0.738) 
NA 15 
(15-15) 
0.238 
(0.098-
0.910) 
0.250 
(0.112-
0.899) 
0.507 
(0.262-
0.975) 
0.004 
(0.001-
0.521) 
1.05 
(1.02-
11.17) 
1.05 
(1.02-
24.38) 
-16555 
Kulatilaka 
[200] 
2010 0.065 
(0.055-
0.128) 
0.001 
(0.001-
0.001) 
0.491 
(0.215-
0.974) 
0.083 
(0.058-
0.374) 
65 
(65-65) 
0.009 
(0.006-
0.035) 
0.260 
(0.221-
0.514) 
3.61 
(3.12-
7.20) 
7.31 
(6.07-
16.67) 
-1566 
Lin 
[200] 
Taiwan 2003/09 0.001 
(0.000-
0.003) 
0.221 
(0.069-
0.933) 
0.429 
(0.211-
0.963) 
NA 75 
(55-85) 
0.010 
(0.006-
0.051) 
0.033 
(0.017-
0.334) 
0.527 
(0.270-
0.973) 
0.002 
(0.001-
0.011) 
1.01 
(1.01-
1.11) 
1.01 
(1.01-
1.14) 
-4241 
Limkittikul 
[201] 
Thailand 200./10 0.044 
(0.038-
0.375) 
0.047 
(0.033-
0.067) 
0.393 
(0.131-
0.974) 
0.069 
(0.038-
0.790) 
80 
(80-80) 
0.030 
(0.016-
0.196) 
0.022 
(0.011-
0.070) 
0.512 
(0.252-
0.978) 
0.174 
(0.154-
0.500) 
3.04 
(2.75-
7.40) 
5.88 
(5.15-
15.79) 
-1387846 
Wichmann 
[193] 
2006/07 0.062 
(0.039-
0.196) 
0.461 
(0.387-
0.944) 
0.591 
(0.364-
0.985) 
NA 10 
(10-15) 
0.183 
(0.067-
0.916) 
0.248 
(0.155-
0.786) 
1.61 
(1.35-
4.05) 
2.34 
(1.63-
13.65) 
-146 
Cuong 
[189] 
Vietnam 1998/09 0.018 
(0.014-
0.026) 
0.021 
(0.010-
0.106) 
0.025 
(0.023-
0.894) 
NA 30 
(15-79) 
0.005 
(0.002-
0.024) 
0.044 
(0.020-
0.270) 
0.523 
(0.284-
0.982) 
0.072 
(0.055-
0.103) 
1.64 
(1.48-
1.98) 
2.31 
(1.91-
3.15) 
-58897 
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Figure 4.18: Model fits of model 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted 
to cumulative incidence data from Brazil (Cordeiro et al., [191] Cardoso et al., [181] and Penna et al. 
[178]). 95% exact confidence intervals around data points, posterior median (line), and 95% credible 
interval (shaded area) shown. 
 
 
 
Figure 4.19: Model fits of models 1 (single reporting rate) and 2 (age-dependent reporting rate) 
fitted to cumulative incidence data from Cambodia (Vong et al. [192] and Wichmann et al. [193]).  
95% exact confidence interval around data points, posterior median (line) and 95% credible interval 
(shaded area) shown. 
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Figure 4.20: Model fits of models 1 (single reporting rate) and 2 (age-dependent reporting rate) 
fitted to cumulative incidence data from China (Luo et al. [190] and Guo et al. [90]). 95% exact 
confidence interval around data points, posterior median (line) and 95% credible interval (shaded 
area) shown. 
 
 
 
Figure 4.21: Model fits of model 1 (single reporting rate) and model 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from Laos (Anker et al. [183]).  95% exact confidence 
interval around data points, posterior median (line) and 95% credible interval (shaded area) shown. 
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Figure 4.22: Model fits of model 1 (single reporting rate) and model 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from Nicaragua (Hammond et al. [184]). 95% exact 
confidence interval around data points, posterior median (line) and 95% credible interval (shaded 
area) shown. 
 
 
 
Figure 4.23: Model fits of model 1 (single reporting rate) and model 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from the Philippines (Anker et al. [183]).  95% exact 
confidence intervals around data points, posterior median (line) and 95% credible interval (shaded 
area) shown. 
  
Page 157 of 228 
 
 
Figure 4.24: Model fits of model 1 (single reporting rate) and model 2 (age-dependent reporting 
rate) fitted to yearly incidence data from Puerto Rico (Rigau-Perez et al. [198]).  95% exact 
confidence intervals around data points, posterior median (line) and 95% credible intervals (shaded 
area) shown. 
 
 
 
Figure 4.25: Model fits of model 1 (single reporting rate) and model 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from Singapore (Anker et al. [183] and Ler et al. [185]).  
95% exact confidence interval around data points, posterior median (line) and 95% credible interval 
(shaded area) shown. 
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Figure 4.26: Model fits from model 1 (single reporting rate) and model 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from Sri Lanka (Kulatilaka et al. [200] and Anker et al. [183]).  
95% exact confidence interval around data points, posterior median (line) and 95% credible interval 
(shaded area) shown. 
 
 
 
Figure 4.27: Model fits from model 1 (single reporting rate) and model 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from Taiwan (Lin et al. [186]).  95% exact confidence 
intervals around data points, posterior median (line) and 95% credible intervals (shaded area) shown. 
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Figure 4.28: Model fits from model 1 (single reporting rate) and model 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from Thailand (Limkittikul et al. [201] and Wichmann et al. 
[193]).  95% exact confidence intervals around data points, posterior median (line) and 95% credible 
interval (shaded area) shown. 
 
 
 
Figure 4.29: Model fits from model 1 (single reporting rate) and model 2 (age-dependent reporting 
rate) fitted to cumulative incidence data from Vietnam (Cuong et al. [189]).  95% exact confidence 
intervals around data points, posterior median (line) and 95% credible interval (shaded area) shown. 
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Estimates of R0i varied according to the assumptions made regarding host immunity. 
Assuming only primary and secondary infections are infectious (assumption 2) gave up to 
two-fold higher estimates than assuming tertiary and quaternary infections are also 
infectious (Figure 4.3 and Figure 4.16). This is consistent with our previous results analysing 
seroprevalence data ([174] and chapters 2 and 3). Some force of infection estimates in 
Cambodia were very high, perhaps a result of the active surveillance undertaken as part of 
the study by Vong et al. [192]. There was greatest variation in dengue transmission intensity 
in Asia (Table 4.4 - Table 4.7). The baseline reporting rate (), which is defined as the 
probability of detecting a secondary infection, was 10% (range: 1% - 79%) and 16% (range: 
1%-55%) when fitted to yearly and cumulative incidence data respectively assuming a single 
reporting rate for all ages. When we allowed for age-dependent reporting rates, estimates 
of   increased to between 26% - 33% and 13% - 37% when fitted to yearly and cumulative 
incidence data respectively. Figure 4.30 shows the dataset-specific estimates of the baseline 
reporting rate (  , y , and o ) and the probability of detecting a primary ( 1 ) case relative 
to the baseline reporting rate, and the probability of detecting a tertiary/quaternary ( 3 ) 
case relative to a primary case by model type. The median probability of detecting a primary 
case relative to a secondary case was consistently low at less than 25% for the majority of 
data sets and models. However, the credible intervals for some 1  estimates were wide. The 
data proved uninformative about the contribution of post-secondary infections to disease 
incidence, as our estimates of 3  reflected the prior distribution assumed for that parameter 
(uniform from 0 to 1). 
When we allowed for reporting rates to vary by age, we found that the median probability 
that a secondary infection was detected was higher in older compared with younger 
individuals (Figure 4.30). However, stratifying parameter estimates by country, when o  
was higher than y  the corresponding estimate of the age threshold at which reporting 
rates changed ( thresholdA ) were high (Figure 4.31, Table 4.5 and Table 4.7). In such cases the 
reporting rate y  applied to the majority of age groups and the estimated values were 
comparable to the corresponding baseline reporting rates estimated from the model 
variants which did not incorporate age-dependent reporting. 
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Figure 4.30: Boxplots of estimated reporting rates by model type : A) model 1A, B) model 1B, C) 
model 2A and D) model 2B. Each point represents the posterior median estimate for one dataset. ρ, 
ρ Y, ρ O = baseline reporting rate or probability of detecting a secondary infection for all ages, 
individuals younger than threshold age, and individuals older than the threshold age respectively. γ₁ 
= probability of detecting a primary infection relative to a secondary infection, and γ₃ = probability of 
detecting a tertiary/quaternary infection relative to a primary infection. Model 1a and 1b were fitted 
to yearly and cumulative incidence data respectively assuming a non-age dependent reporting rate, 
while model 2a and 2b were fitted to yearly and cumulative incidence data respectively assuming an 
age-dependent reporting rate. 
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Figure 4.31: Comparison of baseline reporting rates (, Y, O ) and estimated age (years) at which 
reporting rates change (Athreshold) by model. A) model with single reporting rate fitted to yearly 
incidence data, B) model with single reporting rate fitted to cumulative incidence data, C) model 
with age-dependent reporting rate fitted to yearly incidence data, and D) model with age-dependent 
reporting rate fitted to cumulative incidence data. Each point represents the posterior median 
estimate for one dataset. 
 
The baseline reporting rates (  ) varied substantially by country (Figure 4.31), likely 
reflecting differences in healthcare seeking behaviour and surveillance. Generally, estimated 
reporting rates in the Americas were higher than in South East Asia, with Singapore having 
the highest rate within SE Asia. Reporting rates also varied within each country depending 
on survey year or survey region, which may reflect differences in local healthcare systems or 
changes in public awareness after epidemics. Estimates from Cambodia were high due to 
the active surveillance employed during that study (Vong et al. 2006-2008 [192]). The 
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estimated age at which reporting rates changed was consistently lower in South East Asia 
(Cambodia, Laos, Sri Lanka, and the Philippines – except Singapore) than in the Americas 
(Brazil and Puerto Rico). Comparing models fitted to yearly incidence and cumulative 
incidence data, model 2 provided a better fit to the data 62% and 59% of the time 
respectively as assessed by the DIC (Table 4.8 and Table 4.9). 
 
Table 4.8: Summary DIC comparison of model fits to yearly incidence data. Models 1 (single 
reporting rate) and 2 (age-dependent reporting rate) fitted to yearly incidence data. Smaller DIC for 
each dataset is highlighted in bold where the difference is greater than 5. 
  Author [Ref] Year # serotypes Country DIC 
    Model 1 Model 2 
Cordeiro [191] 1995 2 Brazil 35710 35703 
 1996 2 80771 80769 
 1997 2 115423 115414 
 1998 2 186560 186511 
 1999 2 128229 128227 
 2000 3 101163 101163 
 2001 3 62048 62035 
 2002 3 418449 418448 
 2003 3 95070 94633 
 2004 3 23166 23163 
 2005 3 47099 47095 
 2006 3 68804 68797 
Penna [178] 2001 4 27771 28830 
 2002 4 13788 17822 
 2003 4 20633 20681 
 2004 4 3032 10996 
 2005 4 16643 16998 
 2006 4 15566 15592 
Vong [192] 2006 4 Cambodia 41711 41710 
 2007 4 221410 221390 
 2008 4 68562 68544 
Wichmann [193] 2006 4 65 65 
 2007 4 1088 1087 
Anker [183] 2000 4 Laos 2104 2055 
 2001 4 7257 6585 
 2002 4 16365 15530 
 2003 4 34578 32495 
 2004 4 6557 4009 
 2005 4 10482 9734 
 2006 4 11876 10165 
Khampapongpane [195] 2010 4 64888 67566 
Prasith [194] 2010 4 45456 44129 
Anker [194] 1998 4 Philippines 67732 65607 
 1999 4 18300 11191 
 2001 4 47633 47674 
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Table 4.8 continued (2/2). 
 
  
Author Year # serotypes Country DIC  
    Model 1 Model 2 
Anker [194] 2002 4 Philippines 32395 32374 
 2003 4 57113 53741 
 2004 4 44004 44018 
 2005 3 64390 64353 
Rigau-Perez [198] 1994 3 Puerto 
Rico 
100776 100727 
 1995 3 6127 6128 
 1996 3 5393 5396 
 1997 4 6742 6747 
Ramos [196] 2006 4 409 409 
Sharp [173] 2007 4 48497 48514 
Tomashek [197] 2010 4 14076 14014 
Anker [194] 1999 4 Singapore 1041 785 
 2000 4 725 474 
 2001 4 1879 690 
 2002 4 3013 917 
 2003 4 3719 1133 
 2004 4 8270 7606 
 2005 4 13714 13514 
Koh [199] 2005 4 41122 41121 
Ler [185] 2005 4 50174 50175 
 2007 4 29440 29440 
Anker [183] 1996 4 Sri Lanka 2279 1967 
 1997 4 1621 1621 
 1998 4 1980 2210 
 1999 4 2350 1800 
 2000 4 4605 3594 
 2001 4 4422 4672 
 2002 4 4509 3736 
 2003 4 2426 2425 
 2004 4 5722 1706 
 2005 4 1763 1738 
Kulatilaka [200] 1997 4  3124 3138 
Limkittikul [201] 2000 4 Thailand 58282 59755 
 2001 4 450738 451213 
 2002 4 371748 376250 
 2003 4 206304 214588 
 2004 4 124400 133462 
 2005 4 157060 159895 
 2006 4 156750 160942 
 2007 4 225396 225623 
 2008 4 318403 318907 
 2009 4 190752 206441 
 2010 4 430542 430608 
Wichmann [193] 2006 4 64 64 
 2007 4 227 228 
Bangkok [186] 2000 4 22938 22939 
Ratchaburi [186] 2000 4 5624 5624 
Rayong [186] 2010 4 8259 8236 
Ghouth [202] 2010 3 Yemen 3582 3576 
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Table 4.9: Summary DIC comparison of model fits to cumulative incidence data.  Models 1 (single 
reporting rate) and 2 (age-dependent reporting rate) fitted to cumulative incidence data. Smaller DIC 
for each dataset is highlighted in bold where the difference is greater than 5. 
  Author Year Country Model 1 Model 2 
Cordeiro [191] 1995/01 
Brazil 
710366 710318 
 
2002/06 652964 652966 
Cardoso [181] 2000/09 8670 8671 
Penna [178] 2001/06 111819 111696 
Vong [192] 2006/08 
Cambodia 
111870 111861 
Wichmann [193] 2006/07 64 64 
Luo [190] 1978/88 
China 
25826 25826 
 1989/99 23810 24861 
 2000/09 8823 8818 
Guo [90] 2005/11 6914 6895 
Anker [183] 2000/06 Laos 90188 58722 
Hammond [184] 1995/97 Nicaragua 2358 2335 
Anker [183] 1998/05 Philippines 332153 331296 
Rigau-Perez [198] 1994 
Puerto Rico 
100773 100697 
 
1995/97 18219 18231 
Anker [183] 1999/05 
Singapore 
32360 26429 
Ler [185] 2005/07 80303 80304 
Anker [183] 1996/05 Sri Lanka 33110 29570 
Lin [186] 2003/09 Taiwan 8458 8434 
Limkittikul [201] 2000/10 
Thailand 
2775619 2775687 
Wichmann [193] 2006/07 292 289 
Cuong [189] 1998/09 Vietnam 117807 117801 
Page 166 of 228 
 
4.3.4 Comparison of Estimates Obtained from Seroprevalence and Incidence 
data. 
We used weighted regression to compare the force of infection estimates obtained from 
age-stratified seroprevalence data to cumulative incidence data. Estimates obtained from 
the model fitted to the cumulative incidence data assuming a single reporting rate (Model 
1B) were comparable to force of infection estimates from seroprevalence data. The majority 
of the total force of infection ( total ) estimates from incidence data (calculated by 
multiplying the serotype-specific force of infection by the number of serotypes in 
circulation) were comparable for both models to those obtained from seroprevalence data 
when total  was smaller than ~0.1 with greater uncertainty as force of infection increases 
(Figure 4.32). 
 
 
Figure 4.32: Comparison of weighted deming regression of force of infection estimates by country 
from cumulative incidence data and seroprevalence data for A) model 1B (non-age dependent 
reporting) and B) model 2B (age-dependent reporting rate). Each point is weighted depending on the 
error in both serology and incidence estimates, represented by the size of circles (larger circles 
indicating greater weight). See Table 4.1 for summary of matched datasets. 
 
In two of the three locations in Thailand where region and time matching seroprevalence 
and incidence data were available [187], the force of infection estimates obtained from the 
models fitted to incidence data and serology data had overlapping 95% credible intervals. In 
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Ratchaburi the estimate obtained from seroprevalence data was smaller than that from 
incidence data (Figure 4.33).  
 
 
Figure 4.33: Comparison of force of infection estimates derived from incidence data and 
seroprevalence data.  Comparison of posterior median estimates and 95% CrI of the total force of 
infection from Models 1 (single reporting rate) and 2 (age-dependent reporting rate) fitted to 
incidence data and model A (as described in [174]) to age-stratified seroprevalence data from 
Thailand where incidence and serology data were available from the same year and location . 
 
4.3.5 Regression Analysis 
Multiple regression analysis was conducted to explore the relationship between estimated 
dengue transmission intensity and the covariates summarised in Table 4.10. Figure 4.34 
summarises the analysis results. The multiple regression with all 7 predictors produced 
R2=0.40. Absolute latitude (distance from the equator) and GDP per capita (USD) were both 
negatively associated with the force of infection (p=0.03 and p=0.01 respectively). The 
remaining predictors were not associated with the outcome variable. 
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Figure 4.34: Scatterplots showing the relationship between estimated force of infection, and 
demographic and environmental covariates. A) absolute latitude, B) average maximum temperature, 
C) sample size, D) population size of study region, E) whether the study was conducted in an urban 
or rural setting, F) GDP per capita (USD), and G) lab confirmation. Each point represents an estimate 
for a single year. 
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Table 4.10: Weighted multiple regression results 
Variable Correlation with   Coefficients (95% CI) p-value 
Intercept - 3.19x10-2 
(3.01x10-3 – 6.08x10-2) 
0.03 
Absolute latitude -0.16 -1.07x10-3 
(-2.05x10-3 – 8.38x10-5) 
0.03 
Average maximum temperature 0.31 -5.23x10-4 
(-1.36x10-3 – 3.51x10-4) 
0.23 
Sample size -0.22 4.80x10-11 
(-4.09x10-10 – 5.05x10-10) 
0.83 
Population size of study region -0.07 9.94x10-11 
(-3.13x10-10 – 5.12x10-10) 
0.62 
Urban/Rural^ 0.13 2.29x10-3 
(-2.72x10-3 – 7.29x10-3) 
0.36 
GDP per capita (USD) -0.29 -7.89x10-7 
(-1.40x10-6 – -1.75x10-7) 
0.01 
Laboratory confirmation* 0.06 1.59x10-2 
(-5.07x10-3 – 3.69x10-2) 
0.13 
^coded as 1=urban, 0=rural, 3=both. *coded as 0=no, 1=yes.  
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4.4 Discussion 
From a literature search we selected 23 papers reporting age-stratified case notification 
data in 13 countries from 1978-2010. When reported incidence data were split into yearly 
notifications, this gave a total of 96 survey years. For each dataset we estimated dengue 
transmission intensity as quantified by the force of infection ( i ) and the basic reproduction 
number (R0i). The total force of infection ( total ) estimated from cumulative incidence data 
were compared with previous   estimates from seroprevalence data.  
The incidence models presented in this chapter provide a method for estimating dengue 
transmission intensity in areas where seroprevalence data are not available. Force of 
infection estimates and corresponding basic reproduction numbers varied widely across and 
within countries as expected, highlighting the heterogeneous nature of dengue transmission 
spatially and temporally. The majority of our R0i estimates ranged from 1 to 5, similar to our 
estimates obtained from seroprevalence data [174]. As for our serology-based estimates, 
force of infection estimates were generally higher in South East Asia than for Latin America.  
Since we had no serotype-specific notification data, we assumed that all serotypes were 
equally transmissible. If serotype-specific notification data were available, a serotype-
specific force of infection might be estimated.  
Generally model 2 provided a better fit to yearly incidence (62% of the time) and cumulative 
incidence data (59% of the time) as assessed by the DIC. However if the data were age-
stratified more finely we predict that model 2 would perform better consistently since it 
allows for age-dependent reporting rates. 
Due to the lack of incidence and serology data collected in the same year and region, we 
matched incidence and serology datasets according to the year or study region (Table 4.1). 
While overall estimates from incidence data were comparable with those derived from 
seroprevalence data, it would nonetheless be beneficial to validate this model with multiple 
incidence and serology datasets collected simultaneously in the same geographical location. 
Similarly to the force of infection estimates obtained from seroprevalence data (chapters 2 
and 3), weighted multiple regression was conducted to explore the relationship between 
the estimated forces of infection and various potential predictors. We fitted the single 
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reporting rate model to cumulative incidence data where possible. Distance from the 
equator and GDP per capita (USD) were negatively associated with the force of infection 
(p=0.03 and p=0.01 respectively). This is somewhat consistent with the results from the 
multiple regression in the previous chapter where these two covariates were weakly 
associated with the force of infection. However, whether the study was conducted in an 
urban or rural environment was not associated with transmission intensity unlike the 
estimates obtained from seroprevalence studies. This is likely due to many of the studies 
reporting dengue cases at the national level. Ideally we would have explored the 
associations using a meta-regression, allowing for the between trial variance. However 
again, we could not calculate sampling variances from our data since our variable of interest 
– the force of infection is in itself a model output. 
Generally, estimated reporting rates (  ) in the Americas were higher than those in South 
East Asia with Singapore having the highest rate within South East Asia, consistent with their 
well-established dengue surveillance program [205]. Reporting rate estimates for Cambodia 
were very high compared with the rest of South East Asia, presumably due to the active 
surveillance employed during the study which collected the data [192]. Reporting rate 
estimates also varied within each country depending on survey year or survey region 
reflecting variation in healthcare and surveillance systems [53]. Reporting rates are also 
likely to change in response to recent or current epidemics which affect public awareness of 
dengue thus affecting healthcare seeking behaviour [206]. Additionally, in an epidemic year 
clinicians may preferentially diagnose a febrile illness as dengue without laboratory testing 
[50].  
For models 2A and 2B we hypothesised that severity or disease reporting differed by age 
group and estimated age-dependent reporting rates ( y  and o ) and  the age at which 
reporting rates changed ( thresholdA ). Allowing reporting rates to vary with age in this manner 
generally provided a better fit to the data broken down by survey year (model 2A) and 
cumulative data (model 2B), as assessed by the DIC. In the Americas the threshold age at 
which reporting rates changed was high (over 50 years of age) and so the majority of age 
groups had the same reporting rate ( y ) – effectively equivalent to assuming the same 
reporting rate for all ages (i.e. model 1). In contrast, the estimated age at which reporting 
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rates changed was generally much younger in South East Asia, with the reporting rate in 
younger individuals ( y ) estimated as slightly higher than that of older individuals ( o ). 
This is consistent with dengue tending to be viewed as a paediatric infection in South East 
Asia (and thus perhaps less likely to  be diagnosed in adults), but being widely accepted as a 
disease affecting all ages in the Americas [6]. Yet with the rapidly changing demographics in 
Thailand (lower birth and death rates) increasing the average age of DHF, reporting rates in 
adult age groups may increasing in coming years in such contexts. In contrast to our finding 
of higher estimated reporting rates in children, there is some evidence that the risk that a 
dengue infection is symptomatic increases with age [95,205]. However, the higher reporting 
rates we estimate for children in South East Asia may reflect parents being more likely to 
seek healthcare for a child than for an adult, or clinicians being more likely to diagnose 
dengue in children. Importantly estimating the age at which reporting rates changed 
( thresholdA ) was limited by the age aggregation used in each study, therefore for surveys with 
few age groups this estimated threshold should be treated with caution. 
Since the majority of notified dengue cases are diagnosed as secondary dengue infections 
[3,4,20,122,173], we assumed that the probability of detecting a primary case would be 
smaller than the probability of detecting a secondary case, and that the probability of 
detecting a tertiary/quaternary case would be smaller than the probability of detecting a 
primary case ( 3 1     ). The probability of detecting a primary case was consistently low 
relative to a secondary case (Figure 4.30) at less than 50%, the majority being under 25%. 
However, we were not able to estimate the probability of detecting a tertiary/quaternary 
case (relative to a primary case) from the available data. A prospective cohort study in 
Nicaragua found that the proportion of inapparent to symptomatic infection did not differ 
according to whether an individual had a primary, secondary, or tertiary infection [207]. 
Overall, the impact of cross-immunity and the contribution of tertiary and quaternary 
infections to onward transmission are still not well quantified. While there is evidence that 
tertiary and quaternary infections occur [25,28], there is little quantitative data on the 
infectiousness or severity of such infections relative to primary and secondary infections. 
Additionally, clinically apparent tertiary or quaternary infections are not routinely reported, 
nor can they be tested for retrospectively [25]. Wikramaratna et al. showed that tertiary 
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and quaternary infections allows for the high seroprevalence at very young ages observed in 
Haiti [29] and Nicaragua [30] better than when assuming complete protection after two 
heterologous infections [25].  
Since the majority of dengue infections are mild or asymptomatic, even sensitive healthcare 
systems can substantially underestimate true rates of infection even for the supposedly 
more severe secondary infections, as shown by the low baseline reporting rates [122,123]. 
Furthermore, dengue has a wide spectrum of clinical manifestations making it difficult to 
accurately diagnose in the first instance [52]. Although incidence data are the most 
abundant form of data available on dengue transmission, surveillance systems and reporting 
procedures are not standardised within or across countries making it very difficult to reliably 
compare estimates [52]. Laboratory capacity and general public health infrastructure and 
surveillance systems vary widely and there is often no integration between private and 
public health sectors. With such variable data it is very difficult to estimate dengue burden 
(or transmission intensity) consistently. Since non-serotype specific serological (IgG) surveys 
are relatively inexpensive to collect, it would be beneficial for such seroprevalence data to 
be collected routinely. Such data would provide better baseline estimates of overall 
transmission intensity against which incidence based-estimates could be calibrated to assess 
changes in transmission and identify weaknesses in surveillance systems.  
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5 Estimating the global burden of dengue and the impact of control 
measures 
In this chapter I present methods to estimate the global burden of dengue. Data on the 
probability of dengue occurrence is used in conjunction with the force of infection estimates 
I estimated in chapters 2, 3, and 4. The incidence model developed in chapter 4 is then used 
to estimate the global burden of dengue. The potential impact of novel control measures 
such as the release of Wolbachia infected mosquitoes was explored.  The work in this 
chapter was conducted in collaboration with Dr. Oliver Brady and Prof. Simon Hay 
(University of Oxford) who shared the probability of dengue occurrence data, and Dr. Wes 
Hinsley (Imperial College London) who coded the model in Java. 
5.1 Introduction 
Recent estimates of the global distribution of dengue have refined our understanding of the 
burden of dengue disease, but remain ambiguous. In particular, Bhatt et al.’s estimate of 
390 million dengue infections per year (and 96 million apparent infections) is three times 
higher than previous official World Health Organisation (WHO) estimates, with India 
accounting for 34% of that total [108]. Motivated by previous work on malaria, the Bhatt et 
al. analysis relied on correlating their geographic niche-modelling based estimates of 
dengue presence with burden estimates derived from serological surveys. They built a 
boosted regression tree (BRT) statistical model of dengue transmission risk using an 
extensive database of geo-located dengue occurrence records, a global evidence-based 
consensus map of dengue in 2010 [208], and incorporated covariates known to affect 
dengue transmission such as rainfall and temperature. They then mapped the probability of 
occurrence (PO) or risk of dengue infection globally for each 5km x 5km pixel. This was 
further combined with serological cohort studies looking at dengue sero-incidence to build a 
non-parametric Bayesian hierarchical model to predict the number of inapparent and 
clinically apparent dengue infections [108]. One weakness of this analysis is that infection 
incidence was not bounded by population birth rates. Furthermore, unlike malaria, the 
number of dengue infections an individual can acquire in their lifetime is finite (up to four), 
yet in the Bhatt et al. analysis individuals were allowed to have an infinite number of 
dengue infections in their lifetime.  
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Obtaining robust estimates of the geographic variation in average dengue transmission 
intensity – as quantified by the basic reproduction number, 0R , of each serotype – is key to 
improving the reliability of burden estimates. In addition, a quantitative understanding of 
variation in transmission intensity is essential in assessing the likely impact of interventions 
such as a vaccine [60,61] or novel vector control measures such as Wolbachia infected 
mosquitoes [70,74,110]. Given the highly heterogeneous nature of dengue transmission, 
age-stratified seroprevalence surveys (preferably serotyped) with high spatial resolution 
provides the best estimates of dengue transmission intensity ([174] and chapters 2 and 3). I 
have also shown previously that force of infection ( ) estimates from age-stratified 
notification data can provide estimates comparable to   estimates from serological data 
(chapter 4). However, in areas where dengue is not reported, or areas where dengue is not 
thought to be endemic, such data are harder to collect. Hence if the presence-absence data 
can be reliably translated into quantitative measures of dengue burden - such as   and 0R , 
then more robust estimates can be made.  
Here I develop a model to estimate   and 0R  from presence-absence data by regressing 
the force of infection estimates derived from seroprevalence and incidence data from 
previous work (chapters 2-4) on probability of occurrence estimates from the Bhatt et al. 
model [108]. I then use this regression relationship to generate global force of infection and 
R0 estimates at 5 km resolution. This allows me to generate corresponding disease burden 
estimates that constrain the number of lifelong infections an individual can experience. 
Furthermore, I look at the potential impact that control measures, specifically Wolbachia-
infected Aedes aegypti can have on the burden of dengue. 
 
5.2 Methods                                                                                                                                                                                      
5.2.1 Regression of Presence-absence Against Force of Infection 
Global positioning system (GPS) coordinates of age-stratified seroprevalence and incidence 
surveys previously identified were used to extract the probability of dengue occurrence (PO, 
also referred to here as ‘presence-absence data’) from the corresponding latitude and 
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longitude at the same spatial scale as the survey in question [108]. The force of infection for 
each survey was estimated previously ([174] and chapters 2-4).  
A simple linear model (5.1), exponential model (5.2), and power model (5.3) were fitted to 
the force of infection and corresponding presence-absence values using linear least squares 
(linear model) and non-linear least squares (exponential and power model).  
 
Linear Model: 
Since the force of infection should be 0 when the probability of dengue occurrence is also 0, 
we assume that the intercept is (0, 0) and regress through the origin. 
p    (5.1) 
where   is the total force of infection,   is the slope, and p  is the probability of dengue 
occurrence. 
Exponential Model: 
 expa kp       (5.2) 
where   is the total force of infection, a  is the scaling factor, p  is the probability of 
dengue occurrence, and k  is the exponent. 
Power Model: 
kap    (5.3) 
where   is the total force of infection, a  is the scaling factor, p  is the probability of 
dengue occurrence, and k  is the exponent. 
We chose to use an unweighted regression given the lack of seroprevalence surveys 
available and the inconsistencies in terms of survey design, survey year, and diagnostic test 
([174] and chapters 2-3).  
Since   estimates were available from both seroprevalence surveys (one estimate from the 
IgG model (chapters 2 and 3) and incidence data (two estimates from two model variants 1b 
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and 2b as described in chapter 4)), the   estimates used in equation (5.1)-(5.3) were either 
from; (i) seroprevalence surveys only, (ii) or were a combined estimate from seroprevalence 
surveys and incidence data model 1b, (iii) or seroprevalence surveys and incidence data 
model 1b. The strength of association between   and PO (combinations i – iii) was assessed 
by a pseudo R-squared (R2) statistic and the non-linear regression correlation coefficient. 
The best model was then selected to estimate the force of infection across the globe. All 
models were fitted in the R Statistical Package [159]. 
Comparing goodness of fit 
The 2R  statistic was calculated by; 
2
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where iy  are the data, 
^
iy  are the associated predicted values, and 
_
y  is the mean y-value.  
For non-linear least square fittings, the correlation coefficient is calculated by: 
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 , where iy are the data, 
^
iy  are the 
associated predicted values, and 
_
y  is the mean y-value. 
The 95% confidence region was calculated for the two parameters a  and k  according to 
Beale’s criterion using the R package nlstools [209,210]. 5000 parameter sets were randomly 
sampled from this region and used to calculate the burden of dengue. The maximum and 
minimum burden from the 5000 sets represents the uncertainty around the estimated 
dengue burden. 
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5.2.2 Mapping the Estimated Burden of Dengue 
The best fitting model was then used to map the predicted  , serotype-specific basic 
reproduction number  0iR , and the burden of dengue (number of dengue infections) 
across the globe. The global presence-absence data for each 5x5km pixel were generated as 
described in Bhatt et al. [108]. The force of infection at any 5km by 5km area was estimated 
by transforming the presence-absence data of each pixel into a force of infection estimate 
using equation (5.1), (5.2), or (5.3). From this, 0iR  and the expected number of dengue cases 
could be estimated as described in sections 5.2.3 and 5.2.4. All mapping and burden 
estimates were done in Java. 
5.2.3 Estimating the Basic Reproduction Number  
Using   values estimated from the power model, 0iR  were calculated under two different 
assumptions in keeping with previous chapters. Under assumption 1, we assumed that there 
was no cross-protection between different serotypes, and that individuals can be infected 
up to four times. Under assumption 2, we assumed that individuals acquired protective 
immunity after the second heterologous infection. The population age-structure of each 
country were taken from the 2010 United Nations (UN) world population estimates [128]. 
A) 0iR  calculation assumption 1 – individuals can be infected 4 times. 
The basic reproduction number for a single serotype is given by: 
0
0
1
1 ( ) ( )
i
i
R
f a z a da


 
, 
 
(5.4) 
where  f a  is the proportion of the population aged a  , and  iz a  is the proportion of 
the population seropositive calculated by: 
  1
a
n
iz a e


   , 
 
(5.5) 
where n  is the number of serotypes in circulation. 
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Substituting (5.5) into (5.4): 
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(5.6) 
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(5.7) 
 
B) 0iR  calculation assumption 2 – individuals become immune after two infections: 
The basic reproduction number for a single serotype is given by: 
       
0
0
1
1
i
i
R
f a x a n z a da


   
, 
 
(5.8) 
where  f a  is the proportion of the population in age group a , n  is the number of 
serotypes in circulation,  x a  is the proportion of the population seronegative at age a  
given by: 
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   expx a a    (5.9) 
and  z a  is the proportion of the population seropositive for a single serotype at age a  
given by:   
     
   
   
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(5.10) 
Integrating between ages 1a  and 2a  gives: 
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(5.11) 
 
5.2.4 Calculating the Expected Number of Cases 
The expected number of cases in each age group can be calculated from the estimated force 
of infection (equation (5.1)-(5.3)), the population density of a country, and the weighted 
sum of primary to quaternary infections (chapter 4, equations (4.1) – (4.5)). The population 
density for each pixel was taken from the Global Rural-Urban Mapping Project [211] and 
age-structure from the UN Population Estimates [128]. 
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The expected number of cases is given by: 
        1 1 2 2 3 3 4 4ii
i
n
C w I a w I a w I a w I a
width
   
, 
 (5.12) 
where in  is the number of individuals in age group i , iwidth  is the width of that age-group, 
and 1 4w w  are the relative weights, or the probability of detecting a primary to quaternary 
infections respectively. The total number of expected cases over the entire population is 
simply: 
ii
Total C .  (5.13) 
 
5.2.5 Incorporating Temporary Cross-immunity 
For 0iR  calculated above (equations (5.7) and (5.11)), we assumed dengue transmission was 
at endemic equilibrium. However, to investigate the effect that temporary cross-immunity 
may have on dengue burden (as quantified by 0iR ), we allowed for short-term cross-
immunity against the remaining serotypes following infection with one serotype. 
The proportion of the population who are infectious at age a ,  Y a  is given by: 
       '
0
' '
a a a
Y a S a e I a da
 
  , 
 
(5.14) 
where  S a  is the survival function – the probability of surviving until age a . We assumed 
an exponential survival function 
ae   where   is the mortality rate.   is the recovery rate 
or the rate at which individuals leave the infectious compartment – note that the movement 
out of the infectious compartment occurs relative to when an individual was infected.  I a  
is the weighted sum of primary to quaternary infection incidences which are identical to 
those equations in chapter 4 for calculating dengue incidence. However the limits of 
integration have been adjusted to take into account the period of temporary cross immunity 
(in years) given by d . The lower limit was reset to 0 if a d  was negative. To look at the 
impact of the duration of temporary cross-immunity after infection with one serotype, the 
duration of immunity was varied between 6 months to 2 years [21–24] under the three 
scenarios described in Table 5.1. 
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The serotype-specific basic reproduction number can then be calculated by 
   0
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f a I a
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(5.15) 
where   is the force of infection,  f a  is the proportion of the population aged a , n  is 
the number of serotypes in circulation, and  I a  is the weighted sum of primary to 
quaternary infection incidence (chapter 4 equation (4.5)). If there are fewer than 4 
serotypes in circulation, the equations change as described in chapter 4. 
 
5.2.6 Estimating the Global Burden of Dengue Under Different Reporting 
Scenarios 
Changing the probability of detecting dengue infection 
The expected burden of dengue was calculated under several different scenarios. The 
weights 1 4w w  (equation (5.12)) were varied to reflect the probability of detecting a 
primary – quaternary infection (Table 5.1). In scenario 1 we assumed that all infections are 
reported which is the equivalent to the total number of infections. In contrast, in scenario 3 
the best estimates of the probability of detecting a primary – quaternary infection were 
used [60,61]. This reflects the number of apparent infections. 
 
Table 5.1: Different scenarios under which the burden of dengue was calculated. 
*Under assumption 1, individuals can be infected up to four times. Under assumption 2 individuals 
develop protective immunity after their second infection. 
  
Scenario  Assumption* 
1w  2w  3w  4w  
1 Perfect reporting, maximum burden 1 1 1 1 1 
  2 1 1 0 0 
2 Only secondary cases are observed 1 0 1 0 0 
  2 0 1 0 0 
3 Best estimates of proportion of cases observed 1 0.25 0.5 0.1 0.1 
  2 0.25 0.5 0 0 
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5.3 Results 
5.3.1 Linear and Non-linear Regression 
Although the simple linear regression had similar correlation coefficients to the non-linear 
models (Table 5.2-Table 5.4), the 2R values were much smaller, and the model failed to 
capture the high force of infection at higher values of the probability of occurrence (Figure 
5.1).  
Table 5.2: Parameter estimates of the simple linear model and corresponding R2 values. 
^Model 1b: incidence model with single reporting rate fitted to cumulative incidence data. Model 2b: 
incidence model with age-dependent reporting rate fitted to cumulative incidence data as described in chapter 
4. 
 
 
 
Figure 5.1: Linear regression of probability of occurrence on force of infection. Points show the data, 
the solid line shows the line of best fit, and the shaded area shows the 95% CI. A) Seroprevalence 
surveys results only, B) seroprevalence survey and incidence model 1b results, and C) 
seroprevalence and incidence model 2b results. 
 
The non-linear regression correlation coefficient and 2R  of the exponential and power 
model were similar for all three combinations (Table 5.3 and Table 5.4). Since the force of 
infection could not be 0 when the probability of dengue occurrence was 0 with the 
exponential model, the power model was chosen for subsequent analysis. The best fitting 
Combinations   (95% CI) Correlation 
Coefficient 
2R  Fig 
Serology 0.108 (0.078-0.139) 0.59 0.35 Figure 5.1a 
Serology + Incidence Model 
1b^ 
0.105 (0.082-0.128) 0.52 0.27 Figure 5.1b 
Serology + Incidence Model 
2b^ 
0.102 (0.076-0.128) 0.52 0.27 Figure 5.1c 
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power model as assessed by 2R  and the non-linear regression correlation coefficient was 
when only the force of infection estimates from seroprevalence surveys were used with 
corresponding presence-absence values (Table 5.4 and Figure 5.3). Therefore all subsequent 
calculations were based on Figure 5.3a. The parameter sets randomly sampled from the 
95% confidence region of the two parameters ( a  and k ) from which the 95% CI were 
calculated are shown in Figure 5.4. 
 
Table 5.3: Parameter estimates of the exponential model and corresponding 
2R  values. 
*Non-linear least squares correlation coefficient. ^Model 1b: incidence model with single reporting rate fitted 
to cumulative incidence data. Model 2b: incidence model with age-dependent reporting rate fitted to 
cumulative incidence data as described in chapter 4. 
 
 
Figure 5.2: Non-linear exponential model regression of probability of occurrence on force of 
infection. Points show the data, the solid line shows the line of best fit, and the shaded area shows 
the 95% CI. A) Seroprevalence surveys results only, B) seroprevalence survey and incidence model 1b 
results, and C) seroprevalence and incidence model 2b results. 
 
 
Combinations Parameter values (95% CI) 2R  Correlation 
Coefficient* 
Fig. 
 a  k     
Serology 0.001 
(0.00002-0.009) 
5.47 
(2.68-9.55) 
0.44 0.67 Figure 5.2a 
Serology + Incidence Model 
1b^ 
0.005 
(0.001-0.022) 
3.36 
(1.63-5.55) 
0.30 0.55 Figure 5.2b 
Serology + Incidence Model 
2b^ 
0.004 
(0.0003-0.027) 
3.61 
(1.48-6.15) 
0.25 0.50 Figure 5.2c 
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Table 5.4: Parameter estimates of the power model and corresponding R2 values. 
*Non-linear least squares correlation coefficient. ^Model 1b: incidence model with single reporting rate fitted 
to cumulative incidence data. Model 2b: incidence model with age-dependent reporting rate fitted to 
cumulative incidence data as described in chapter 4. 
 
 
Figure 5.3: Non-linear power model regression of probability of occurrence on force of infection. 
Points show the data, the solid line shows the line of best fit, and the shaded area shows the 95% CI. 
A) Seroprevalence surveys results only, B) seroprevalence survey and incidence model 1b results, 
and C) seroprevalence and incidence model 2b results. 
 
For all combinations shown above (Figure 5.3), the power model captured the gradual 
increase in   with increasing PO up to a PO of ~0.7. However the model was unable to 
capture the wide variation in   for PO values above 0.7.  
 
Combinations Parameter values (95% CI) 2R  Correlation 
Coefficient* 
Fig. 
 a  k     
Serology 0.161 
(0.125-0.211) 
4.852 
(2.408-8.410) 
0.44 0.66 Figure 5.3a 
Serology + Incidence Model 1b^ 0.132 
(0.107-0.166) 
2.834 
(1.370-4.599) 
0.30 0.54 Figure 5.3b 
Serology + Incidence Model 2b^ 0.131 
(0.101-0.171) 
3.014 
(1.154-5.140) 
0.25 0.50 Figure 5.3c 
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Figure 5.4: Minimum convex polygon of 5000 parameter sets randomly sampled from the 95% 
confidence region of the two parameters of the power function fitted to seroprevalence survey 
results only (Fig. 5.1a). 
 
5.3.2 The estimated annual global burden of dengue 
The maximum estimated annual global burden (scenario 1 - perfect reporting, maximum 
burden) based on the 2010 population was 109 million (95% CI: 80 M – 147 M) under the 
assumption that all countries had four serotypes in circulation and that individuals could be 
infected up to four times. When we assumed that individuals were immune after two 
infections the burden decreased to 75 million (95% CI: 56 M – 104 M). Under our most 
realistic assumptions about the relative contribution of primary – quaternary infections to 
observed cases (scenario 3) and using the reported number of serotypes for each country 
where available, the estimated observed case burden was 28 million (95% CI: 21 M – 39 M), 
decreasing to 25 million (95% CI: 19 M – 35 M) when assuming immunity after two 
infections. Table 5.5 lists the burden estimates under the three scenarios tested. 
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Table 5.5: Global burden estimates and 95% CI under different assumptions. 
Scenario* Assumption^ Serotypes¯ Burden** 95% CI 
1 1 Fixed (4) 108,000,000 79,700,000 – 147,000,000 
 1 Free 102,000,000 75,100,000 – 139,000,000 
 2 Fixed (4) 74,800,000 56,000,000 – 104,000,000 
 2 Free 71,600,000 53,600,000 – 99,100,000 
2 1 Fixed (4) 31,900,000 23,800,000 – 44,300,000 
 1 Free 28,900,000 21,600,000 – 40,200,000 
 2 Fixed (4) 31,900,000 23,800,000 – 44,300,000 
 2 Free 28,900,000 21,600,000 – 40,200,000 
3 1 Fixed (4) 30,100,000 22,300,000 – 41,300,000 
 1 Free 28,200,000 20,900,000 – 38,800,000 
 2 Fixed (4) 26,700,000 19,900,000 – 37,000,000 
 2 Free 25,100,000 18,800,000 – 34,800,000 
*See Table 5.1. ^Assumption 1: individuals can be infected up to four times, assumption 2: individuals are 
immune after their second infection. ¯Fixed: the number of serotypes in circulation in each country is fixed to 4. 
Free: reported number of serotypes used. **Shown to three significant figures. 
 
The estimated burden, probability of dengue occurrence, force of infection, and basic 
reproduction number were mapped for every 5x5km pixel globally. Figure 5.5 shows these 
estimates for scenario 3 using the reported number of serotypes for each country under the 
assumption that individuals can be infected up to four times. As expected the burden was 
highest in South East Asia with heterogeneity within countries. Country-specific estimates of 
dengue burden (scenario 3 and using the reported number of serotypes) were then 
compared to the inapparent and apparent dengue infection estimates by Bhatt et al. and 
the WHO estimates where available [108]. Figure 5.6 to Figure 5.9 show that our estimates 
are consistently lower than the apparent dengue infection estimates made by Bhatt et al. 
and are generally more consistent with the reported WHO cases. Table 5.6 compares 
average 0R  values by country estimated here with previously estimated values of 0R
(chapters 2-4), and published values. 
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Table 5.6: Comparison of R0 estimates to previously published estimates by country. 
*Range given for assumption 1: individuals can be infected 4 times, and assumption 2: immune after 2 
infections. 
Country Estimated average 
0R  in 2010* 
Range of previously estimated point 
estimates of 0R  from Serology and 
Incidence Models (ch. 2- 5) 
Published 0R
estimates  
Ref 
Brazil 1.97 – 2.11 1.09 – 2.48 1.6 – 2.5 [119,174] 
   3.6 – 12.9 [212] 
   2 – 103 [118] 
   2.3 - 11 [114] 
   0.28 – 5.04  [213] 
   2 – 3.3 [167] 
Cambodia 1.56 – 1.62 2.01 – 3.40   
Costa Rica 1.85 – 1.92 1.87 – 2.77  [174] 
China 0 – 0.32 1.19 – 3.53   
Cuba 3.09 – 3.50 1.14 – 1.52  [174] 
Dominican Republic 2.88 – 3.03 1.84 – 2.67  [174] 
El Salvador 2.26 – 2.41 1.82 – 2.67  [174] 
French Polynesia 3.50 – 3.95 3.73 – 6.90  [174] 
Haiti 1.64 – 1.71 3.67 – 6.32   
India 1.73 – 1.82 1.01  [174] 
Indonesia 2.45 – 2.65 1.89 – 2.81  [174] 
Laos 1.25 – 1.27 1.13 – 2.56  [174] 
Mayotte 1.21 – 1.24 1.06 – 1.07  [174] 
Mexico 1.19 – 1.25 1.23 – 1.40 1.3 – 2.4 [174,214] 
   1.1 – 1.3 [115] 
   1.9 [215] 
   1.9 – 2.4 [167] 
Nicaragua 1.86 – 1.96 1.06 – 6.42  [174] 
Pakistan 1.07 – 1.11 1.05 – 1.34  [174] 
Papua New Guinea 0.80 – 0.82 2.55 – 4.11  [174] 
Peru 0.98 – 1.02 1.11 – 2.94 1.76 (0.83-4.46) [117,174] 
Philippines 2.18 – 2.32 1.04 – 1.05 2.1 – 3.9 [167] 
Puerto Rico 3.87 – 4.42 1.57 – 2.86 1.2 – 2.7 [167] 
Singapore 4.33 – 5.11 1.21 – 2.05 3.9 – 4.7 [174,216] 
Sri Lanka 2.64 – 2.89 1.03 – 9.86  [174] 
Thailand 2.21 – 2.42 2.16 – 4.26 4 – 6 or 8 [104,174] 
  1.81 – 3.33 5.2 – 6.7 [121,174] 
   3.3 (3.1-3.4) [165] 
   3.2 (2.7-3.3) [165] 
   1.9 – 2.3 [217] 
   2.2 – 5.2 [167] 
USA 0.05 – 0.05 1.08 – 1.12  [174] 
Vietnam 1.98 – 2.11 2.02 – 3.62 1.25 – 1.75 [155] 
   5 – 7  [218] 
   3 [219] 
   2 – 3 [167] 
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Figure 5.5: Global A) probability of dengue occurrence, B) force of infection, C) R0, and D) observed 
dengue cases in 2010 at 5x5km spatial resolution. Results are mapped for scenario 3 assuming 
individuals can be infected up to 4 times and using the reported number of serotypes for each 
country. The upper limit shown in panels C and D are fixed at 3 and 1500 respectively. 
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Figure 5.6: Comparisons of the estimated burden of dengue in Africa to estimates from Bhatt et al. 
[108] and where reported, the WHO.  Here only estimates from scenario 3 are presented under 
assumption 1 (individuals can have up to 4 infections) using the reported number of serotypes for 
each country. Points represent the posterior median estimate, and the lines the 95% CrI. 
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Figure 5.7: Comparisons of the estimated burden of dengue in the Americas to estimates from Bhatt 
et al. [108] and where reported, the WHO. Here only estimates from scenario 3 are presented under 
assumption 1 (individuals can have up to 4 infections) using the reported number of serotypes for 
each country. Points represent the posterior median estimate, and the lines the 95% CrI. 
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Figure 5.8: Comparisons of the estimated burden of dengue in Asia to estimates from Bhatt et al. 
[108] and where reported, the WHO. Here only estimates from scenario 3 are presented under 
assumption 1 (individuals can have up to 4 infections) using the reported number of serotypes for 
each country. Points represent the posterior median estimate, and the lines the 95% CrI. 
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Figure 5.9: Comparisons of the estimated burden of dengue in Europe and Oceania to estimates 
from Bhatt et al. [108] and where reported, the WHO. Here only estimates from scenario 3 are 
presented under assumption 1 (individuals can have up to 4 infections) using the reported number 
of serotypes for each country. Points represent the posterior median estimate, and the lines the 95% 
CrI. 
 
To look at the impact of the duration of temporary cross-immunity after infection with one 
serotype, the duration of immunity was varied from 6 months to 2 years [21–24] . As 
expected the reduction in the number of cases was greater when the duration of immunity 
was longer under all scenarios. Although the percentage reduction in cases was minimal 
when allowing for temporary cross-immunity compared to no cross-immunity post-infection, 
reduction in terms of absolute number of cases was still substantial (Table 5.7). 
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Table 5.7: Estimated global burden of disease (and 95% CI) with and without temporary cross 
immunity using reported number of serotypes 
*See Table 5.1. ^Assumption 1: individuals can be infected up to four times, assumption 2: individuals are 
immune after their second infection **Shown to three significant figures.
Scenario* Assumption^ Burden with No 
Temporary Cross-
Immunity** (95% CI) 
Burden with Temporary Cross Immunity** (95% CI) 
   6 months 2 years 
1 1 102,000,000 
(75,100,000 – 
139,000,000) 
101,000,000 
(74,400,000-
137,000,000) 
98,700,000 
(72,400,000-
134,000,000) 
2 71,600,000 
(53,600,000 – 99,100,000) 
71,500,000 
(53,500,000-98,800,000) 
71,000,000 
(53,100,000-98,100,000) 
3 1 28,200,000 
(20,900,000 – 38,800,000) 
28,100,000 
(20,800,000-38,500,000) 
27,600,000 
(20,500,000-37,900,000) 
2 25,100,000 
(18,800,000 – 34,800,000) 
25,100,000 
(18,700,000-34,700,000) 
24,800,000 
(18,500,000-34,300,000) 
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5.4 Discussion 
Using the global evidence consensus of dengue occurrence and subsequent dengue 
infection risk map [108] we estimated the force of infection, basic reproduction number, 
and apparent dengue cases at high spatial resolution. Dengue transmission was spatially 
highly heterogeneous both between and within countries. Force of infection estimates from 
seroprevalence surveys (chapters 2 and 3) rather than incidence data (chapter 4) resulted in 
the best fitting power model when regressed on the probability of dengue occurrence as 
assessed by 2R  and the non-linear regression correlation coefficient. Seroprevalence 
datasets where the estimated force of infection corresponded to a PO below 25% were not 
available. At a PO of 25% the power model was able to capture the low force of infection 
gradually increasing up to a PO of 70%. However above 70% it is very difficult to capture the 
wide variation in the force of infection (Figure 5.3) due to dengue endemicity at this 
probability. Consequently in the resulting burden maps, the same   is mapped for the same 
PO values. Therefore PO are unable to differentiate between different areas of high 
transmission – for example Singapore and Malaysia. However this regression produced 
more realistic estimates of dengue burden compared to the Bhatt et al. model where they 
regressed dengue incidence data on the PO (Figure 5.10). Their model predicted close to 
10% infection rate per year at a high PO, and the infection rate declined slowly with 
decreasing PO. The lack of demographic constraints (such as birth rates) and allowing 
individuals to have an unlimited number of infections during their lifetime led to 
unrealistically high estimates of 390 million dengue infections and 96 million symptomatic 
cases per year [108].  
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Figure 5.10: Bayesian modelled relationship between the probability of occurrence and incidence for 
inapparent and apparent number of infections. Reproduced from Bhatt et al. [108]. The data are the 
points, the bold lines are the medians and the envelopes are the 0.25, 0.5 and 0.95 credible intervals 
centred on the median displayed with progressively lighter shades.  
 
In endemic countries the actual force of infection can fluctuate widely year on year and this 
dynamic cannot be captured by either the power model nor the probability of dengue 
occurrence [28,189]. Thus PO data are generally only useful in marginal settings. 
Additionally, the calculation of the PO itself relies heavily on notification data, however the 
lack of reported cases does not equate to the lack of dengue transmission. Therefore in 
ongoing work, we are now directly regressing independent force of infection estimates on 
environmental covariates, such as temperature, humidity, and rainfall, in endemic settings. 
The maximum annual burden estimated was 102 million infections (95% CI: 75.1 M – 139 M) 
assuming individuals can be infected four times, or 72 million infections (95% CI: 54 M – 99 
M) assuming individuals develop protective immunity after two heterologous infections. The 
apparent infection burden estimated was 28 million cases (95% CI: 21 M – 39 M) and 25 
million cases (95% CI: 19 M – 35 M) under the same two assumptions (Table 5.7). The 
maximum burden estimates are three times smaller than those estimated by Bhatt et al.: a 
total of 390 million infections (95% CrI 284 M – 528 M) and 96 million apparent infections 
(95% CrI 67 M – 136 M) using the same data on probability of dengue occurrence [108].  
Figure 5.6 - Figure 5.9 also show consistently lower estimates for every country with our 
estimates being closer (where reported) to the WHO estimates. Analogous to malaria 
modelling, Bhatt et al. have allowed individuals to have an infinite number of dengue 
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infections during their lifetime [108]. This is indeed a valid assumption for non-immunising 
infections such as malaria [220]. However as an acute immunising infection, the number of 
dengue infections an individual can acquire is finite (maximum of 4 infections, one for each 
serotype) [4,221]. This has therefore resulted in a significant discrepancy in the two dengue 
burden estimates. However a recent study analysing serotype-specific seroprevalence data 
collected from longitudinal cohort studies in Peru have suggested that protection from 
homologous re-infection may be incomplete in some circumstances for DENV-2 [19]. 
However it is not known whether an individual with a homologous re-infection is also then 
infectious and can contribute to onwards transmission. Comparing the average estimated 
0R  by country, my estimates are generally consistent with 0R  values previously estimated 
or published (Table 5.6). The slight discrepancy arises as our estimates are a weighted 
average of the 0R  values in each country, whereas published basic reproduction numbers 
or 0R  estimated from incidence or seroprevalence data are often site-specific, highlighting 
the heterogeneity in dengue transmission at small spatial scales. 
Spatial information on the distribution of dengue burden is essential for the allocation of 
correct resources, and the planning and evaluation of targeted control programmes. Thus 
these maps can help identify areas where dengue transmission is high and therefore may 
benefit the most from interventions.  
The estimated duration of short-term cross-protection varies widely from 4 months to 9 
years [21], 5–12 months [22], 2 years [23], and 1–3 years [24]. However whether this 
protects against infection or just against clinically apparent disease, i.e. the individual may 
still be infectious is unknown. Therefore individuals may still contribute to onward 
transmission [23,25,26] and it is now known that asymptomatic humans can be infectious to 
mosquitoes despite their lower average viremia [27]. Inclusion of temporary cross-immunity 
decreased the burden of dengue as expected (Table 5.7). This is consistent with previous 
studies where a short interval between primary and secondary infection was associated 
with protection against clinical disease i.e. infection occurred during the period of cross-
protection. Predictably when the duration of cross-immunity was increased, there was a 
corresponding decrease in the overall burden of dengue. Additionally under assumption 2 
where we assumed that individuals develop protective immunity after two heterologous 
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infections, the impact of temporary cross-immunity was unsurprisingly smaller than when 
assuming individuals could be infected up to four times. However our model is unable to 
capture the more detailed temporal aspects of cross-protection since it does not take into 
account the actual time between infection events which will determine whether a second 
infection results in immunity, asymptomatic infection, or severe apparent infection. 
There are a number of additional limitations to these results, primarily in the initial 
estimation of the force of infection from the probability of dengue occurrence (Figure 5.3). 
Only 37 datasets were used in the regression with surveys being conducted between 1980 
and 2010 with few contemporary surveys, which is not a true representation of dengue 
transmission in 2010 which I was trying to estimate. The corresponding 2R  values were also 
fairly low. Additionally the surveys were inconsistent in terms of survey design and 
diagnostic test (chapters 2 and 3, [174]). As highlighted in chapters 2 and 3, it would be 
beneficial if countries were to conduct more affordable IgG serosurveys yearly which could 
be matched to local notification data for validation. 
Nevertheless this method utilises the majority of the currently available data on dengue 
transmission from the evidence-based consensus and environmental covariates informing 
the probability of dengue occurrence statistics, to seroprevalence surveys conducted at a 
more local level. The high spatial resolution at which dengue burden can be quantified in 
multiple ways – the force of infection, basic reproduction number, and the number of 
apparent and inapparent cases will be highly beneficial in identifying and targeting control 
measures to key areas of high dengue transmission. 
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6 Discussion 
The main motivation behind this thesis has been to refine the baseline estimates of dengue 
transmissibility, quantified by the force of infection ( )  or the basic reproduction number 
0( )R , given the currently available data. I additionally assessed how comparable force of 
infection estimates obtained from incidence data  inc  were with those derived from 
serological data  sero . Finally using the force of infection estimated from these data, I 
mapped the estimated burden of dengue disease globally and considered the impact that 
novel control measures may have. 
 
6.1 Summary of Findings 
In chapter 2 and previously published work [174], I estimated the   and 0R  from age-
stratified non-serotype specific seroprevalence data identified from a literature search. I 
fitted simple catalytic models to these mostly IgG data and found that the estimates of the 
serotype specific 0iR  varied according to the assumptions made regarding host immunity. 
When I assumed that two heterologous infections were sufficient for complete immunity 
(assumption 2), the estimates of 0iR  were up to two-fold higher compared to when I 
assumed that quaternary infections were required for complete immunity (assumption 1). I 
additionally fitted a catalytic model to 7 years’ worth of cross-sectional data from Managua, 
Nicaragua [30,140] which allowed for the force of infection to vary sinusoidally over time 
and to change at a (fitted) age threshold. I also identified a general paucity of 
seroprevalence surveys, particularly of serotype-specific data and cohort data. 
In chapter 3 and previously published work [174], I estimated serotype-specific dengue 
force of infection ( )i  from serotype-specific PRNT seroprevalence data. For comparison 
purposes, I fitted a simple catalytic model that tracked individuals from a seronegative to 
seropositive state (model A described in chapter 2) to the same PRNT data. I defined 
individuals with PRNT titres below the detection limit for all four dengue serotypes as 
seronegative and individuals with at least one PRNT titre over the detection limit as 
seropositive. The resulting force of infection estimates generated using model A were 
consistent with the sum of the individual serotype-specific λ estimates obtained from the 
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full PRNT datasets. This showed that while PRNT data provided more information, the less 
expensive ELISA-based assays could still provide reasonable baseline estimates of overall 
transmission intensity. 
In chapter 4, I collated age-stratified incidence data from the literature and fitted catalytic 
models to estimate the force of infection and basic reproduction number. To assess the 
level of under-reporting of dengue disease, I then compared   estimates derived from 
seroprevalence data (chapters 2 and 3) to estimates derived from incidence data. In 
addition, I estimated the relative contribution of primary to quaternary infections to the 
observed burden of dengue disease incidence. For the three locations in Thailand where 
region and time matching seroprevalence and incidence data were available, the   
estimates obtained from the models fitted to incidence data were generally comparable to 
those estimated from seroprevalence data. I showed that the contribution of primary 
infections to the observed burden of dengue was consistently low (<25% relative to 
secondary infections), while the contribution of tertiary infections was inconclusive. 
Finally in chapter 5, I used the results from chapters 2, 3, and 4 to estimate the force of 
infection from the probability of dengue occurrence (presence-absence statistic) across the 
globe at a 5km x 5km spatial resolution [108]. The incidence model developed in chapter 4 
was then used to calculate the global burden of dengue. We estimated the maximum 
annual burden based on the 2010 world population to be 109 million infections (95% CI: 79 
M – 147 M) under the assumption that all countries had four serotypes in circulation and 
that individuals could be infected up to four times.  
 
6.2 Future Work and Limitations 
The major limitation of this work has been the quantity and quality of available age-
stratified data. In particular, serotype-specific seroprevalence data (PRNT data) have been 
sparse, and more importantly the data were outdated with most identified studies 
conducted in the 1980s and 1990s. Although we have shown that IgG data can provide 
robust estimates, with the imminent release of the dengue vaccine (Mexico and the 
Philippines having already approved the use of Dengvaxia® developed by Sanofi Pasteur 
[59]) it is crucial to have detailed baseline data of dengue transmission in all age groups in 
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order to accurately assess the impact the introduction of the vaccine may have on disease 
burden at the population level. However, given the cost of large-scale PRNT surveys, 
estimates of dengue force of infection and basic reproduction number could still be greatly 
improved by conducting the less expensive IgG surveys more frequently. 
Although incidence data are abundant, surveillance systems and reporting procedures are 
not standardised within or across countries making it very difficult to reliably compare 
estimates [52]. Laboratory capacity and general public health infrastructure and surveillance 
systems vary widely and there is often no integration between private and public health 
sectors. The WHO collates surveillance data from dengue affected countries via its 
DengueNet system, but the data are not always updated regularly and there can be 
inconsistencies with other sources of national and subnational data such as those from 
WHO regional offices [53]. With such variable data, accurate estimation of the true dengue 
burden is difficult [52]. 
The aggregation of age-groups in datasets affected the accuracy of the resulting estimates. 
Datasets with wide age bands (e.g. 0-5 years, 5-15 years, and 15+ years) were less 
informative than datasets where seroprevalence or cases were presented for every age. 
Estimates could therefore be improved if age-stratified data were reported at a higher 
resolution, or at least in equal age widths (e.g. 5 year age bands). In this thesis I have not 
explicitly looked at the impact of maternal antibodies on estimates of dengue 
transmissibility or disease burden. Recent studies have shown that infant cases (<1 year old) 
can yield information about type-specific disease severity given the presence of maternal 
antibodies, as well as information about transmission within the whole population [222]. 
Throughout my analysis I have either excluded cases in infants to avoid skewed estimates, 
or have been unable to explicitly take them into account due to the aggregation of data in 
the younger age groups. If the same models could be fitted to data from infants, it would be 
interesting to explore whether there are significant differences in dengue transmission in 
infants compared to the general population. However, such data can be difficult to obtain 
since parents can be reluctant to have very young children bled.  
Improvement could also be made to the way 0iR  was calculated in chapters 2, 3, and 4. In 
translating   estimates into estimates of 0iR , I relied on a model which assumed exposure 
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was due to endemic transmission. This meant that all resulting 0iR  estimates were by 
definition greater than one. Clearly this is less appropriate for settings with low 
seroprevalence and incidence such as Texas (USA), where some or all of the seropositivity 
detected is due to imported cases rather than local transmission. The 0iR  calculation could 
therefore be adapted in such situations.  
In chapter 4, I found that the relative contribution of tertiary and quaternary cases could not 
be estimated from incidence data. Although there is evidence that tertiary and quaternary 
infections occur [25,28], there is little quantitative data on the infectiousness or severity of 
such infections relative to primary and secondary infections. Additionally, clinically apparent 
tertiary or quaternary infections are not routinely reported, nor can they be tested for 
retrospectively [25]. Therefore this model could be simplified by assuming all reported cases 
are due to primary and secondary infections only. Furthermore, a recent study analysing 
serotype-specific seroprevalence data collected from longitudinal cohort studies in Peru 
have suggested that protection from homologous re-infection may be incomplete in some 
circumstances for DENV-2 [19]. Therefore some infection events classed as secondary or 
tertiary may actually be due to re-infection with the same serotype. Although the relative 
contribution of such infections to the observed burden of dengue is unknown, they could 
invalidate the assumption that infection with one serotype provides lifelong protection 
against re-infection with the same serotype. This may well impact future dengue vaccine 
formulations.  
Finally in chapter 5, in the initial estimation of the force of infection from the probability of 
dengue occurrence only 37 datasets were used in the regression with surveys being 
conducted between 1980 and 2010 with few contemporary surveys, which cannot be a true 
representation of dengue transmission in 2010 which I was trying to estimate. Additionally 
the surveys were inconsistent in terms of survey design and diagnostic test (chapters 2 and 
3, [174]). As highlighted in chapters 2 and 3, it would be beneficial if countries were to 
conduct more affordable IgG serosurveys yearly which could be matched to local 
notification data for validation. Furthermore, seroprevalence datasets where the estimated 
force of infection corresponded to a probability of dengue occurrence (PO) below 25% were 
not available. Therefore this regression could be improved if more data were available from 
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low-transmission settings. Alternatively a model with a threshold could be fitted where the 
force of infection could vary over a wider ranger above a certain PO (e.g. >75% in endemic 
settings). However the probability of occurrence is a poor predictor of the force of infection 
in high transmission settings. Therefore it cannot distinguish differences in the force of 
infection between different SE Asian countries – e.g. Singapore from Malaysia. Global 
estimates of dengue burden could be best improved by switching from probability of 
occurrence data to more reliable spatially stratified estimates of the force of infection from 
geo-located age-stratified data. Therefore in ongoing work, we are now directly regressing 
independent geo-located force of infection estimates on environmental covariates, such as 
temperature, humidity, and rainfall, in endemic settings. 
6.3 Implications of Research 
The research presented here has focused on refining the baseline estimates of dengue 
transmissibility given the currently published data. With the dengue vaccine due to be rolled 
out, and other novel control methods such as Wolbachia in development, reliable estimates 
of transmission intensity – and of the health burden due to dengue – will be important in 
strategic planning and resource allocation in different contexts. 
This thesis has collated a comprehensive body of age-stratified seroprevalence and 
incidence data since 1980 from across the globe. By fitting the same models to these data I 
have demonstrated the spatio-temporal heterogeneity in dengue transmission. Additionally 
I have evaluated these data under the same assumptions about immunity when estimating 
the basic reproduction number for both seroprevalence and incidence data. This allows a 
more direct comparison of dengue transmission intensity between different regions. 
Reporting standards are highly variable with different diagnostic criteria across regions or 
countries. Consequently the quality, quantity, and the type of data that are collated globally 
cannot be easily standardised. Therefore the work presented in this thesis where I have 
compared   estimates from non-serotype specific (IgG) to serotype-specific (PRNT) 
seroprevalence data and case-notification data to seroprevalence data will provide a basis 
for comparing estimates when the data source and data type might differ. 
Since dengue and other vector-borne infections are spatially highly heterogeneous, 
methods (such as those presented in chapter 5) to resolve heterogeneity in dengue 
Page 204 of 228 
 
transmission intensity (and thus burden) at a fine spatial resolution will be beneficial for 
identifying and targeting control measures to key areas of high transmission. These tools 
can be used to estimate the effectiveness of intervention strategies in dengue control. Since 
trials and field studies are expensive and difficult to conduct, mathematical modelling is a 
powerful tool to obtain reliable estimates of baseline transmission and estimate the 
reduction in transmission and disease burden to quantify the success of a control program. 
The methods presented in this thesis to estimate the force of infection and basic 
reproduction number from seroprevalence and notification data will also be applicable to 
other acute immunising pathogens – most notably chikungunya and Zika viruses. 
6.4 Conclusions 
With its re-emergence and spread across the globe, dengue now affects more than 100 
countries, causing an estimated 109 million (95% CI: 79 M – 147 M) infections annually. 
However it is only now, in 2015, that a dengue vaccine is being licensed and new control 
methods such as Wolbachia-infected and genetically modified mosquitoes are being actively 
developed and tested [67,73,223]. Robust estimates of baseline dengue transmissibility are 
essential for the assessment and ongoing evaluation of any control measures that may be 
implemented and the work presented here is a significant contribution to such efforts. 
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